

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: MARCELA M. CORDERO GARCIA Examiner #: 80381 Date: 11/15/04
 Art Unit: 80381 Phone Number 30 2-2939 Serial Number: PCT/US03/26233
 Mail Box and Bldg/Room Location: REM 3C18/3C35 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: CORTICOSTEROID CONJUGATES AND USES THEREOF

Inventors (please provide full names): TEICHER, MARTIN H. AND ANDERSEN-NAVALTA, SUSAN L.

Earliest Priority Filing Date: 23/AUGUST/2002

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

PARENT 60/405688

NO CHILD

PLEASE SEARCH CLAIM 1 AND
 CLAIM 3

(IF TOO MANY HITS ON CLM 3, PLEASE USE CLM 4 TO RESTRICT)

THANKS

Marcia M. Cordero

(SIC)

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>D. Schwabe</u>	NA Sequence (#) _____	STN <u>699.63</u>
Searcher Phone #: <u>272-2520</u>	AA Sequence (#) _____	Dialog _____
Searcher Location: <u>Remsen EOL H11</u>	Structure # <u>1</u>	Questel/Trin _____
Date Searcher Picked Up: _____	Bibliographic <u>✓</u>	Dr Link _____
Date Completed: <u>12/7</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>14</u>	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>142</u>	Other _____	Other (specify) _____



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 137881

TO: Marcela Cordero Garcia
Location: rem/3c35/3c18
Art Unit: 1654
Tuesday, December 07, 2004

Case Serial Number: ^{10/646 063} pctus0326233

From: David Schreiber
Location: Biotech-Chem Library
Remsen E01A61
Phone: 272-2526

david.schreiber@uspto.gov

ALSO PERTAINS TO

Search Notes

10/646,063 CORTICOSTEROID CONJUGATES

=> fil reg

FILE 'REGISTRY' ENTERED AT 12:31:21 ON 07 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2004 HIGHEST RN 792236-36-3

DICTIONARY FILE UPDATES: 5 DEC 2004 HIGHEST RN 792236-36-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d stat que 112

L10 STR



VAR G1=24/26

VAR G2=H/X

VAR G3=H/CH₃/X

VAR G4=H/X

VAR G5=31/CH₂

VAR G6=H/C/O

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE
L12 12038 SEA FILE=REGISTRY SSS FUL L10

100.0% PROCESSED 18173 ITERATIONS 12038 ANSWERS
SEARCH TIME: 00.00.01

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 12:31:50 ON 07 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Dec 2004 VOL 141 ISS 24
FILE LAST UPDATED: 6 Dec 2004 (20041206/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l46 all hitstr 1-65

L46 ANSWER 1 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:934146 HCAPLUS
ED Entered STN: 06 Nov 2004
TI Aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compounds for treating and diagnosing cancer and viral infections
IN Thorpe, Philip E.; Ran, Sophia
PA USA
SO U.S. Pat. Appl. Publ., 181 pp., Cont.-in-part of U.S. Ser. No. 621,269.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K039-395
ICS C07K016-46
NCL 424178100; 530391100
CC 15-3 (Immunochemistry)
Section cross-reference(s): 1, 63
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2004219155	A1	20041104	US 2003-642099	20030815
	US 2004170620	A1	20040902	US 2003-621269	20030715
PRAI	US 2002-396263P	P	20020715		
	US 2003-621269	A2	20030715		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20040219155	ICM	A61K039-395
	ICS	C07K016-46
	NCL	424178100; 530391100
US 2004219155	ECLA	A61K039/395+M; A61K039/395C3+M; C07K016/28A30; C07K016/44
US 2004170620	ECLA	A61K039/395+M; A61K039/395C3+M; C07K016/28A30; C07K016/44
AB	The invention provides new methods and compns. for safe and effective tumor vascular targeting, anti-angiogenesis and tumor destruction, which methods and compns. are also surprisingly effective in treating viral infections and related diseases. The invention is based, in part, on discoveries concerning the expression and role of anionic phospholipids in tumor vasculature and the involvement of aminophospholipids and anionic phospholipids in viral entry, replication and spread. The present invention further provides particularly advantageous antibodies and immunoconjugates that bind to aminophospholipids and anionic phospholipids, and a new class of peptide-based derivs., such as duramycin-based compns., that bind to phosphatidylethanolamine.	
ST	antibody aminophospholipid duramycin immunoconjugate diagnosis cancer viral infection; anticancer antiviral antibody aminophospholipid duramycin immunoconjugate	
IT	DNA sequences	
	Protein sequences	
	(3G4 antibody-specifying; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)	
IT	Ricins	
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)	
	(A, deglycosylated; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)	
IT	Chemokines	
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)	
	(ELR- CXC; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)	
IT	Antibodies and Immunoglobulins	
	RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)	
	(IgG; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)	
IT	Viscum album coloratum	
	(Korean mistletoe, extract; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)	
IT	Leukemia inhibitory factor	
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)	
	(LIF; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)	
IT	Chemokines	
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)	
	(Mig (monokine induced by interferon- γ); aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for	

- treating and diagnosing cancer and viral infections)
- IT Proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(RIP (ribosome-inactivating protein); aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Chemokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SDF-1 (stromal-derived factor-1); aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Enzymes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Serratia protease, antibody **conjugates**; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TRAIL (tumor necrosis factor-related apoptosis-inducing ligand); aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Annexins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(V; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(VCAM-1; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Phospholipids
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acidic; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Drug delivery systems
(aerosols; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Diagnosis
(agents, antibody **conjugates**; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Phospholipids
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amine-containing; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Alkylating agents, biological
Angiogenesis inhibitors
Antibiotics
Antitumor agents
Antiviral agents

Chemotherapy
 Coagulants
 Cytotoxic agents
 Human
 Imaging agents
 Immunotherapy
 Linking agents
 Molecular cloning
 Neoplasm
 Radiotherapy
 Tumor markers
 (aminophospholipid-specific antibodies, immunoconjugates and
 duramycin-based compds. for treating and diagnosing cancer and viral
 infections)

IT Antibodies and Immunoglobulins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (aminophospholipid-specific antibodies, immunoconjugates and
 duramycin-based compds. for treating and diagnosing cancer and viral
 infections)

IT Cardiolipins
 Nucleosides
 Phosphatidic acids
 Phosphatidylethanolamines
 Phosphatidylglycerols
 Phosphatidylinositols
 Phosphatidylserines
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aminophospholipid-specific antibodies, immunoconjugates and
 duramycin-based compds. for treating and diagnosing cancer and viral
 infections)

IT Fusion proteins (chimeric proteins)
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (aminophospholipid-specific antibodies, immunoconjugates and
 duramycin-based compds. for treating and diagnosing cancer and viral
 infections)

IT Radionuclides
 RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)
 (aminophospholipid-specific antibodies, immunoconjugates and
 duramycin-based compds. for treating and diagnosing cancer and viral
 infections)

IT Anthracyclines
 Cytokines
 Glucocorticoids
 Interferons
 Interleukin 12
 Osteonectin
 Retinoids
 Steroids
 Taxanes
 Thrombospondins
 Tumor necrosis factors
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aminophospholipid-specific antibodies, immunoconjugates and
 duramycin-based compds. for treating and diagnosing cancer and viral
 infections)

- infections)
- IT Blood serum
(anal.; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT CD20 (antigen)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(anti-; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Drugs
(antibody **conjugates**; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Cytotoxic agents
(antimetabolites; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bispecific; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Diagnosis
(cancer; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Drug delivery systems
(carriers; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chimeric; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Annexins
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chimeric; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Imaging
X-ray
(diagnostic; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Toxins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diphtheria; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Blood vessel
(endothelium, tumor; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and

diagnosing cancer and viral infections)

IT Immunoassay
(enzyme-linked immunosorbent assay; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)

IT Toxins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(exotoxins, Pseudomonas; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fragments, Fv, Fab', Fab, diabody, linear antibody or F(ab'), CDR, univalent fragment; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heavy chain; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(humanized; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)

IT Drug delivery systems
(immunoconjugates; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)

IT Diagnosis
(immunodiagnosis; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)

IT Drug delivery systems
(immunotoxins; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)

IT Cytomegalovirus
(infection; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)

IT Tubulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)

IT Drug delivery systems
(injections, i.v.; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)

IT Chemokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

- (interferon γ -inducible protein-10, IP-10; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT NMR (nuclear magnetic resonance)
(isotopes; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chain; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal, 3G4, (ATCC PTA 4545); aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Fibronectins
Laminins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Toxins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(plant-, fungus- or bacteria-derived; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Drug delivery systems
(prodrugs; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proinflammatory; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Bond
(releasable; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Diagnosis
(serodiagnosis; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

- DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (single chain, scFv; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Neoplasm
 (solid; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Apoptosis
 (tumor cell, inducing; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Alkaloids
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vinca; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Infection
 (viral; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Interferons
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (α ; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Transforming growth factors
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (B1-; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Interferons
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (β ; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Interferons
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (γ ; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT Enzymes
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (D-Alanylcarboxypeptidase, antibody **conjugates**; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT 92769-12-5, Proliferin (protein)
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (-related protein; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT 9002-62-4, Prolactin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (16 kDa, fragment; aminophospholipid-specific antibodies, immunoconjugates and duramycin-based compds. for treating and diagnosing cancer and viral infections)
- IT 790789-26-3DP, humanized or chimeric derivs. and **conjugates**

790789-28-5DP, humanized or chimeric derivs. and **conjugates**
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; aminophospholipid-specific antibodies,
 immunoconjugates and duramycin-based compds. for treating and
 diagnosing cancer and viral infections)

IT 9035-58-9, Blood-coagulation factor III

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)

(aminophospholipid-specific antibodies, immunoconjugates and
 duramycin-based compds. for treating and diagnosing cancer and viral
 infections)

IT 54-42-2, Idoxuridine 70-00-8, Trifluorothymidine 127-07-1, Hydroxyurea
 768-94-5, Amantadine 1391-36-2D, Duramycin, **conjugates**

2056-98-6 3056-17-5, Stavudine 5536-17-4, Vidarabine 7481-89-2,
 Zalcitabine 13392-28-4, Rimantadine 30516-87-1, AZT 36791-04-5,
 Ribavirin 39809-25-1, Penciclovir 59277-89-3, Acyclovir 69655-05-6,
 Didanosine 77181-69-2, Sorivudine 82410-32-0, Gancyclovir
 113852-37-2, Cidofovir 114977-28-5, Docetaxel 120082-86-2
 127779-20-8, Saquinavir 129556-87-2, Adefovir diphosphate 129618-40-2,
 Nevirapine 134678-17-4, Lamivudine 136470-78-5, Abacavir
 136817-59-9, Delavirdine 139110-80-8, Zanamivir 142340-99-6, Adefovir
 dipivoxil 142937-65-3 143188-53-8, Lamivudine triphosphate
 145819-92-7, Emtricitabine triphosphate 150378-17-9, Indinavir
 154598-52-4, Efavirenz 155213-67-5, Ritonavir 159989-64-7, Nelfinavir
 161814-49-9, Amprenavir 196618-13-0, Oseltamivir 717854-15-4,
 Multinucleoside resistance A 717854-16-5, Multinucleoside resistance B
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(aminophospholipid-specific antibodies, immunoconjugates and
 duramycin-based compds. for treating and diagnosing cancer and viral
 infections)

IT 50-02-2, Dexamethasone 50-18-0, Cyclophosphamide 50-35-1,
 Thalidomide 50-76-0, Actinomycin D 51-21-8, Fluorouracil

53-06-5, Cortisone 53-79-2, Puromycin 55-86-7, Nitrogen
 mustard 57-22-7, Vincristine 59-05-2, Methotrexate 64-86-8,
 colchicine 66-22-8, Uracil 66-81-9, Cycloheximide 67-99-2,
 Aspergillin 145-63-1, Suramin 147-94-4, Cytarabine 148-82-3,
 Melphalan 305-03-3, Chlorambucil 362-07-2 477-30-5, Colcemid
 865-21-4, Vinblastine 1404-00-8, Mitomycin 1406-72-0, Restrictocin
 2998-57-4, Estramustine 4375-07-9, epipodophyllotoxin 7689-03-4,
 Camptothecin 9001-67-6D, Neuraminidase, antibody **conjugates**
 9001-78-9D, Alkaline phosphatase, antibody **conjugates**
 9001-99-4, Ribonuclease 9004-08-4D, Cathepsin, antibody
conjugates 9014-01-1D, Subtilisin, antibody **conjugates**
 9014-06-6D, Penicillin amidase, antibody **conjugates** 9015-68-3,
 L-Asparaginase 9016-17-5D, Arylsulfatase, antibody **conjugates**
 9025-05-2D, Cytosine deaminase, antibody **conjugates**
 9031-11-2D, β -Galactosidase, antibody **conjugates**
 9031-98-5D, Carboxypeptidase, antibody **conjugates** 9073-60-3D,
 antibody **conjugates** 9073-78-3D, Thermolysin, antibody
conjugates 10540-29-1, Tamoxifen 11056-06-7, Bleomycin
 15663-27-1, cisplatin 17902-23-7, Tegafur 20830-81-3, Daunorubicin
 21679-14-1, Fludarabine 23110-15-8, Fumagillin 23214-92-8, Doxorubicin
 25316-40-9, Adriamycin 29767-20-2, Teniposide 31441-78-8,
 Mercaptopurine 33069-62-4, Paclitaxel 33419-42-0, Etoposide
 37270-94-3, Platelet factor 4 56420-45-2, Epirubicin 62996-74-1,
 staurosporine 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide

70641-51-9, Edelfosine 74578-38-4, UFT 75037-46-6, Gelonin
 82855-09-2, Combretastatin 83150-76-9, Octreotide 84088-42-6, Linomide
 86090-08-6, Angiostatin 86243-64-3, α Sarcin 95058-81-4,
 Gemcitabine 97682-44-5, Irinotecan 98319-26-7, Finasteride
 112953-11-4, 7-Hydroxystaurosporine 123948-87-8, Topotecan
 129298-91-5, AGM-1470 146426-40-6, Flavopiridol 156511-34-1
 160141-09-3, L-744832 187888-07-9, Endostatin 188417-67-6, CM 101
 220127-57-1, STI571

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aminophospholipid-specific antibodies, immunoconjugates and
 duramycin-based compds. for treating and diagnosing cancer and viral
 infections)

IT 9034-40-6, LHRH

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antagonists; aminophospholipid-specific antibodies, immunoconjugates
 and duramycin-based compds. for treating and diagnosing cancer and
 viral infections)

IT 80449-01-0, topoisomerase 105913-11-9, Plasminogen activator
 124861-55-8, TIMP 2 140208-23-7 140208-24-8, TIMP 1 142243-03-6
 145809-21-8, TIMP 3 186207-03-4, TIMP 4

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; aminophospholipid-specific antibodies, immunoconjugates
 and duramycin-based compds. for treating and diagnosing cancer and
 viral infections)

IT 9068-38-6, Reverse transcriptase 144114-21-6, HIV protease

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (inhibitors; aminophospholipid-specific antibodies, immunoconjugates
 and duramycin-based compds. for treating and diagnosing cancer and
 viral infections)

IT 790789-25-2DP, humanized or chimeric derivs. and **conjugates**

790789-27-4DP, humanized or chimeric derivs. and **conjugates**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (nucleotide sequence; aminophospholipid-specific antibodies,
 immunoconjugates and duramycin-based compds. for treating and
 diagnosing cancer and viral infections)

IT 790794-10-4

RL: PRP (Properties)
 (unclaimed nucleotide sequence; aminophospholipid-specific antibodies,
 immunoconjugates and duramycin-based compds. for treating and
 diagnosing cancer and viral infections)

IT 790794-11-5

RL: PRP (Properties)
 (unclaimed protein sequence; aminophospholipid-specific antibodies,
 immunoconjugates and duramycin-based compds. for treating and
 diagnosing cancer and viral infections)

IT 650591-60-9 716329-62-3 790794-12-6

RL: PRP (Properties)
 (unclaimed sequence; aminophospholipid-specific antibodies,
 immunoconjugates and duramycin-based compds. for treating and
 diagnosing cancer and viral infections)


IT 50-02-2, Dexamethasone 53-06-5, Cortisone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aminophospholipid-specific antibodies, immunoconjugates and
 duramycin-based compds. for treating and diagnosing cancer and viral
 infections)

RN 50-02-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
(11 β ,16 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-06-5 HCAPLUS

CN Pregn-4-ene-3,11,20-trione, 17,21-dihydroxy- (7CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 2 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:877933 HCAPLUS

DN 141:365149

ED Entered STN: 22 Oct 2004

TI Anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation

IN Levanon, Avigdor; Ben-Levy, Rachel; Plaksin, Daniel; Szanton, Esther; Hagai, Yocheved; Mar-Chaim, Hagit Hoch

PA Israel

SO U.S. Pat. Appl. Publ., 49 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM C12Q001-68

ICS A61K039-395; C07K016-40

NCL 424146100; 530388260

CC 15-3 (Immunochemistry)

Section cross-reference(s): 1, 3, 8, 9, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004208877	A1	20041021	US 2003-611588	20030630

PRAI US 2002-393491P P 20020701

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004208877	ICM	C12Q001-68
	ICS	A61K039-395; C07K016-40
	NCL	424146100; 530388260
US 2004208877	ECLA	C07K016/28Z
AB	The present invention provides antibodies or fragments thereof that bind to cancer cells and are important in physiol. phenomena, such as cell rolling and metastasis. Therapeutic and diagnostic, prognostic or staging methods and compns. using such antibodies or fragments thereof are also provided. The methods and compns. according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, autoimmune disease, and inflammatory disease.	
ST	PSGL1 monoclonal antibody scFv fragment cancer metastasis autoimmune disease; inflammation leukemia cancer diagnosis therapy prognosis scFv antibody PSGL1	
IT	Leukemia (B-cell; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)	
IT	Antibodies and Immunoglobulins RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (IgG; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)	
IT	Glycoproteins RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (PSGL-1 (P-selectin glycoprotein ligand-1); anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)	
IT	Leukemia (T-cell, acute; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)	
IT	Leukemia (acute myelogenous; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)	
IT	Adhesion, biological Cell aggregation Leukemia Thrombosis (anti-; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)	
IT	Animal tissue culture Anti-inflammatory agents Antibacterial agents Anticoagulants Antitumor agents Antiviral agents Autoimmune disease Cardiovascular system, disease DNA sequences	

Drugs
 Epitopes
 Genetic vectors
 Human
 Imaging agents
 Immunotherapy
 Infection
 Inflammation
 Isotope indicators
 Molecular cloning
 Multiple myeloma
 Phage display library
 Prognosis
 Protein sequences
 Susceptibility (genetic)
 T cell (lymphocyte)
 Test kits
 (anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and
 therapy of cancer, metastasis, autoimmune disease and inflammation)
 IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and
 therapy of cancer, metastasis, autoimmune disease and inflammation)
 IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP
 (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and
 therapy of cancer, metastasis, autoimmune disease and inflammation)
 IT Anthracyclines
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and
 therapy of cancer, metastasis, autoimmune disease and inflammation)
 IT Infection
 (bacterial; anti-PSGL-1 antibodies and scFv fragments for diagnosis,
 prognosis and therapy of cancer, metastasis, autoimmune disease and
 inflammation)
 IT Drug delivery systems
 (carriers; anti-PSGL-1 antibodies and scFv fragments for diagnosis,
 prognosis and therapy of cancer, metastasis, autoimmune disease and
 inflammation)
 IT Cell migration
 (cell rolling; anti-PSGL-1 antibodies and scFv fragments for diagnosis,
 prognosis and therapy of cancer, metastasis, autoimmune disease and
 inflammation)
 IT Biology
 (cell, host; anti-PSGL-1 antibodies and scFv fragments for diagnosis,
 prognosis and therapy of cancer, metastasis, autoimmune disease and
 inflammation)
 IT Immunity
 (cell-mediated, antibody-dependent; anti-PSGL-1 antibodies and scFv
 fragments for diagnosis, prognosis and therapy of cancer, metastasis,
 autoimmune disease and inflammation)
 IT Leukemia
 (chronic B-lymphocytic; anti-PSGL-1 antibodies and scFv fragments for
 diagnosis, prognosis and therapy of cancer, metastasis, autoimmune
 disease and inflammation)
 IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
 (complexes; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)

IT Antibodies and Immunoglobulins
 Ricins
 Toxins
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**conjugates**; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)

IT Artery, disease
 (coronary, restenosis, anti-; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)

IT X-ray
 (emitters; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)

IT Carbohydrates, biological studies
 Glycolipids
 Glycoproteins
 Lipids, biological studies
 Lipopolysaccharides
 Lipoproteins
 Peptides, biological studies
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (epitope; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)

IT Pseudomonas
 (exotoxin; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)

IT Toxins
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (exotoxins, **conjugate**; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fragments, scFv; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (heavy chain, variable; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)

IT Diagnosis
 (immunodiagnosis; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)

IT Heart, disease

- (infarction; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Human immunodeficiency virus
 - (infection; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Antibodies and Immunoglobulins
 - RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (light chain, variable; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Polymers, biological studies
 - RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (lipophilic; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Drug delivery systems
 - (liposomes; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Conformation
 - (loop, protein; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Neoplasm
 - (metastasis, anti-; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Antibodies and Immunoglobulins
 - RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (monoclonal; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Lymphocyte
 - (natural killer cell; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Drug delivery systems
 - (polymer-bound; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Radionuclides, biological studies
 - RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (positron or X-ray emitters; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Molecular association
 - (protein-protein interaction, sulfated tyrosine-dependent; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Artery, disease
 - (restenosis, anti-; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)

- IT Eye, disease
(retinopathy; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Infection
(viral; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Radionuclides, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α emitters; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Interferons
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α ; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Radionuclides, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β emitters; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT Radionuclides, biological studies
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ emitters; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT 779371-02-7P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT 212783-20-5P 212783-31-8P 642928-14-1P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT 40704-75-4, N-(2-Hydroxypropyl)methacrylamide homopolymer 75037-46-6D, Gelonin, **conjugates**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and therapy of cancer, metastasis, autoimmune disease and inflammation)
- IT 50-18-0, Cyclophosphamide 50-35-1D, Thalidomide, derivs. 50-78-2, Aspirin **53-03-2D**, Prednisone, derivs. 53-86-1, Indomethacin 57-22-7D, Vincristine, derivs. 127-07-1D, Hydroxyurea, derivs. 147-94-4D, Cytarabine, derivs. 305-03-3D, Chlorambucil, derivs. 9004-54-0, Dextran, biological studies **9004-61-9**, **Hyaluronic acid** 9041-08-1, Dalteparin sodium 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90, biological studies 11056-06-7D, Bleomycin, derivs. 13968-53-1, Ruthenium-103,

biological studies 13981-56-1, Fluorine-18, biological studies
 13982-78-0, Mercury-203, biological studies 14041-48-6, Thulium-165,
 biological studies 14119-09-6, Gallium-67, biological studies
 14158-32-8, Iodine-126, biological studies 14191-71-0, Indium-115,
 biological studies 14331-95-4, Ruthenium-105, biological studies
 14390-71-7, Tellurium-122, biological studies 14391-22-1, Thulium-167,
 biological studies 14834-67-4, Iodine-133, biological studies
 14885-78-0, Indium-113, biological studies 14900-13-1, Thulium-168,
 biological studies 14932-42-4, Xenon-133, biological studies
 15307-86-5, Diclofenac 15663-27-1D, cis-Platinum, derivs. 15687-27-1,
 Ibuprofen 15715-08-9, Iodine-123, biological studies 15756-62-4,
 Ruthenium-95, biological studies 15757-14-9, Gallium-68, biological
 studies 15758-35-7, Ruthenium-97, biological studies 15765-39-6,
 Bromine-77, biological studies 15776-20-2, Bismuth-213, biological
 studies 20830-81-3D, Daunorubicin, derivs. 21679-14-1D, Fludarabine,
 derivs. 22204-53-1, Naproxen 23214-92-8D, Doxorubicin, derivs.
 30516-87-1, Zidovudine 33069-62-4D, Taxol, derivs. 33455-08-2,
 Mercury-207, biological studies 35014-81-4, Rhenium-199, biological
 studies 38194-50-2, Sulindac 39472-31-6D, Carminomycin, derivs.
 51146-56-6, Dexibuprofen 51692-52-5, Rhenium-201, biological studies
 51692-56-9, Rhenium-205, biological studies 51803-78-2, Nimesulide
 52549-17-4, Pranoprofen 56420-45-2D, Epirubicin, derivs. 58957-92-9D,
 Idarubicin, derivs. 59277-89-3, Acyclovir 63521-85-7D, Esorubicin,
 derivs. 66211-92-5D, Detorubicin, derivs. 73963-72-1, Cilostazol
 74397-12-9, Limaprost 74711-43-6, Zaltoprofen 75706-12-6, Leflunomide
 79867-78-0D, Morphinodaunorubicin, derivs. 80790-68-7D,
 Morphinodoxorubicin, derivs. 82410-32-0, Ganciclovir 83712-60-1,
 Defibrotide 85622-93-1D, Temozolomide, derivs. 87344-06-7, Amtolmetin
 guacil 90101-16-9, Droxicam 108852-90-0D,
 Methoxymorpholinyl-doxorubicin, derivs. 113440-58-7D, Calicheamicin,
 derivs. 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 173146-27-5,
 Denileukin diftitox 262423-20-1, Subreum 378253-17-9, Krypton-81m,
 biological studies 378784-45-3, Technetium-99m, biological studies
 378784-46-4, Tellurium-121m, biological studies 378784-50-0,
 Tellurium-125m, biological studies 425603-01-6, WinRho SDF
 640734-07-2, Clorcromene

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and
 therapy of cancer, metastasis, autoimmune disease and inflammation)

IT 12585-85-2, Positron

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)

(emitters; anti-PSGL-1 antibodies and scFv fragments for diagnosis,
 prognosis and therapy of cancer, metastasis, autoimmune disease and
 inflammation)

IT 956-46-7, L-Tyrosine O-sulfate

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (motif; anti-PSGL-1 antibodies and scFv fragments for diagnosis,
 prognosis and therapy of cancer, metastasis, autoimmune disease and
 inflammation)


IT	145646-22-6	212783-21-6	330163-86-5	442527-56-2	442527-66-4
	442527-67-5	442528-29-2	442528-31-6	485815-21-2	640723-99-5
	640724-08-9	642928-16-3	642928-17-4	642928-18-5	779332-25-1
	779371-78-7	779371-79-8			

RL: PRP (Properties)

(unclaimed sequence; anti-PSGL-1 antibodies and scFv fragments for
 diagnosis, prognosis and therapy of cancer, metastasis, autoimmune
 disease and inflammation)

IT 53-03-2D, Prednisone, derivs. 9004-61-9,
Hyaluronic acid
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (anti-PSGL-1 antibodies and scFv fragments for diagnosis, prognosis and
 therapy of cancer, metastasis, autoimmune disease and inflammation)
 RN 53-03-2 HCAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- (8CI, 9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 9004-61-9 HCAPLUS
 CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L46 ANSWER 3 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:856929 HCAPLUS
 DN 141:348831
 ED Entered STN: 18 Oct 2004
 TI Antibodies specific to epitopes involving cell rolling, metastasis and
 inflammation for treatment of tumor, restenosis, thrombosis, autoimmune
 disease and inflammation
 IN Lazarovits, Janette; Nimrod, Abraham; Hoch, Mar-Chaim Hagit; Levanon,
 Avigdor
 PA Israel
 SO U.S. Pat. Appl. Publ., 22 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K039-395
 NCL 424178100
 CC 15-3 (Immunochemistry)
 Section cross-reference(s): 1, 3

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	US 2004202665	A1	20041014	US 2003-610843	20030630
PRAI	US 2002-393453P	P	20020701		

PATENT NO.		CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004202665	ICM	A61K039-395	
	NCL	424178100	

AB The present invention relates to compns. utilizing an agent and an

antibody, or fragment thereof. In these compns., the agents, including agents such as anti-cancer, anti-metastasis, anti-leukemia, anti-disease, anti-adhesion, anti-thrombosis, anti-restenosis, anti-autoimmune, anti-aggregation, anti-bacterial, anti-viral, and anti-inflammatory agents, can be complexed or combined with or **conjugated** to the antibodies, or fragments thereof. In addition, the agent and/or the antibody, or fragment thereof, can be present in the composition in a sub-clin. amount, which is an amount that is less than the amount of the agent generally found to be clin. effective when the agent is administered alone. Preferably, in these compns. of the present invention, the agent is an anthracycline or a derivative thereof, e.g., doxorubicin (adriamycin) or a derivative thereof. The invention provides the protein sequence of human anti-platelet single chain antibodies.

- ST antibody sulfated tyrosine epitope cell rolling metastasis inflammation autoimmune; restenosis thrombosis immunotherapy antibody; human anti platelet single chain antibody sequence
- IT Platelet (blood)
 (-matrix, -platelet, -cell complex formation, inhibiting; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Leukemia
 (B-cell, treatment of; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Complement
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CC4, **conjugated** or complexed with antibody; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Glycoproteins
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (GPIb, α , **conjugated** or complexed with antibody; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Glycoproteins
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (PSGL-1 (P-selectin glycoprotein ligand-1), **conjugated** or complexed with antibody; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Leukemia
 (acute myelogenous, treatment of; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Anti-inflammatory agents
 Antibacterial agents
 Anticoagulants
 Antitumor agents
 Antiviral agents
 Epitopes
 Human
 Immunoradiotherapy
 Immunotherapy

X-ray
 (antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT Polyoxyalkylenes, biological studies
 Radionuclides, biological studies
 Ricins
 Toxins
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT Drug delivery systems
 (carriers; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT Cell migration
 (cell rolling; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT Leukemia
 (chronic B-lymphocytic, treatment of; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT Pseudomonas
 (exotoxin; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT Toxins
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (exotoxins, PE40 and PE38; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT Anthracyclines
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (for therapy; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT Antibodies and Immunoglobulins
 RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fragments; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT Drug delivery systems
 (immunoconjugates; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT Drug delivery systems
 (immunotoxins; antibodies specific to epitopes involving cell rolling,

- metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Adhesion, biological
(inhibition of; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Polymers, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipophilic and hydrophilic; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Drug delivery systems
(liposomes; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Proteoglycans, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lumicans, **conjugated** or complexed with antibody; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Neoplasm
(metastasis, treatment of; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Protein sequences
(of human antibodies; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Sulfation
(of tyrosine; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Cell aggregation
(platelet, inhibition of; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Drug delivery systems
(polymer-bound; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Artery, disease
(restenosis, treatment of; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(single chain; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

- IT Protein motifs
(sulfated L-tyrosine; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Autoimmune disease
Inflammation
Leukemia
Multiple myeloma
Neoplasm
Thrombosis
(treatment of; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Cell proliferation
(tumor, inhibition of; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Radionuclides, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α emitters, for radiotherapy; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Interferons
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α , for therapy; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Radionuclides, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β emitters, for radiotherapy; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Radionuclides, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ emitters, for radiotherapy; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT Fibrinogens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ' , **conjugated** or complexed with antibody; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT 21442-01-3, N-(2-Hydroxypropyl)methacrylamide
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HPMA, based drug delivery; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT 774612-27-0 774612-28-1 774612-29-2
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor,

- restenosis, thrombosis, autoimmune disease and inflammation)
- IT 50-18-0D, Cyclophosphamide, **conjugated** or complexed with antibody 50-78-2D, Aspirin, **conjugated** or complexed with antibody 53-86-1D, Indomethacin, **conjugated** or complexed with antibody 60-18-4D, Tyrosine, sulfated derivative 9001-26-7D, Prothrombin, **conjugated** or complexed with antibody 9004-61-9D, **Hyaluronic acid.**, **conjugated** or complexed with antibody 9005-49-6D, Heparin, **conjugated** or complexed with antibody 9041-08-1D, Dalteparin sodium, **conjugated** or complexed with antibody 15307-86-5D, Diclofenac, **conjugated** or complexed with antibody 15687-27-1D, Ibuprofen, **conjugated** or complexed with antibody 22204-53-1D, Naproxen, **conjugated** or complexed with antibody 30516-87-1D, Zidovudine, **conjugated** or complexed with antibody 38194-50-2D, Sulindac, **conjugated** or complexed with antibody 51146-56-6D, Dexibuprofen, **conjugated** or complexed with antibody 51803-78-2D, Nimesulide, **conjugated** or complexed with antibody 52549-17-4D, Pranoprofen, **conjugated** or complexed with antibody 59277-89-3D, Acyclovir, **conjugated** or complexed with antibody 73963-72-1D, Cilostazol, **conjugated** or complexed with antibody 74397-12-9D, Limaprost, **conjugated** or complexed with antibody 74711-43-6D, Zaltoprofen, **conjugated** or complexed with antibody 75706-12-6D, Leflunomide, **conjugated** or complexed with antibody 82410-32-0D, Ganciclovir, **conjugated** or complexed with antibody 83712-60-1D, Defibrotide, **conjugated** or complexed with antibody 87344-06-7D, Amtolmetin guacil, **conjugated** or complexed with antibody 90101-16-9D, Droxicam, **conjugated** or complexed with antibody 162011-90-7D, Rofecoxib, **conjugated** or complexed with antibody 169590-42-5D, Celecoxib, **conjugated** or complexed with antibody 173146-27-5D, Denileukin diftiox, **conjugated** or complexed with antibody 262423-20-1D, Subreum, **conjugated** or complexed with antibody 425603-01-6D, WinRho SDF, **conjugated** or complexed with antibody 640734-07-2D, Clorcromene, **conjugated** or complexed with antibody
- RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT 212783-20-5 268723-76-8 442527-61-9
- RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (antibody CDR1 region; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT 642928-14-1
- RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (antibody CDR2 region; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT 212783-31-8
- RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (antibody CDR3 region; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)
- IT 9004-54-0, Dextran, biological studies 25322-68-3, Polyethylene glycol
- RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(drug delivery; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT 10043-66-0, Iodine131, biological studies 10098-91-6, Yttrium90, biological studies 12585-85-2, Positron 13968-53-1, Ruthenium103, biological studies 13981-51-6, Mercury197, biological studies 13981-56-1, Fluorine18, biological studies 13982-78-0, Mercury203, biological studies 14041-48-6, Thulium165, biological studies 14119-09-6, Gallium67, biological studies 14133-76-7, Technetium99, biological studies 14158-32-8, Iodine126, biological studies 14304-79-1, Tellurium121, biological studies 14331-95-4, Ruthenium105, biological studies 14378-53-1, Rh 101, biological studies 14390-71-7, Tellurium122, biological studies 14390-73-9, Tellurium125, biological studies 14391-22-1, Thulium167, biological studies 14834-67-4, Iodine133, biological studies 14885-78-0, Indium113, biological studies 14900-13-1, Thulium168, biological studies 14913-89-4, Rh 105, biological studies 14932-42-4, Xe 133, biological studies 15678-91-8, Krypton81, biological studies 15715-08-9, Iodine123, biological studies 15750-15-9, Indium111, biological studies 15756-62-4, Ruthenium95, biological studies 15757-14-9, Gallium68, biological studies 15758-35-7, Ruthenium97, biological studies 15765-39-6, Bromine77, biological studies 15765-79-4, Rh 99, biological studies 15776-20-2, Bismuth213, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(for radiotherapy; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT 50-18-0, Cyclophosphamide 50-35-1, Thalidomide 53-03-2, Prednisone 57-22-7, Vincristine 127-07-1, Hydroxyurea 147-94-4, Cytarabine 305-03-3, Chlorambucil 11056-06-7, Bleomycin 15663-27-1, cis-Platinum 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 33069-62-4, Taxol 58957-92-9, Idarubicin 79867-78-0, Morpholinodaunorubicin 80790-68-7, Morpholinodoxorubicin 85622-93-1, Temozolomide 108852-90-0, Methoxymorpholinylodoxorubicin 113440-58-7, Calicheamicin

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(for therapy; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

IT **9004-61-9D, Hyaluronic acid., conjugated or complexed with antibody**

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

RN 9004-61-9 HCAPLUS

CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **53-03-2, Prednisone**


RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(for therapy; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for treatment of tumor, restenosis, thrombosis, autoimmune disease and inflammation)

RN 53-03-2 HCAPLUS

CN Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 4 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:802607 HCAPLUS
 DN 141:312949
 ED Entered STN: 01 Oct 2004
 TI Anti-CD22 antibodies **conjugated** with cytotoxic drug for treating
 cancer, carcinoma, sarcoma and B cell lymphoma/leukemia
 IN Kunz, Arthur; Moran, Justin Keith; Rubino, Joseph Thomas; Jain, Neera;
 Vidunas, Eugene Joseph; Simpson, John Mclean; Merchant, Nishith; Dijoseph,
 John Francis; Ruppen, Mark Edward; Damle, Nitin Krishnaji; Robbins, Paul
 David; Popplewell, Andrew George
 PA Wyeth Holdings Corporation, USA
 SO U.S. Pat. Appl. Publ., 90 pp., Cont.-in-part of U.S. Ser. No. 428,894.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM C07K016-46
 ICS C07K014-47
 NCL 530391100; 530403000; 530409000
 CC 15-3 (Immunochemistry)
 Section cross-reference(s): 3, 9, 63
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004192900	A1	20040930	US 2003-699874	20031103
	US 2004082764	A1	20040429	US 2003-428894	20030502
PRAI	US 2002-377440P	P	20020502		
	US 2003-428894	A2	20030502		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004192900	ICM	C07K016-46
	ICS	C07K014-47
	NCL	530391100; 530403000; 530409000
US 2004192900	ECLA	A61K041/00; A61K041/00W; A61K047/48T2C8H; A61K047/48T4B28

AB Methods for preparing monomeric cytotoxic drug/carrier **conjugates** with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low **conjugate** fraction (LCF) are described. Cytotoxic drug derivative/antibody **conjugates**, compns. comprising the **conjugates** and uses

of the **conjugates** are also described. Monomeric calicheamicin derivative/anti-CD22 antibody **conjugates**, compns. comprising the **conjugates** and uses of the **conjugates** are also

described. The anti-CD22 antibody is a monoclonal antibody, human antibody, chimeric antibody, humanized antibody or fragment. The cytotoxic drug is a calicheamicin, thiotepa, taxane, vincristine, daunorubicin, doxorubicin, epirubicin, esperamicin, actinomycin, anthramycin, azaserine, bleomycin, tamoxifen, idarubicin, etc.

ST cytotoxic drug antibody CD22 immunoconjugate carcinoma sarcoma cancer therapy; B cell lymphoma leukemia calicheamicin deriv antibody **conjugate**

IT Leukemia

Lymphoma

(B-cell; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT CD antigens

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CD33; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Fatty acids, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(C6-18, salts as additive; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Anion exchange liquid chromatography

(FPLC or fast protein liquid chromatog.; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Carbohydrates, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(aldonic acids; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Carbohydrates, biological studies

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(aldoses; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Carbohydrates, biological studies

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(amino sugars; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Hormones, animal, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antagonists; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Alkylating agents, biological

Antitumor agents

Buffers

Carcinoma

Chromatography

Combination chemotherapy

Cryoprotectants
 Cytotoxic agents
 DNA sequences
 Genetic engineering
 HPLC
 Human
 Hydrophobic interaction chromatography
 Liquid chromatographic stationary phases
 Molecular cloning
 Neoplasm
 Protein sequences
 Sarcoma
 Size-exclusion chromatography
 Solubilizers
 Surfactants

(anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for
 treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Alditols

RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for
 treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT CD19 (antigen)

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for
 treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT CD20 (antigen)

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for
 treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT CD22 (antigen)

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for
 treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Interferons

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for
 treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Interleukin 2

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for
 treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Interleukins

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for
 treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Tumor necrosis factors

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Keratins
 Lactones
 Pentoses
 Polyoxyalkylenes, biological studies
 Uronic acids
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Peptidomimetics
 (antibody; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Linking agents
 (bifunctional or hydrolyzable; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Polymerization
 (biochem., tubulin; inhibitors; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Polymers, biological studies
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (bulking agent; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Reagents
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (bulking; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Antibodies and Immunoglobulins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (chimeric; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Estrogens
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**conjugated**; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Antibodies and Immunoglobulins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (**conjugates**; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Androgens
Corticosteroids, biological studies
 Growth factors, animal

Hormones, animal, biological studies

Progestogens

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(conjugates; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Drugs

(cytotoxic; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT B cell (lymphocyte)

(disease, malignancy; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT DNA

RL: BSU (Biological study, unclassified); BIOL (Biological study) (disruption; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (engineering; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Drug delivery systems

(enteric; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (fragments; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Drug delivery systems

Drug delivery systems

(freeze-dried; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (heavy chain; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Steroids, biological studies

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hormones; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (humanized; anti-CD22 antibodies **conjugated** with cytotoxic

- drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Drug delivery systems
(immunoconjugates; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Translation, genetic
(inhibitors; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Drug delivery systems
(injections, i.a.; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Drug delivery systems
(injections, i.p.; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Drug delivery systems
(injections, i.v.; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Drug delivery systems
(injections, s.c.; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Drug delivery systems
(intramedullary; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Drug delivery systems
(intrathecal; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Monosaccharides
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ketoses; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(light chain; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Affinity
(maturation; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(monoclonal; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT Drug delivery systems
(nasal, intra-; anti-CD22 antibodies **conjugated** with

cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Lymphoma
(non-Hodgkin's; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Solvents
(organic, co-; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Tubulins
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymerization inhibitors; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Disease, animal
(proliferative; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Drug delivery systems
(rectal; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Drug delivery systems
(solns.; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Drug delivery systems
(sublingual; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Animal cell
(target; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Drug delivery systems
(topical; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Drug delivery systems
(transcutaneous; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Drug delivery systems
(transdermal; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT Drug delivery systems
(vaginal; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT 635715-01-4, CMC 544
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CMC 544; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT 765780-67-4DP, humanized deivs. and **conjugates** 765831-50-3P
765831-51-4P 765831-53-6P 765831-54-7P 765831-55-8P 765831-56-9P
765831-57-0P 765831-58-1P 765831-59-2P 765831-60-5DP, humanized deivs. and **conjugates**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

- (amino acid sequence; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT 124-07-2D, Octanoic acid, salts 334-48-5D, Decanoic acid, salts 65623-82-7D, 4-(4-Acetylphenoxy)butanoic acid, salts
 RL: BSU (Biological study, unclassified); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT 335197-32-5 369632-97-3 369632-98-4 623141-79-7 623141-80-0 623141-81-1
 RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)
- IT 50-02-2D, Dexamethasone, **conjugates** 50-18-0D, Cyclophosphamide, **conjugates** 50-91-9D, Floxuridine, **conjugates** 51-21-8D, Fluorouracil, derivs. and **conjugates** 51-75-2D, Mechlorethamine, **conjugates** 52-24-4D, Thiotepea, **conjugates** 53-03-2D, Prednisone, **conjugates** 53-79-2D, Puromycin, **conjugates** 57-22-7D, Vincristine, **conjugates** 58-05-9D, Leucovorin, **conjugates** 59-05-2D, Methotrexate, **conjugates** 59-14-3D, Broxuridine, **conjugates** 69-89-6D, Xanthine, derivs. and **conjugates** 70-00-8D, Trifluridine, **conjugates** 83-43-2D, Methylprednisolone, **conjugates** 115-02-6D, Azaserine, derivs. and **conjugates** 147-94-4D, Cytarabine, **conjugates** 305-03-3D, Chlorambucil, **conjugates** 320-67-2D, Azacitidine, **conjugates** 671-16-9D, Procarbazine, **conjugates** 865-21-4D, Vinblastine, **conjugates** 1402-38-6D, Actinomycin, **conjugates** 1404-00-8D, Mitomycin, **conjugates** 1404-15-5D, Nogalamycin, **conjugates** 1605-68-1D, Taxane, derivs. and **conjugates** 2096-42-6D, Gougerotin, **conjugates** 2353-33-5D, Decitabine, **conjugates** 3094-09-5D, Doxifluridine, **conjugates** 3778-73-2D, Ifosfamide, **conjugates** 4291-63-8D, Cladribine, **conjugates** 4342-03-4D, Dacarbazine, **conjugates** 4803-27-4D, Anthramycin, **conjugates** 10540-29-1D, Tamoxifen, **conjugates** 11056-06-7D, Bleomycin, derivs. and **conjugates** 13010-47-4D, Lomustine, **conjugates** 15663-27-1D, Cisplatin, **conjugates** 17902-23-7D, Tegafur, **conjugates** 20830-81-3D, Daunorubicin, **conjugates** 21679-14-1D, Fludarabine, **conjugates** 23214-92-8D, Doxorubicin, **conjugates** 25316-40-9D, Adriamycin, **conjugates** 31698-14-3D, Ancitabine, **conjugates** 33069-62-4D, Taxol, analogs and **conjugates** 33419-42-0D, Etoposide, **conjugates** 35846-53-8D, Maytansin, derivs. 41575-94-4D, Carboplatin, **conjugates** 50935-04-1D, Carubicin, **conjugates** 53910-25-1D, Pentostatin, **conjugates** 54083-22-6D, Zorubicin, **conjugates** 55726-47-1D, Enocitabine, **conjugates** 56124-62-0D, Valrubicin, **conjugates** 56420-45-2D, Epirubicin, **conjugates** 57576-44-0D, Aclarubicin, **conjugates** 58957-92-9D, Idarubicin, **conjugates** 60084-10-8D, Tiazofurin, **conjugates** 62683-29-8D, Colony-stimulating factor, **conjugates** 65271-80-9D, Mitoxantrone, **conjugates** 71628-96-1D, Menogaril, **conjugates** 79394-15-3D, Dolastatin 1, derivs. and **conjugates** 83869-56-1D, GM-CSF, **conjugates** 95058-81-4D, Gemcitabine, **conjugates** 108212-75-5D,

Calicheamicin γ 1, **conjugates** 108212-76-6D,
 N-Acetyl- γ -calicheamicin, **conjugates** 113440-58-7D,
 Calicheamicin, derivs and **conjugates** 114797-28-3D,
 Esperamicin, derivs. and **conjugates** 138441-31-3D,
conjugates 143011-72-7D, G-CSF, **conjugates**
 154361-50-9D, Capecitabine, **conjugates** 157207-90-4D,
 Hemiasterlin, derivs. and **conjugates** 160800-57-7D, Auristatin
 E, derivs. and **conjugates** 174722-31-7D, Rituximab,
conjugates

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(anti-CD22 antibodies **conjugated** with cytotoxic drug for
 treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT 50-69-1, Ribose 50-70-4, Sorbitol, biological studies 50-81-7,
 Ascorbic acid, biological studies 50-99-7, Glucose, biological studies
 56-81-5, Glycerol, biological studies 56-82-6D, Glyceraldehyde, derivs.
 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological
 studies 58-86-6, Xylose, biological studies 59-23-4, Galactose,
 biological studies 63-42-3, Lactose 65-42-9, Lyxose 69-65-8,
 Mannitol 69-79-4, Maltose 77-86-1, Tromethamine 87-79-6, Sorbose
 87-89-8, Inositol 89-65-6, Isoascorbic acid 97-30-3, Methyl
 α -glucopyranoside 99-20-7, Trehalose 107-21-1, Ethylene glycol,
 biological studies 114-04-5, Neuraminic acid 115-77-5,
 Pentaerythritol, biological studies 147-81-9, Arabinose 526-95-4,
 Gluconic acid 551-84-8, Xylulose 685-73-4, Galacturonic acid
 1398-61-4, Chitin 1758-51-6, Erythrose 2152-76-3, Idose 3416-24-8,
 Glucosamine 3458-28-4, Mannose 5556-48-9, Ribulose 5987-68-8,
 Altrose 6038-51-3, Allose 6556-12-3, Glucuronic acid 6814-36-4,
 Mannuronic acid 7535-00-4, Galactosamine 7647-14-5, Sodium chloride,
 biological studies 9000-07-1, Carrageenan 9000-69-5, Pectin
 9004-34-6, Cellulose, biological studies 9004-54-0, Dextran, biological
 studies **9004-61-9**, Hyaluronic acid 9005-25-8,
 Starch, biological studies 9005-32-7, Alginic acid 9005-65-6,
 Polysorbate 80 9005-79-2, Glycogen, biological studies 9005-82-7,
 Amylose 9007-27-6, Chondroitin 9012-36-6, Agarose 9012-72-0, Glucan
 9013-95-0, Levan 9014-63-5D, Xylan, derivs. 9036-88-8D, Mannan,
 derivs. 9037-22-3, Amylopectin 9037-55-2D, Galactan, derivs.
 9037-90-5D, Fructan, derivs. 9046-38-2D, Galacturonan, derivs.
 9046-40-6D, Pectic acid, derivs. 9057-02-7, Pullulan 9060-75-7D,
 Arabinan, derivs. 9072-19-9, Fucoidan 11138-66-2, Xanthan gum
 17598-81-1, Tagatose 19163-87-2, Gulose 23140-52-5, Psicose
 25322-68-3, Polyethylene glycol 25322-69-4, Polypropylene glycol
 25525-21-7, Glucaric acid 29884-64-8, Threose 30077-17-9, Talose
 37331-28-5, Pustulan 40031-31-0, Erythrulose 60495-58-1,
 Galactocarolose 64612-25-5D, Fucan, derivs. 71927-65-6, Heptose
 75634-40-1, Dermatan 93780-23-5, Hexose

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)

(anti-CD22 antibodies **conjugated** with cytotoxic drug for
 treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT 65546-95-4, Sephacryl S-200 122985-81-3, Toyopearl 650M 157885-28-4,
 Butyl Sepharose 4FF 204784-37-2, Octyl Sepharose 4 Fast Flow
 204784-38-3, Phenyl Sepharose 6 Fast Flow 507453-58-9, Macro-Prep
 t-Butyl 507453-59-0, Macro-Prep methyl

RL: BUU (Biological use, unclassified); DEV (Device component use); BIOL
 (Biological study); USES (Uses)

(anti-CD22 antibodies **conjugated** with cytotoxic drug for
 treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT 80449-02-1, Tyrosine kinase

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibitors; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT 765831-49-0P 765831-52-5P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(nucleotide sequence; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT 765831-98-9 765831-99-0 765832-00-6 765832-01-7 765832-02-8

765832-03-9 765832-04-0 765832-05-1 765832-06-2 765832-07-3

765832-08-4 765832-09-5 765832-10-8 765832-11-9 765832-12-0

765832-13-1 765832-14-2 765832-15-3 765832-16-4 765832-17-5

RL: PRP (Properties)

(unclaimed nucleotide sequence; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT 765831-96-7 765831-97-8

RL: PRP (Properties)

(unclaimed protein sequence; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT 145061-00-3 380648-61-3 623141-82-2 623141-83-3 623141-84-4

623901-97-3 623901-98-4 623901-99-5 623902-00-1 623902-01-2

RL: PRP (Properties)

(unclaimed sequence; anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

IT 50-02-2D, Dexamethasone, **conjugates** 53-03-2D,

Prednisone, **conjugates** 83-43-2D, Methylprednisolone,

conjugates


RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anti-CD22 antibodies **conjugated** with cytotoxic drug for treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

RN 50-02-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 53-03-2 HCAPLUS

CN Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- (8CI, 9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 83-43-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-,
(6 α ,11 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 9004-61-9, **Hyaluronic acid**RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)(anti-CD22 antibodies **conjugated** with cytotoxic drug for
treating cancer, carcinoma, sarcoma and B cell lymphoma/leukemia)

RN 9004-61-9 HCAPLUS

CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L46 ANSWER 5 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:182656 HCAPLUS

DN 140:193853

ED Entered STN: 05 Mar 2004

TI Preparation of **corticosteroid conjugates** and
therapeutic uses thereof as anti-inflammatory agentsIN **Teicher, Martin H.; Andersen-Navalta, Susan L.**

PA The McLean Hospital Corporation, USA

SO PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DT Patent

LA English
 IC ICM A61K
 CC 2-4 (Mammalian Hormones)
 Section cross-reference(s): 32

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004017904	A2	20040304	WO 2003-US26233	20030822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004157810	A1	20040812	US 2003-646063	20030822
PRAI	US 2002-405688P	P	20020823		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2004017904	ICM	A61K
OS	MARPAT 140:193853		
AB	The invention features corticosteroids conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage, the resulting conjugate is a peripherally acting steroid with reduced activity in the central nervous system . The invention provides a method for treating a patient having an inflammatory disease by administering to the patient a corticosteroid conjugate		
ST	corticosteroid conjugate synthesis		
	antiinflammatory autoimmune disease		
IT	Cations (-derived corticosteroid ; preparation of corticosteroid conjugates and therapeutic uses thereof as anti- inflammatory agents)		
IT	Glycoproteins Peptides, reactions Polymers, reactions Polyoxyalkylenes, reactions Polysaccharides, reactions α 1-Acid glycoprotein RL: RCT (Reactant); RACT (Reactant or reagent) (-derived corticosteroid ; preparation of corticosteroid conjugates and therapeutic uses thereof as anti- inflammatory agents)		
IT	Intestine, disease (Crohn's; preparation of corticosteroid conjugates and therapeutic uses thereof as anti- inflammatory agents)		
IT	Kidney, disease (Goodpasture's syndrome; preparation of corticosteroid conjugates and therapeutic uses thereof as anti- inflammatory agents)		
IT	Blood vessel, disease (Raynaud's phenomenon; preparation of corticosteroid conjugates and therapeutic uses thereof as anti-		

- inflammatory agents)
- IT Respiratory distress syndrome
(adult; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Anemia (disease)
(autoimmune hemolytic anemia; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Thyroid gland, disease
(autoimmune thyroiditis; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Nervous system
(central, reduced activity of the **corticosteroid** derivative in; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Corticosteroids, biological studies
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**conjugates** and derivs.; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Liver
(**corticosteroid conjugates**-induced tyrosine aminotransferase activity; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Tendon
(disease, tendinitis; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Thymus gland
(effect of **corticosteroid conjugates** treatment on; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Intestine, disease
(enterocolitis, necrotizing; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Kidney, disease
(glomerulonephritis; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Transplant and Transplantation
(graft-vs.-host reaction; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Liver
(hepatocyte, **corticosteroid conjugates**-induced tyrosine aminotransferase activity; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Lung, disease
(hypersensitivity pneumonitis; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Addison's disease
(idiopathic; preparation of **corticosteroid conjugates**

- and therapeutic uses thereof as anti-inflammatory agents)
- IT Blood-brain barrier
 - (inhibited passage of corticosteroid conjugate;
 - preparation of corticosteroid conjugates and therapeutic
 - uses thereof as anti-inflammatory agents)
- IT Diabetes mellitus
 - (insulin-dependent; preparation of corticosteroid
 - conjugates and therapeutic uses thereof as anti-
 - inflammatory agents)
- IT Connective tissue, disease
 - (mixed connective tissue disease; preparation of corticosteroid
 - conjugates and therapeutic uses thereof as anti-
 - inflammatory agents)
- IT Toxicity
 - (neurotoxicity, corticosteroid conjugates-induced;
 - preparation of corticosteroid conjugates and therapeutic
 - uses thereof as anti-inflammatory agents)
- IT Toxicity
 - (oxygen; preparation of corticosteroid conjugates and
 - therapeutic uses thereof as anti-inflammatory agents)
- IT Biological transport
 - (permeation, blood-brain barrier, inhibited passage of
 - corticosteroid conjugate; preparation of
 - corticosteroid conjugates and therapeutic uses
 - thereof as anti-inflammatory agents)
- IT Anions
 - (polyvalent, -derived corticosteroid; preparation of
 - corticosteroid conjugates and therapeutic uses
 - thereof as anti-inflammatory agents)
- IT Anti-inflammatory agents
 - Antiarthritics
 - Antiasthmatics
 - Antidiabetic agents
 - Antirheumatic agents
 - Asthma
 - Autoimmune disease
 - Dermatitis
 - Eczema
 - Encephalomyelitis
 - Graves' disease
 - Human
 - Inflammation
 - Lupus erythematosus
 - Meningitis
 - Multiple sclerosis
 - Psoriasis
 - Rheumatoid arthritis
 - Shock (circulatory collapse)
 - Sjogren's syndrome
 - Skin preparations (pharmaceutical)
 - Transplant rejection
 - Urticaria
 - (preparation of corticosteroid conjugates and
 - therapeutic uses thereof as anti-inflammatory agents)
- IT Arthritis
 - (reactive; preparation of corticosteroid conjugates and
 - therapeutic uses thereof as anti-inflammatory agents)
- IT Purpura (disease)
 - (thrombocytopenic, autoimmune; preparation of corticosteroid

- conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Nerve
(toxicity, **corticosteroid conjugates**-induced; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Intestine, disease
(ulcerative colitis; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Eye, disease
(uveitis; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT Blood vessel, disease
(vasculitis; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT 9004-61-9, Hyaluronic acid 25322-68-3, Polyethylene glycol
RL: RCT (Reactant); RACT (Reactant or reagent)
(-derived **corticosteroid**; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT 9014-55-5, Tyrosine aminotransferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(liver activity, **corticosteroid conjugates**-induce; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT 50-24-8DP, Prednisolone, C21 and polyguanidine peptoid derivs. 124-94-7DP, Triamcinolone, C16-C17 cyclic acetals and hyaluronic acid conjugates 51333-22-3DP, Budesonide, mPEG conjugates 663178-13-0P 663178-15-2P 663178-16-3P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT 35410-28-7 105702-59-8
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT 50-24-8, Prednisolone 108-24-7, Acetic anhydride 124-94-7, Triamcinolone 144-62-7, Oxalic acid, reactions 693-23-2D, 1,10-Decanedicarboxylic acid, bis activated ester 4023-02-3, 1H-Pyrazole-1-carboxamide hydrochloride 4419-39-0, Beclomethasone 51333-22-3, Budesonide 115446-51-0 152120-54-2, 1H-Pyrazole-1-[N,N'-bis(tert-butoxycarbonyl)carboxamide] 152120-55-3 174569-25-6 663178-12-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT 663178-14-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)
- IT 50-22-6, Corticosterone
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(suppression following treatment; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)

IT 7782-44-7, Oxygen, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (toxicity; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)

IT 9004-61-9, Hyaluronic acid

RL: RCT (Reactant); RACT (Reactant or reagent) (-derived **corticosteroid**; preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)

RN 9004-61-9 HCAPLUS

CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 50-24-8DP, Prednisolone, C21 and polyguanidine peptoid derivs.

124-94-7DP, Triamcinolone, C16-C17 cyclic acetals and

hyaluronic acid **conjugates** 51333-22-3DP,

Budesonide, mPEG **conjugates** 663178-13-0P

663178-15-2P 663178-16-3P


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of **corticosteroid conjugates** and therapeutic uses thereof as anti-inflammatory agents)

RN 50-24-8 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 124-94-7 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11 β ,16 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51333-22-3 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-,
(11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 663178-13-0 HCAPLUS


CN Glycinamide, N-[(11 β)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl]-2-oxoglycyl-6-aminohexanoyl-N-[6-[(aminoiminomethyl)amino]hexyl]glycyl-N-[6-[(aminoiminomethyl)amino]hexyl]glycyl-N-[6-[(aminoiminomethyl)amino]hexyl]glycyl-N-[6-[(aminoiminomethyl)amino]hexyl]glycyl-N-[6-[(aminoiminomethyl)amino]hexyl]glycyl-N-[6-[(aminoiminomethyl)amino]hexyl]glycyl-N-[6-[(aminoiminomethyl)amino]hexyl]glycyl-N2-[6-[(aminoiminomethyl)amino]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 3-A



PAGE 4-A




RN 663178-15-2 HCAPLUS


CN Dodecanediamide, N,N'-bis[(11β,16β)-9-chloro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 663178-16-3 HCAPLUS

CN Guanidine, [(11 β ,16 α)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 35410-28-7 105702-59-8


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological

activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of **corticosteroid conjugates** and
 therapeutic uses thereof as anti-**inflammatory** agents)

RN 35410-28-7 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[(methylsulfonyl)oxy]-,
 (11 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 105702-59-8 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-chloro-11,17-dihydroxy-16-methyl-21-
 [(methylsulfonyl)oxy]-, (11 β ,16 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 50-24-8, Prednisolone 124-94-7, Triamcinolone
 4419-39-0, Beclomethasone 51333-22-3, Budesonide
 115446-51-0

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of **corticosteroid conjugates** and
 therapeutic uses thereof as anti-**inflammatory** agents)

RN 50-24-8 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11 β)- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 124-94-7 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-,
(11 β ,16 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 4419-39-0 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-chloro-11,17,21-trihydroxy-16-methyl-,
(11 β ,16 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51333-22-3 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-,
(11 β ,16 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 115446-51-0 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 21-amino-9-fluoro-11,17-dihydroxy-16-methyl-,
(11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 663178-14-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of corticosteroid conjugates and therapeutic uses thereof as anti-inflammatory agents)

RN 663178-14-1 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 16,17,21-tris(acetyloxy)-9-fluoro-11-hydroxy-
 , (11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 50-22-6, Corticosterone

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (suppression following treatment; preparation of **corticosteroid**
conjugates and therapeutic uses thereof as anti-
inflammatory agents)

RN 50-22-6 HCAPLUS

CN Pregn-4-ene-3,20-dione, 11,21-dihydroxy-, (11 β)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



L46 ANSWER 6 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:182368 HCAPLUS
 DN 140:229401
 ED Entered STN: 05 Mar 2004
 TI Three hybrid assay system for isolating ligand-binding polypeptides and
 for isolating small mol. ligands
 IN Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph
 PA USA
 SO U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM C12Q001-68
 ICS G01N033-53; C07H021-04
 NCL 435006000; 435007100; 536023100; 530350000; 552653000; 552500000;
 536123000; 546001000; 540200000; 530317000
 CC 1-1 (Pharmacology)
 Section cross-reference(s): 9, 28
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004043388	A1	20040304	US 2002-234985	20020903
	US 2003165873	A1	20030904	US 2002-91177	20020304
PRAI	US 2001-272932P	P	20010302		
	US 2001-278233P	P	20010323		
	US 2001-329437P	P	20011015		
	US 2002-91177	A2	20020304		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004043388	ICM	C12Q001-68
	ICS	G01N033-53; C07H021-04
	NCL	435006000; 435007100; 536023100; 530350000; 552653000; 552500000; 536123000; 546001000; 540200000; 530317000
US 2004043388	ECLA	C07D231/54; C07D487/04+239B+231B; C07F009/6558B;

C07F009/6561; G01N033/68A10

- AB The invention provides compns. and methods for isolating ligand-binding polypeptides for a user-specified ligand, and for isolating small mol. ligands for a user-specified target polypeptide using an improved class of hybrid ligand compds. Preparation of compds., e.g a methotrexate moiety linked by a polyethylene glycol moiety to dexamethasone, is described.
- ST three hybrid assay system ligand polypeptide; methotrexate dexamethasone **conjugate** prepn three hybrid assay system
- IT Proteins
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (55,000-mol.-weight; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Gene, microbial
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ADE2, reporter gene; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Gene, microbial
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CAN1, reporter gene; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Peptides, biological studies
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CBD tag; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Gene, microbial
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CYH1, reporter gene; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Cyclins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (D1; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT DNA
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (DNA binding domain; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Peptides, biological studies
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (E tag; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Cyclins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (E; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Immunophilins
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (FKBP-12 (FK 506-binding protein, 12 kDa), fusion protein including domain of; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Transcription factors
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GAL4; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT Proteins
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (GyrB, fusion protein including domain of; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT Proteins
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (H-1; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT Gene, microbial
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (HIS3, reporter gene; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT Gene, microbial
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (LEU2, reporter gene; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT Gene, microbial
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (LYS2, reporter gene; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT Proteins
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (MBP (maltose-binding protein), fusion protein including domain of; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT Peptides, biological studies
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Myc tag; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT Proteins
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (PLV, **conjugates**; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT Peptides, biological studies
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (S tag; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT Peptides, biological studies
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (T7 tag; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT Gene, microbial
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (TRP1, reporter gene; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

- IT Gene, microbial
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TRP2, reporter gene; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Peptides, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Tag 100; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Proteins
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Tet-R, fusion protein including domain of; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Proteins
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(URA3, **conjugates**; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Gene, microbial
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(URA3, reporter gene; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Peptides, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(V5 tag; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Peptides, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(VSV tag; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Peptides, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Xpress tag; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Transcriptional regulation
(activation, transcriptional activation domain; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Genomic library
(bacterial or eukaryotic genomic DNA fragment library; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Peptides, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calmodulin binding peptide tag; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Gene, microbial
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cat, reporter gene; three hybrid assay system for isolating

ligand-binding polypeptides and for isolating small mol. ligands)

IT Estrogens
Ligands
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(**conjugated**; three hybrid assay system for isolating
ligand-binding polypeptides and for isolating small mol. ligands)

IT Acid halides
Alcohols, biological studies
Aldehydes, biological studies
Alkaloids, biological studies
Alkanes, biological studies
Alkenes, biological studies
Alkyl halides
Alkynes
Amides, biological studies
Amine oxides
Amines, biological studies
Amino acids, biological studies
Anhydrides
Aromatic hydrocarbons, biological studies
Aryl halides
Cannabinoids
Carboxylic acids, biological studies
Cyanohydrins
Enamines
Enzymes, biological studies
Esters, biological studies
Ethers, biological studies
Imines
Lipids, biological studies
Nitriles, biological studies
Nucleic acids
Nucleosides, biological studies
Nucleotides, biological studies
Organometallic compounds
Peptides, biological studies
Polysaccharides, biological studies
Prostaglandins
Proteins
Quaternary ammonium compounds, biological studies
Steroids, biological studies
Transcription factors
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(**conjugates**; three hybrid assay system for isolating
ligand-binding polypeptides and for isolating small mol. ligands)

IT Sulfonic acids, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(esters, **conjugates**; three hybrid assay system for isolating
ligand-binding polypeptides and for isolating small mol. ligands)

IT Cell
(extract; three hybrid assay system for isolating ligand-binding
polypeptides and for isolating small mol. ligands)

IT Proteins
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(fluorescent, **conjugates**; three hybrid assay system for

- isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Androgen receptors
Cannabinoid receptors
Estrogen receptors
Glucocorticoid receptors
Progesterone receptors
Retinoic acid receptors
Steroid receptors
Vitamin D receptors
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fusion protein including domain of; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Gene, microbial
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gfp, reporter gene; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Proteins
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(green fluorescent, **conjugates**; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Analysis
(halo growth assay; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Aldehydes, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy, **conjugates**; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Peptides, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(intein/chitin binding domain tag; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Gene, microbial
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lacZ, reporter gene; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Transcription factors
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactose repressors; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Oligonucleotides
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(library; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Structure-activity relationship
(ligand-binding; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)
- IT Proteins

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(ligand-binding; three hybrid assay system for isolating ligand-binding
polypeptides and for isolating small mol. ligands)

IT Microtiter plates
(microtiter plate growth assay; three hybrid assay system for isolating
ligand-binding polypeptides and for isolating small mol. ligands)

IT Proteins
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(phi-29 terminal protein; three hybrid assay system for isolating
ligand-binding polypeptides and for isolating small mol. ligands)

IT DNA formation factors
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(rep; three hybrid assay system for isolating ligand-binding
polypeptides and for isolating small mol. ligands)

IT Hemagglutinins
Thioredoxins
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(tag; three hybrid assay system for isolating ligand-binding
polypeptides and for isolating small mol. ligands)

IT Drug screening
Fluorometry
Immobilization, molecular or cellular
Linking agents
Molecular association
Protein motifs
Surface plasmon resonance
cDNA library
(three hybrid assay system for isolating ligand-binding polypeptides
and for isolating small mol. ligands)

IT Chimeric gene
Fusion proteins (chimeric proteins)
Glycoconjugates
Polynucleotides
Reporter gene
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(three hybrid assay system for isolating ligand-binding polypeptides
and for isolating small mol. ligands)

IT Lactams
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(β -, antibiotics, **conjugates**; three hybrid assay system
for isolating ligand-binding polypeptides and for isolating small mol.
ligands)

IT Antibiotics
(β -lactam, **conjugates**; three hybrid assay system for
isolating ligand-binding polypeptides and for isolating small mol.
ligands)

IT 9002-03-3, Dihydrofolate reductase 9073-60-3, β -Lactamase
50812-37-8, Glutathione-S-transferase
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(fusion protein including domain of; three hybrid assay system for
isolating ligand-binding polypeptides and for isolating small mol.
ligands)

IT 9002-88-4, Polyethylene
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (linker; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT 60267-61-0, Ubiquitin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (subdomain; three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT 9031-44-1, Kinase 109136-49-4, Ubiquitin-specific protease
 141349-86-2, Cdk2 kinase 147014-97-9, Cdk4 kinase 150428-23-2, Cyclin-dependent kinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT 454221-45-5P 454221-46-6P 454221-47-7P 454221-48-8P 666839-17-4P 668481-63-8P, GPC 285985
 RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT 50-02-2D, Dexamethasone, **conjugates** 53-06-5D, Cortisone, **conjugates** 57-83-0D, Progesterone, **conjugates**, biological studies 58-22-0D, Testosterone, **conjugates** 58-85-5D, Biotin, **conjugates** 59-05-2D, Methotrexate, **conjugates** 60-54-8D, Tetracycline, **conjugates** 69-79-4D, Maltose, **conjugates** 70-18-8D, Glutathione, **conjugates** 108-95-2D, Phenol, **conjugates** 129-56-6D, Anthra[1,9-cd]pyrazol-6(2H)-one, **conjugates** 302-79-4D, Retinoic acid, **conjugates** 303-81-1D, Novobiocin, **conjugates** 446-72-0D, **conjugates** 938-55-6D, **conjugates** 1127-93-1D, 2,4-Diaminopteridine, **conjugates** 1406-16-2D, Vitamin D, **conjugates** 2365-40-4D, **conjugates** 3768-14-7D, **conjugates** 5812-07-7D, **conjugates** 7440-02-0D, Nickel, **conjugates** 7440-43-9D, Cadmium, organocadmium compound **conjugates** 16036-15-0D, **conjugates** 34708-97-9D, **conjugates** 52837-55-5D, **conjugates** 53123-88-9D, Rapamycin, **conjugates** 54714-78-2D, **conjugates** 56767-20-5D, **conjugates** 60868-76-0D, **conjugates** 64134-30-1, Hexahistidine 72873-74-6D, **conjugates** 75706-12-6D, **conjugates** 79217-60-0D, Cyclosporin, **conjugates** 88404-44-8D, **conjugates** 97620-17-2D, **conjugates** 98849-88-8 101622-51-9D, **conjugates** 103745-39-7D, **conjugates** 104987-11-3D, Fk506, **conjugates** 105628-72-6D, **conjugates** 106035-95-4D, **conjugates** 107761-24-0D, **conjugates** 108402-27-3D, **conjugates** 109511-58-2D, **conjugates** 109887-57-2D, **conjugates** 121405-24-1D, **conjugates** 125313-92-0D, **conjugates** 125314-64-9D, **conjugates** 127243-85-0D, **conjugates** 129758-26-5D, **conjugates** 133052-90-1D, **conjugates** 134036-52-5D, **conjugates** 135897-06-2D, **conjugates** 136194-77-9D, **conjugates** 137206-97-4D, **conjugates** 137658-62-9D, **conjugates** 142273-20-9D, **conjugates** 146535-22-0D, **conjugates** 152075-98-4D, **conjugates** 152121-47-6D, **conjugates** 152459-95-5D, **conjugates** 153436-54-5D, **conjugates** 154447-36-6D, **conjugates** 160335-45-5D, **conjugates** 165806-09-7D, **conjugates**

165806-48-4D,	conjugates	165806-53-1D,	conjugates
167869-21-8D,	conjugates	169438-43-1D,	conjugates
170032-58-3D,	conjugates	171178-26-0D,	conjugates
171178-54-4D,	conjugates	171178-82-8D,	conjugates
171178-83-9D,	conjugates	171179-06-9D,	conjugates
171745-04-3D,	conjugates	172889-27-9D,	conjugates
173458-56-5D,	conjugates	174892-57-0D,	conjugates
178909-27-8D,	conjugates	179248-61-4D,	conjugates
183321-74-6D,	conjugates	183738-67-2D,	conjugates
183738-70-7D,	conjugates	183738-79-6D,	conjugates
183738-90-1D,	conjugates	183738-95-6D,	conjugates
184475-35-2D,	conjugates	184475-37-4D,	conjugates
184475-43-2D,	conjugates	184475-44-3D,	conjugates
184475-45-4D,	conjugates	184475-47-6D,	conjugates
184475-48-7D,	conjugates	184475-52-3D,	conjugates
184475-54-5D,	conjugates	185039-89-8D,	conjugates
186611-14-3D,	conjugates	186611-56-3D,	conjugates
186692-46-6D,	conjugates	187667-14-7D,	conjugates
187667-18-1D,	conjugates	187667-74-9D,	conjugates
187667-77-2D,	conjugates	187667-79-4D,	conjugates
187667-82-9D,	conjugates	187668-04-8D,	conjugates
187668-06-0D,	conjugates	187724-30-7D,	conjugates
187724-64-7D,	conjugates	188827-32-9D,	conjugates
189018-86-8D,	conjugates	189018-93-7D,	conjugates
189747-51-1D,	conjugates	190653-73-7D,	conjugates
191728-43-5D,	conjugates	192705-79-6D,	conjugates
193220-02-9D,	conjugates	193220-03-0D,	conjugates
193827-64-4D,	conjugates	194423-15-9D,	conjugates
196504-68-4D,	conjugates	196511-07-6D,	conjugates
196964-11-1D,	conjugates	197525-46-5D,	conjugates
197525-48-7D,	conjugates	198959-83-0D,	conjugates
198959-99-8D,	conjugates	198967-51-0D,	conjugates
199986-75-9D,	conjugates	200285-07-0D,	conjugates
200719-53-5D,	conjugates	202272-68-2D,	conjugates
202272-72-8D,	conjugates	202272-73-9D,	conjugates
204005-46-9D,	conjugates	205256-55-9D,	conjugates
205376-30-3D,	conjugates	207220-31-3D,	conjugates
207220-32-4D,	conjugates	207220-33-5D,	conjugates
207220-34-6D,	conjugates	207220-35-7D,	conjugates
207220-36-8D,	conjugates	207220-37-9D,	conjugates
207220-38-0D,	conjugates	208260-28-0D,	conjugates
208260-29-1D,	conjugates	209410-31-1D,	conjugates
209410-46-8D,	conjugates	209410-92-4D,	conjugates
209412-01-1D,	conjugates	211244-79-0D,	conjugates
211245-14-6D,	conjugates	211245-21-5D,	conjugates
211245-83-9D,	conjugates	211247-20-0D,	conjugates
212141-54-3D,	conjugates	212142-02-4D,	conjugates
212628-43-8D,	conjugates	212630-91-6D,	conjugates
212844-54-7D,	conjugates	213743-29-4D,	conjugates
214485-56-0D,	conjugates	214485-81-1D,	conjugates
214486-70-1D,	conjugates	214487-04-4D,	conjugates
214697-26-4D,	conjugates	214983-24-1D,	conjugates
215306-39-1D,	conjugates	215925-74-9D,	conjugates
216572-95-1D,	conjugates	216573-13-6D,	conjugates
216573-24-9D,	conjugates	216573-25-0D,	conjugates
216573-26-1D,	conjugates	216573-27-2D,	conjugates
216573-32-9D,	conjugates	216573-35-2D,	conjugates
216573-36-3D,	conjugates	216573-37-4D,	conjugates
216573-57-8D,	conjugates	216573-58-9D,	conjugates

216573-59-0D, conjugates	216573-62-5D, conjugates
216573-65-8D, conjugates	216573-66-9D, conjugates
216573-67-0D, conjugates	216573-71-6D, conjugates
216573-73-8D, conjugates	216573-98-7D, conjugates
216574-01-5D, conjugates	216574-02-6D, conjugates
216574-03-7D, conjugates	216574-04-8D, conjugates
216574-05-9D, conjugates	216574-06-0D, conjugates
216574-07-1D, conjugates	216589-05-8D, conjugates
216699-96-6D, conjugates	216752-48-6D, conjugates
219580-11-7D, conjugates	219796-67-5D, conjugates
220654-17-1D, conjugates	220904-59-6D, conjugates
220904-61-0D, conjugates	220904-62-1D, conjugates
220904-65-4D, conjugates	220904-67-6D, conjugates
220904-79-0D, conjugates	220904-82-5D, conjugates
220904-83-6D, conjugates	221061-26-3D, conjugates
221061-42-3D, conjugates	221062-42-6D, conjugates
221243-82-9D, conjugates	221636-05-1D, conjugates
221875-32-7D, conjugates	222034-85-7D, conjugates
222034-86-8D, conjugates	222034-96-0D, conjugates
222034-99-3D, conjugates	222035-13-4D, conjugates
222035-15-6D, conjugates	222035-16-7D, conjugates
222035-20-3D, conjugates	222035-22-5D, conjugates
222035-57-6D, conjugates	222035-58-7D, conjugates
222036-13-7D, conjugates	222036-17-1D, conjugates
222036-18-2D, conjugates	222957-57-5D, conjugates
223645-76-9D, conjugates	223725-07-3D, conjugates
223738-94-1D, conjugates	223784-60-9D, conjugates

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT 223784-70-1D, conjugates	223784-75-6D, conjugates
224435-00-1D, conjugates	224435-99-8D, conjugates
227622-92-6D, conjugates	227622-98-2D, conjugates
227623-09-8D, conjugates	228399-50-6D, conjugates
228400-93-9D, conjugates	228999-48-2D, conjugates
229000-80-0D, conjugates	229155-20-8D, conjugates
229155-47-9D, conjugates	234772-64-6D, conjugates
237430-03-4D, conjugates	240820-00-2D, conjugates
241494-77-9D, conjugates	241494-81-5D, conjugates
243836-51-3D, conjugates	244231-67-2D, conjugates
245036-16-2D, conjugates	247148-40-9D, conjugates
248270-51-1D, conjugates	249937-49-3D, conjugates
249937-52-8D, conjugates	250692-05-8D, conjugates
251106-46-4D, conjugates	251356-16-8D, conjugates
251356-18-0D, conjugates	252003-53-5D, conjugates
252894-30-7D, conjugates	252894-32-9D, conjugates
252916-29-3D, conjugates	254986-07-7D, conjugates
258282-55-2D, Pyrido[2,3-d]pyrimidin-7(1H)-one, conjugates	
258502-99-7D, conjugates	258830-51-2D, conjugates
258831-13-9D, conjugates	260428-60-2D, conjugates
261507-52-2D, conjugates	262430-03-5D, conjugates
262432-51-9D, conjugates	262445-18-1D, conjugates
263149-48-0D, conjugates	263149-49-1D, conjugates
263149-95-7D, conjugates	263150-06-7D, conjugates
263150-07-8D, conjugates	263150-14-7D, conjugates
263150-30-7D, conjugates	263170-24-7D, conjugates
263170-85-0D, conjugates	263170-86-1D, conjugates
263170-87-2D, conjugates	263170-94-1D, conjugates

263170-95-2D,	conjugates	263171-02-4D,	conjugates
263171-04-6D,	conjugates	263171-14-8D,	conjugates
263171-19-3D,	conjugates	263267-59-0D,	conjugates
264136-79-0D,	conjugates	265097-99-2D,	conjugates
265098-00-8D,	conjugates	265098-01-9D,	conjugates
265098-02-0D,	conjugates	265312-49-0D,	conjugates
265312-50-3D,	conjugates	265312-51-4D,	conjugates
267429-89-0D,	conjugates	267654-34-2D,	conjugates
267885-28-9D,	conjugates	267885-29-0D,	conjugates
267885-30-3D,	conjugates	267885-31-4D,	conjugates
267885-32-5D,	conjugates	267885-33-6D,	conjugates
267885-34-7D,	conjugates	267892-01-3D,	conjugates
268559-59-7D,	conjugates	269390-69-4D,	conjugates
273727-89-2D,	conjugates	273920-44-8D,	conjugates
283602-39-1D,	conjugates	284486-91-5D,	conjugates
285125-84-0D,	conjugates	285983-72-4D,	conjugates
287177-30-4D,	conjugates	287177-32-6D,	conjugates
289711-40-6D,	conjugates	294853-11-5D,	conjugates
295327-39-8D,	conjugates	295330-14-2D,	conjugates
295799-47-2D,	conjugates	297754-50-8D,	conjugates
300715-91-7D,	conjugates	300860-00-8D,	conjugates
303195-98-4D,	conjugates	303727-31-3D,	conjugates
303740-80-9D,	conjugates	304664-06-0D,	conjugates
306998-03-8D,	conjugates	307353-61-3D,	conjugates
307353-99-7D,	conjugates	309278-63-5D,	conjugates
311780-08-2D,	conjugates	311819-90-6D,	conjugates
313345-15-2D,	conjugates	313389-73-0D,	conjugates
322681-26-5D,	conjugates	322689-01-0D,	conjugates
322689-07-6D,	conjugates	325781-16-6D,	conjugates
326894-84-2D,	conjugates	329260-68-6D,	conjugates
329260-78-8D,	conjugates	329727-62-0D,	conjugates
329727-65-3D,	conjugates	331662-50-1D,	conjugates
331662-51-2D,	conjugates	331662-52-3D,	conjugates
331662-69-2D,	conjugates	331662-91-0D,	conjugates
333726-41-3D,	conjugates	342647-27-2D,	conjugates
342647-29-4D,	conjugates	343974-64-1D,	conjugates
343974-94-7D,	conjugates	343974-95-8D,	conjugates
343974-96-9D,	conjugates	344359-26-8D,	conjugates
348617-19-6D,	conjugates	355013-01-3D,	conjugates
359886-84-3D,	conjugates	359888-77-0D,	conjugates
360770-48-5D,	conjugates	360770-49-6D,	conjugates
360770-50-9D,	conjugates	360770-51-0D,	conjugates
360770-52-1D,	conjugates	360770-53-2D,	conjugates
360770-55-4D,	conjugates	360770-56-5D,	conjugates
364735-20-6D,	conjugates	364788-37-4D,	conjugates
367927-40-0D,	conjugates	367927-41-1D,	conjugates
367927-47-7D,	conjugates	367927-50-2D,	conjugates
372512-45-3D,	conjugates	380425-05-8D,	conjugates
380425-07-0D,	conjugates	380425-09-2D,	conjugates
380425-11-6D,	conjugates	380425-13-8D,	conjugates
380843-09-4D,	conjugates	380843-12-9D,	conjugates
380843-15-2D,	conjugates	380843-17-4D,	conjugates
380843-20-9D,	conjugates	380843-23-2D,	conjugates
380843-26-5D,	conjugates	380843-29-8D,	conjugates
380843-32-3D,	conjugates	380843-36-7D,	conjugates
380843-39-0D,	conjugates	380843-42-5D,	conjugates
380843-44-7D,	conjugates	380843-47-0D,	conjugates
380843-50-5D,	conjugates	380843-53-8D,	conjugates
380843-55-0D,	conjugates	380843-58-3D,	conjugates

380843-64-1D, conjugates	380843-66-3D, conjugates
380843-68-5D, conjugates	380843-70-9D, conjugates
380843-74-3D, conjugates	380843-75-4D, conjugates
380843-76-5D, conjugates	380843-77-6D, conjugates
380843-79-8D, conjugates	380843-81-2D, conjugates
380843-84-5D, conjugates	380843-86-7D, conjugates
381694-53-7D, conjugates	383123-03-3D, conjugates
388120-05-6D, conjugates	388626-12-8D, conjugates
388626-13-9D, conjugates	388626-14-0D, conjugates
388626-16-2D, conjugates	388626-20-8D, conjugates
388626-23-1D, conjugates	388626-25-3D, conjugates
388626-27-5D, conjugates	388626-31-1D, conjugates
388626-38-8D, conjugates	388626-40-2D, conjugates
388626-46-8D, conjugates	388626-49-1D, conjugates
388626-51-5D, conjugates	388626-54-8D, conjugates
388626-56-0D, conjugates	388626-58-2D, conjugates
388626-60-6D, conjugates	388626-62-8D, conjugates
388626-66-2D, conjugates	388626-68-4D, conjugates
388626-70-8D, conjugates	388626-73-1D, conjugates
388626-75-3D, conjugates	388626-78-6D, conjugates
388626-82-2D, conjugates	388626-84-4D, conjugates
388626-86-6D, conjugates	388626-89-9D, conjugates
388626-91-3D, conjugates	388626-93-5D, conjugates
388626-95-7D, conjugates	388626-97-9D, conjugates
388626-99-1D, conjugates	388627-01-8D, conjugates
388627-11-0D, conjugates	388627-13-2D, conjugates
388627-35-8D, conjugates	388627-55-2D, conjugates
388627-57-4D, conjugates	388627-59-6D, conjugates
388627-61-0D, conjugates	388627-76-7D, conjugates
391937-51-2D, conjugates	393590-60-8D, conjugates
413599-62-9D, conjugates	431916-96-0D, conjugates
439211-02-6, Streptactin	444722-95-6D, conjugates

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(three hybrid assay system for isolating ligand-binding polypeptides
and for isolating small mol. ligands)

IT 452913-20-1D, conjugates	452913-27-8D, conjugates
501684-20-4D, conjugates	521059-79-0D, conjugates
582315-72-8D, conjugates	609359-65-1D, conjugates
666837-86-1D, conjugates	666837-87-2D, conjugates
666837-88-3D, conjugates	666837-89-4D, conjugates
666837-90-7D, conjugates	666837-91-8D, conjugates
666837-92-9D, conjugates	666837-93-0D, conjugates
666837-94-1D, conjugates	666837-95-2D, conjugates
666837-96-3D, conjugates	666837-98-5D, conjugates
666837-99-6D, conjugates	666838-00-2D, conjugates
666838-01-3D, conjugates	666838-02-4D, conjugates
666838-03-5D, conjugates	666838-04-6D, conjugates
666838-05-7D, conjugates	666838-06-8D, conjugates
666838-07-9D, conjugates	666838-08-0D, conjugates
666838-09-1D, conjugates	666838-11-5D, conjugates
666838-12-6D, conjugates	666838-13-7D, conjugates
666838-14-8D, conjugates	666838-15-9D, conjugates
666838-16-0D, conjugates	666838-17-1D, conjugates
666838-18-2D, conjugates	666838-19-3D, conjugates
666838-20-6D, conjugates	666838-21-7D, conjugates
666838-22-8D, conjugates	666838-23-9D, conjugates
666838-24-0D, conjugates	666838-25-1D, conjugates
666838-26-2D, conjugates	666838-27-3D, conjugates

666838-28-4D, conjugates	666838-30-8D, conjugates
666838-31-9D, conjugates	666838-32-0D, conjugates
666838-33-1D, conjugates	666838-34-2D, conjugates
666838-35-3D, conjugates	666838-36-4D, conjugates
666838-37-5D, conjugates	666838-38-6D, conjugates
666838-39-7D, conjugates	666838-40-0D, conjugates
666838-41-1D, conjugates	666838-42-2D, conjugates
666838-45-5D, conjugates	666838-47-7D, conjugates
666838-48-8D, conjugates	666838-49-9D, conjugates
666838-50-2D, conjugates	666838-51-3D, conjugates
666838-53-5D, conjugates	666838-54-6D, conjugates
666838-55-7D, conjugates	666838-56-8D, conjugates
666838-57-9D, conjugates	666838-58-0D, conjugates
666838-59-1D, conjugates	666838-60-4D, conjugates
666838-61-5D, conjugates	666838-62-6D, conjugates
666838-63-7D, conjugates	666838-64-8D, conjugates
666838-65-9D, conjugates	666838-66-0D, conjugates
666838-67-1D, conjugates	666838-68-2D, conjugates
666838-69-3D, conjugates	666838-70-6D, conjugates
666838-71-7D, conjugates	666838-72-8D, conjugates
666838-73-9D, conjugates	666838-74-0D, conjugates
666838-75-1D, conjugates	666838-76-2D, conjugates
666838-77-3D, conjugates	666838-78-4D, conjugates
666838-79-5D, conjugates	666838-80-8D, conjugates
666838-81-9D, conjugates	666838-82-0D, conjugates
666838-84-2D, conjugates	666838-85-3D, conjugates
666838-86-4D, conjugates	666838-87-5D, conjugates
666838-88-6D, conjugates	666838-89-7D, conjugates
666838-90-0D, conjugates	666838-91-1D, conjugates
666838-92-2D, conjugates	666838-93-3D, conjugates
666838-94-4D, conjugates	666838-95-5D, conjugates
666838-96-6D, conjugates	666838-97-7D, conjugates
666838-98-8D, conjugates	666839-00-5D, conjugates
666839-01-6D, conjugates	666839-02-7D, conjugates
666839-03-8D, conjugates	666839-04-9D, conjugates
666839-06-1D, conjugates	666839-07-2D, conjugates
666839-08-3D, conjugates	

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT 383-63-1, Ethyl trifluoroacetate 641-70-3, 3-Nitrophthalic anhydride
 2528-30-5 17376-42-0 19741-14-1 37927-01-8 52853-40-4 54696-05-8
 109745-15-5 134179-38-7 212844-54-7, Purvalanol B 264141-07-3
 666839-13-0 666839-14-1 666839-15-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT 190020-14-5P 452913-11-0P 452913-12-1P 452913-13-2P 452913-14-3P
 452913-15-4P 452913-16-5P 452913-17-6P 452913-18-7P 452913-19-8P
 452913-20-1P 452913-21-2P 452913-23-4P 452913-24-5P 452913-25-6P
 452913-26-7P 452913-27-8P 452913-28-9P 452913-29-0P 452913-30-3P
 452913-31-4P 452913-32-5P 452913-33-6P 452913-34-7P 452913-35-8P
 452913-36-9P 452913-37-0P 452913-38-1P 452913-39-2P 666839-16-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

IT 83335-41-5, Dynorphin B (swine) 145935-81-5 668437-05-6 668514-59-8

668514-60-1 668514-61-2 668514-62-3 668514-63-4 668514-64-5
 668514-65-6 668514-66-7 668514-67-8 668514-68-9 668514-69-0
 668514-70-3 668514-71-4 668514-72-5 668514-73-6 668514-74-7
 668514-75-8 668514-76-9 668514-77-0 668514-78-1 668514-79-2
 668514-80-5 668514-81-6 668514-82-7 668514-83-8 668514-84-9
 668514-85-0 668514-86-1 668514-87-2 668514-88-3 668514-89-4
 668514-90-7 668514-91-8 668514-92-9 668514-93-0 668514-94-1
 668514-95-2

RL: PRP (Properties)

(unclaimed sequence; three hybrid assay system for isolating
 ligand-binding polypeptides and for isolating small mol. ligands)

IT 50-02-2D, Dexamethasone, **conjugates** 53-06-5D,

Cortisone, **conjugates**


RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(three hybrid assay system for isolating ligand-binding polypeptides
 and for isolating small mol. ligands)

RN 50-02-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
 (11 β ,16 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53-06-5 HCAPLUS

CN Pregna-4-ene-3,11,20-trione, 17,21-dihydroxy- (7CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 7 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:20534 HCAPLUS

DN 140:92584

ED Entered STN: 11 Jan 2004

TI Methods for therapeutic treatment utilizing sub-clinical amount of a therapeutic agent combined with or **conjugated** to an antibody, or fragment thereof

IN Lazarovits, Janette; Nimrod, Abraham; Hoch-Mar-Chaim, Hagit; Levanon, Avigdor

PA Savient Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K039-395
ICS A61K051-00; A61K038-00; A61K039-00

CC 15-3 (Immunochemistry)

Section cross-reference(s): 1, 3, 8, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002528	A1	20040108	WO 2003-US20604	20030630
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2002-189025	A	20020701		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004002528	ICM	A61K039-395
	ICS	A61K051-00; A61K038-00; A61K039-00

AB The present invention relates to compns. utilizing an agent and an antibody, or fragment thereof. In these compns., the agents, including agents such as anti-cancer, anti-metastasis, anti-leukemia, anti-disease, anti-adhesion, anti-thrombosis, anti-restenosis, anti-autoimmune, anti-aggregation, anti-bacterial, anti-viral, and anti-inflammatory agents, can be complexed or combined with or **conjugated** to the antibodies, or fragments thereof. In addition, the agent and/or the antibody, or fragment thereof, can be present in the composition in a sub-clin. amount, which is an amount that is less than the amount of the agent generally found to be clin. effective when the agent is administered alone. Preferably, in these compns. of the present invention, the agent is an anthracycline or a derivative thereof, e.g., doxorubicin (adriamycin) or a derivative thereof. The antibodies or fragments are capable of binding to, e.g. PSGL-1, fibrinogen γ' , GPIIb α , heparin, lumican, complement C4 inter- α inhibitor and prothrombin. Antibodies were identified by screening a human antibody phage display library, which has diversity only in the heavy chain CDR3 regions. Specific examples of antibodies disclosed in these applications include the Y1 and Y17 scFv antibody fragments that bind glycolalicin mols. on platelets. In addition, the L32 and L31 scFv antibody fragments were disclosed that bind leukemic cells.

ST human antibody fragment phage display library sequence; platelet antibody thrombosis anticoagulant; anticancer cancer diagnosis antibody leukemia

IT Leukemia
(B-cell; methods for therapeutic treatment utilizing sub-clin. amount of

- therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (GP1b, α , antibody against; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (PSGL-1 (P-selectin glycoprotein ligand-1), antibody against; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Amino acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (acidic, epitope comprising; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Leukemia
(acute myelogenous; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Platelet (blood)
(adhesion, inhibition; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Platelet (blood)
(aggregation, inhibition; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Leukemia
(chronic B-lymphocytic; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Antibodies and Immunoglobulins
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(complexes; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Epitopes
(comprising acidic amino acids and sulfated tyrosine residue; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Antibodies and Immunoglobulins
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**conjugates**; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Drug delivery systems
(dextran, lipophilic polymers, hydrophilic polymers, HPMA; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug delivery using; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Toxins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endotoxins, Pseudomonas, PE40, PE38;; methods for therapeutic
treatment utilizing sub-clin. amount of therapeutic agent combined with
or **conjugated** to antibody, or fragment thereof)

IT Antibodies and Immunoglobulins
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(fragments, scFv or Fab; methods for therapeutic treatment utilizing
sub-clin. amount of therapeutic agent combined with or **conjugated**
to antibody, or fragment thereof)

IT Glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glycocalicins, platelet, antibody against; methods for therapeutic
treatment utilizing sub-clin. amount of therapeutic agent combined with
or **conjugated** to antibody, or fragment thereof)

IT Cell proliferation
(inhibition, tumor; methods for therapeutic treatment utilizing
sub-clin. amount of therapeutic agent combined with or **conjugated**
to antibody, or fragment thereof)

IT Adhesion, biological
Cell aggregation
(inhibition; methods for therapeutic treatment utilizing sub-clin. amount
of therapeutic agent combined with or **conjugated** to antibody,
or fragment thereof)

IT Drug delivery systems
(liposomes, doxorubicin-decorated; methods for therapeutic treatment
utilizing sub-clin. amount of therapeutic agent combined with or
conjugated to antibody, or fragment thereof)

IT Proteoglycans, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lumicans, antibody against; methods for therapeutic treatment
utilizing sub-clin. amount of therapeutic agent combined with or
conjugated to antibody, or fragment thereof)

IT Neoplasm
(metastasis; methods for therapeutic treatment utilizing sub-clin. amount
of therapeutic agent combined with or **conjugated** to antibody,
or fragment thereof)

IT Anti-inflammatory agents
Antibacterial agents
Anticoagulants
Antitumor agents
Antiviral agents
Autoimmune disease
Chemotherapy
Human
Immunotherapy
Inflammation
Leukemia
Molecular cloning
Multiple myeloma
Neoplasm
Phage display library
Platelet (blood)
Platelet aggregation inhibitors
Radiotherapy
Thrombolytics
Thrombosis
(methods for therapeutic treatment utilizing sub-clin. amount of
therapeutic agent combined with or **conjugated** to antibody, or

- fragment thereof)
- IT Antibodies and Immunoglobulins
 RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Anthracyclines
 Radionuclides, biological studies
 Ricins
 Toxins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Protein sequences
 (of antibody fragments; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Artery, disease
 (restenosis; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Cell death
 (tumor, induction; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Interferons
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (α ; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT Fibrinogens
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (γ chain, γ' , antibody against; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT 23214-92-8, Doxorubicin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (-decorated liposome; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT 147-94-4, Cytarabine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Ara-C; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT 9041-08-1, Heparin sodium
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Reviparin, Dalteparin; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT 212783-20-5 212783-31-8 268723-76-8 442527-61-9 642928-14-1
 RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (amino acid sequence, antibody fragment; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT 645004-07-5 645004-08-6 645004-09-7


RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)

- IT 9001-26-7, Prothrombin 9005-49-6, Heparin, biological studies
39346-44-6, Inter-.α.-trypsin inhibitor 80295-48-3, Complement C4
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibody against; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT 9004-54-0, Dextran, biological studies 25322-68-3, Polyethylene glycol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug delivery using; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT 60-18-4D, Tyrosine, sulfated
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(epitope comprising; methods for therapeutic treatment utilizing sub-clin. amount of therapeutic agent combined with or **conjugated** to antibody, or fragment thereof)
- IT 50-18-0, Cyclophosphamide 50-35-1, Thalidomide 50-78-2, Aspirin
53-03-2, Prednisone 53-86-1, Indomethacin 57-22-7, Vincristine
127-07-1, Hydroxyurea 305-03-3, Chlorambucil 7440-15-5D, Rhenium,
isotopes, biological studies 7440-63-3D, Xenon, isotope of mass 33,
biological studies **9004-61-9**, **Hyaluronic acid**
10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90,
biological studies 11056-06-7, Bleomycin 13968-53-1, Ruthenium-103,
biological studies 13981-56-1, Fluorine-18, biological studies
13982-78-0, Mercury-203, biological studies 14041-48-6, Thulium-165,
biological studies 14119-09-6, Gallium-67, biological studies
14133-76-7, Technetium-99, biological studies 14158-32-8, Iodine-126,
biological studies 14331-95-4, Ruthenium-105, biological studies
14390-71-7, Tellurium-122, biological studies 14390-73-9, Tellurium-125,
biological studies 14391-22-1, Thulium-167, biological studies
14834-67-4, Iodine-133, biological studies 14885-78-0, Indium 113,
biological studies 14900-13-1, Thulium-168, biological studies
15307-86-5, Diclofenac 15663-27-1, cis-Platinum 15678-91-8,
Krypton-81, biological studies 15687-27-1, Ibuprofen 15715-08-9,
Iodine-123, biological studies 15750-15-9, Indium 111, biological
studies 15756-62-4, Ruthenium-95, biological studies 15757-14-9,
Gallium-68, biological studies 15758-35-7, Ruthenium-97, biological
studies 15765-39-6, Bromine-77, biological studies 15776-20-2,
Bismuth-213, biological studies 20830-81-3, Daunorubicin 21679-14-1,
Fludarabine 22204-53-1, Naproxen 30516-87-1, Zidovudine 33069-62-4,
Taxol 38194-50-2, Sulindac 51146-56-6, Dexibuprofen 51803-78-2,
Nimesulide 52549-17-4, Pranoprofen 58957-92-9, Idarubicin
59277-89-3, Acyclovir 73963-72-1, Cilostazol 74397-12-9, Limaprost
74711-43-6, Zaltoprofen 75037-46-6D, Gelonin, derivs. 75706-12-6,
Leflunomide 79867-78-0, Morpholinodaunorubicin 80790-68-7,
Morpholinodoxorubicin 82410-32-0, Ganciclovir 83712-60-1, Defibrotide
85622-93-1, Temozolomide 87344-06-7 90101-16-9, Droxicam
108852-90-0, Methoxymorpholinylodoxorubicin 113440-58-7, Calicheamicin
162011-90-7, Rofecoxib 169590-42-5, Celecoxib 173146-27-5, Denileukin
diftitox 262423-20-1, Subreum 425603-01-6, WinRho SDF 640734-07-2,
Clorcromene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for therapeutic treatment utilizing sub-clin. amount of
therapeutic agent combined with or **conjugated** to antibody, or

fragment thereof)
 IT 485815-21-2
 RL: PRP (Properties)
 (unclaimed sequence; methods for therapeutic treatment utilizing
 sub-clin. amount of a therapeutic agent combined with or
conjugated to an antibody, or fragment thereof)
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Manjunath; US 20020058034 A1 2002
 (2) Suiko; US 5716836 A 1998 HCAPLUS
 (3) Thorpe; US 6312694 B1 2001 HCAPLUS
 IT 53-03-2, Prednisone 9004-61-9, **Hyaluronic acid**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods for therapeutic treatment utilizing sub-clin. amount of
 therapeutic agent combined with or **conjugated** to antibody, or
 fragment thereof)
 RN 53-03-2 HCAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- (8CI, 9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 9004-61-9 HCAPLUS
 CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L46 ANSWER 8 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:3647 HCAPLUS
 DN 140:92576
 ED Entered STN: 04 Jan 2004
 TI Antibodies specific to epitopes involving cell rolling, metastasis and
 inflammation for diagnosis and treatment of cancer, metastasis, leukemia,
 autoimmune disease and inflammation
 IN Lazarovits, Janette; Hagay, Yocheved; Plaksin, Daniel; Vogel, Tikva;
 Nimrod, Abraham; Mar-Ham, Hagit; Szanthon, Ester; Richter, Tamar; Amit,
 Boaz; Cooperman, Lena; Peretz, Tuvia; Levanon, Avigdor
 PA Israel
 SO U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Provisional Ser. No.
 258,948.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K038-16
 ICS A61K038-10; A61K038-08; C07K014-16; C07K007-08; C07K007-06
 NCL 514012000; 514013000; 514014000; 514015000; 514016000; 530324000;

530325000; 530326000; 530327000; 530328000

CC 15-3 (Immunochemistry)

Section cross-reference(s): 1, 3, 9, 63

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004002450	A1	20040101	US 2001-32423	20011231
	US 2004073011	A1	20040415	US 2001-29926	20011231
PRAI	US 2000-258948P	P	20001229		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004002450	ICM	A61K038-16
	ICS	A61K038-10; A61K038-08; C07K014-16; C07K007-08; C07K007-06
	NCL	514012000; 514013000; 514014000; 514015000; 514016000; 530324000; 530325000; 530326000; 530327000; 530328000
US 2004002450	ECLA	C07K014/47A11; C07K016/30M
US 2004073011	ECLA	C07K016/00A; C07K016/30M

AB The present invention provides epitopes present on cancer cells and important in physiol. phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compns. using antibodies capable of binding to the epitopes are provided. Methods and compns. according to the present invention can be used in diagnosis of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, inflammatory disease, cardiovascular disease, myocardial infarction, retinopathy, thrombosis, restenosis, and cell aggregation-related disease.

ST antibody sulfated tyrosine epitope cell rolling metastasis inflammation autoimmune

IT Glycoproteins

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GPIb, α ; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Glycoproteins

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PSGL-1 (P-selectin glycoprotein ligand-1); antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Leukemia

(acute myelogenous; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Platelet (blood)

(aggregation; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Adhesion, biological

Anti-inflammatory agents

Antibacterial agents

Anticoagulants

Antitumor agents

Antiviral agents

Apoptosis

Autoimmune disease

Cardiovascular system, disease

Cell proliferation

DNA sequences

Drugs

Epitopes

Human

Imaging agents

Immunoradiotherapy

Immunotherapy

Inflammation

Leukemia

Molecular cloning

Multiple myeloma

Peptidomimetics

Phage display library

Platelet (blood)

Protein sequences

Pseudomonas

Thrombosis

X-ray

(antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Antibodies and Immunoglobulins

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Radionuclides, biological studies

Ricins

Toxins

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Diagnosis

(cancer; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Drug delivery systems

(carriers; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Cell migration

(cell rolling; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Neoplasm

(cells; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Leukemia

(chronic B-lymphocytic; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Peptides, biological studies

- RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (conjugates, sulfated; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Artery, disease
 (coronary, restenosis; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Test kits
 (diagnostic; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Toxins
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (exotoxins, PE40 and PE38; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Antibodies and Immunoglobulins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (fragments, scFv; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Antibodies and Immunoglobulins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (heavy chain; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Drug delivery systems
 (immunoconjugates; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Diagnosis
 (immunodiagnosis; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Drug delivery systems
 (immunotoxins; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Heart, disease
 (infarction; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Antibodies and Immunoglobulins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (light chain; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Polymers, biological studies
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
 (lipophilic; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Drug delivery systems
 (liposomes; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Proteoglycans, biological studies
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (lumicans; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Neoplasm
 (metastasis; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Antibodies and Immunoglobulins
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (monoclonal; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Peptides, biological studies
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oligopeptides; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Drug delivery systems
 (polymer-bound; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Sulfation
 (post-translational modification; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Eye, disease
 (retinopathy; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Protein motifs
 (sulfated L-tyrosine; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Carbohydrates, biological studies
 Glycolipids
 Lipids, biological studies
 Lipopolysaccharides
 Lipoproteins
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (sulfated; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT Interferons

- RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α ; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT Fibrinogens
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ' ; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT 442528-31-6D, tyrosine-sulfated derivative 442528-33-8D, tyrosine-sulfated derivative 442528-34-9D, tyrosine-sulfated derivative 639862-76-3D, tyrosine-sulfated derivative
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GP1b- α epitope; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT 442528-29-2D, tyrosine-sulfated derivative
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PSGL-1 (P-selectin glycoprotein ligand-1) epitope; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT 442527-66-4 442527-67-5
RL: PRP (Properties)
(Unclaimed; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT 641641-60-3P 641644-37-3P 641644-38-4P 641644-39-5P 641644-40-8P 641644-41-9P 641644-42-0P 641644-44-2P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT 268723-76-8 268723-77-9
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-platelet scFv Y1 CDR peptide; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT 212783-31-8
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-platelet scFv Y1 CDR3 peptide; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)
- IT 442527-61-9
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-platelet scFv Y17 CDR3 peptide; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and

inflammation)

IT 56-40-6, Glycine, biological studies 56-45-1, L-Serine, biological studies 61-90-5, L-Leucine, biological studies 63-91-2, L-Phenylalanine, biological studies 73-32-5, L-Isoleucine, biological studies 147-85-3, L-Proline, biological studies 956-46-7, L-Tyrosine O-sulfate 80498-17-5 84628-87-5, Restriction endonuclease NdeI 129430-53-1 171040-76-9, Mocarhagin

RL: BSU (Biological study, unclassified); BIOL (Biological study) (antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT 639019-58-2 639019-60-6 639019-62-8 639019-64-0 639019-66-2 639019-68-4 639019-70-8 639019-72-0 639019-74-2 639019-76-4

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT 50-18-0, Cyclophosphamide 50-35-1, Thalidomide 50-78-2, Aspirin 53-03-2, Prednisone 53-86-1, Indomethacin 57-22-7, Vincristine 127-07-1, Hydroxyurea 147-94-4, Cytarabine 305-03-3, Chlorambucil 9004-54-0, Dextran, biological studies **9004-61-9**, **Hyaluronic acid** 9041-08-1, Dalteparin sodium 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90, biological studies 11056-06-7, Bleomycin 13968-53-1, Ruthenium-103, biological studies 13981-56-1, Fluorine-18, biological studies 13982-78-0, Mercury-203, biological studies 14041-48-6, Thulium-165, biological studies 14119-09-6, Gallium-67, biological studies 14158-32-8, Iodine-126, biological studies 14331-95-4, Ruthenium-105, biological studies 14390-71-7, Tellurium-122, biological studies 14391-22-1, Thulium-167, biological studies 14885-78-0, Indium-113, biological studies 14900-13-1, Thulium-168, biological studies 14932-42-4, Xenon-133, biological studies 15307-86-5, Diclofenac 15663-27-1, cis-Platinum 15687-27-1, Ibuprofen 15715-08-9, Iodine-123, biological studies 15750-15-9, Indium-111, biological studies 15756-62-4, Ruthenium-95, biological studies 15757-14-9, Gallium-68, biological studies 15758-35-7, Ruthenium-97, biological studies 15765-39-6, Bromine-77, biological studies 15776-20-2, Bismuth-213, biological studies 20830-81-3, Daunorubicin 21442-01-3 21679-14-1, Fludarabine 22204-53-1, Naproxen 23214-92-8, Doxorubicin 25316-40-9, Adriamycin 30516-87-1, Zidovudine 33069-62-4, Taxol 35014-81-4, Rhenium-199, biological studies 38194-50-2, Sulindac 51146-56-6, Dexibuprofen 51633-78-4, Mercury-167, biological studies 51692-52-5, Rhenium-201, biological studies 51692-56-9, Rhenium-205, biological studies 51803-78-2, Nimesulide 52549-17-4, Pranoprofen 58957-92-9, Idarubicin 59277-89-3, Acyclovir 68206-94-0, Cloricromene 73963-72-1, Cilostazol 74397-12-9, Limaprost 74711-43-6, Zaltoprofen 75037-46-6, Gelonin 75706-12-6, Leflunomide 80790-68-7 82410-32-0, Gancyclovir 83712-60-1, Defibrotide 85622-93-1, Temozolomide 87344-06-7, Amtolmetin guacil 90101-16-9, Droxicam 113440-58-7, Calicheamicin 117989-72-7, Uro-Vaxom 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 173146-27-5, Denileukin diftitox 378253-17-9, Krypton-81m, biological studies 378784-45-3, Technetium-99m, biological studies 378784-46-4, Tellurium-121m, biological studies 378784-50-0, Tellurium-125m, biological studies 425603-01-6, WinRho SDF

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis,

leukemia, autoimmune disease and inflammation)

IT 640723-68-8D, tyrosine-sulfated derivative
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (complement C4 epitope; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT 9001-26-7, Prothrombin 9005-49-6, Heparin, biological studies
 80295-48-3, Complement C4
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (epitope; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT 442528-35-0D, tyrosine-sulfated derivative
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (fibrinogen γ' epitope; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT 641644-43-1P 641644-45-3P
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (nucleotide sequence; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT 442528-30-5D, tyrosine-sulfated derivative
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (platelet surface protein epitope; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT 9001-92-7, Endoproteinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (protease; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT 641648-05-7 641648-06-8 641648-07-9 641648-08-0 641648-09-1
 641648-10-4 641648-11-5 641648-12-6 641648-13-7 641648-14-8
 641648-15-9 641648-16-0 641648-17-1 641648-18-2 641648-19-3
 641648-20-6 641648-21-7 641665-56-7
 RL: PRP (Properties) (unclaimed nucleotide sequence; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT 641647-25-8 641647-26-9 641647-27-0 641647-28-1 641647-29-2
 641647-30-5 641647-31-6 641647-32-7 641647-33-8 641647-34-9
 641647-35-0 641647-36-1 641647-37-2 641647-38-3 641647-39-4
 641647-40-7 641647-41-8 641647-42-9 641647-43-0 641647-44-1
 641647-45-2 641647-46-3 641647-47-4 641647-48-5 641647-49-6
 641647-50-9 641647-51-0 641647-52-1 641647-53-2 641647-54-3
 641647-55-4 641647-56-5 641647-57-6 641647-58-7 641647-59-8
 641647-60-1 641647-61-2 641647-62-3 641647-63-4 641647-64-5
 641647-65-6 641647-66-7 641647-67-8 641647-68-9 641647-69-0
 641647-70-3 641647-71-4 641647-72-5 641647-73-6 641647-74-7
 641647-75-8 641647-76-9 641647-77-0 641647-78-1 641647-79-2

641647-80-5	641647-81-6	641647-82-7	641647-83-8	641647-84-9
641647-85-0	641647-86-1	641647-87-2	641647-88-3	641647-89-4
641647-90-7	641647-91-8	641647-92-9	641647-93-0	641647-94-1
641647-95-2	641647-96-3	641647-97-4	641647-98-5	641647-99-6
641648-00-2	641648-01-3	641648-02-4	641648-03-5	641648-04-6
642103-96-6				

RL: PRP (Properties)

(unclaimed protein sequence; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT	122024-47-9	149298-29-3	245330-86-3	245330-96-5	245331-07-1
	245331-15-1	245331-22-0	245331-32-2	245331-36-6	245331-39-9
	245331-51-5	245331-68-4	245331-74-2	245332-10-9	245333-35-1
	245333-43-1	245333-53-3	245333-62-4	245333-65-7	245333-66-8
	245333-74-8	245333-75-9	245333-76-0	245333-82-8	245333-90-8
	245333-98-6	245334-15-0	245334-24-1	245334-37-6	245334-46-7
	245334-69-4	245334-81-0	245334-95-6	245335-03-9	245335-22-2
	245335-28-8	245335-54-0	245336-31-6	245448-41-3	245448-42-4
	245448-43-5	245448-44-6	245448-45-7	245448-46-8	245448-47-9
	245448-48-0	245448-49-1	245448-50-4	245448-51-5	245448-52-6
	245448-53-7	245448-54-8	245448-55-9	245448-56-0	245448-57-1
	245448-58-2	245448-59-3	245448-60-6	245448-61-7	245448-62-8
	245448-95-7	245448-96-8	245448-97-9	245448-98-0	245448-99-1
	245449-00-7	245449-01-8	245449-02-9	245449-03-0	245449-04-1
	245449-05-2	245449-06-3	245449-07-4	245449-08-5	245449-09-6
	245449-10-9	245449-11-0	245449-12-1	245449-13-2	245449-15-4
	268723-83-7	442527-49-3	442527-50-6	442527-51-7	442527-53-9
	442527-54-0	442527-55-1	442527-56-2	442527-57-3	442527-58-4
	442527-59-5	442527-60-8	442527-62-0	442527-63-1	442527-64-2
	442527-65-3	442527-68-6	442527-69-7	442527-70-0	442527-71-1
	442527-72-2	442527-73-3	442527-74-4	442527-76-6	444882-10-4
	640723-97-3	641616-77-5			

RL: PRP (Properties)

(unclaimed sequence; antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

IT 53-03-2, Prednisone 9004-61-9, Hyaluronic acid


RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antibodies specific to epitopes involving cell rolling, metastasis and inflammation for diagnosis and treatment of cancer, metastasis, leukemia, autoimmune disease and inflammation)

RN 53-03-2 HCAPLUS

CN Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9004-61-9 HCAPLUS
 CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L46 ANSWER 9 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:3463 HCAPLUS
 DN 140:75946
 ED Entered STN: 04 Jan 2004
 TI Multimers of peptide epitopes containing sulfated moieties, antibodies to
 such epitopes, and diagnostic and therapeutic uses thereof
 IN Levanon, Avigdor; Hagay, Yocheved; Plaksin, Daniel; Vogel, Tikva; Nimrod,
 Abraham; Mar-Haim, Hagit; Szanthon, Ester; Richter, Tamar; Amit, Boaz;
 Cooperman, Lena; Peretz, Tuvia; Lazarovits, Janette
 PA Israel
 SO U.S. Pat. Appl. Publ., 149 pp., Cont.-in-part of U.S. Provisional Ser. No.
 258,948.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K039-395
 ICS C07K014-46
 NCL 424178100; 530391100
 CC 15-2 (Immunochemistry)
 Section cross-reference(s): 1, 3, 14, 63
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004001839	A1	20040101	US 2001-29988	20011231
	US 2004073011	A1	20040415	US 2001-29926	20011231
PRAI	US 2000-258948P	P	20001229		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004001839	ICM	A61K039-395
	ICS	C07K014-46
	NCL	424178100; 530391100
US 2004001839	ECLA	C07K014/47A11; C07K016/30M
US 2004073011	ECLA	C07K016/00A; C07K016/30M

OS MARPAT 140:75946

AB The present invention provides epitopes present on cancer cells and
 important in physiol. phenomena such as cell rolling, metastasis, and
 inflammation. Therapeutic and diagnostic methods and compns. using
 antibodies capable of binding to the epitopes are provided. Methods and
 compns. according to the present invention can be used in diagnosis of and

therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, autoimmune disease, and inflammatory disease. The preferred epitope comprises a peptide with a sulfated tyrosine or a peptide **conjugate** with a sulfated carbohydrate or a sulfated lipid mol. The invention provides sequences for peptide epitopes and for human antibody clones directed against a sulfated epitope. Epitopes of the invention are found on human glycoproteins GPIb in CD42 and P-Selectin Glycoprotein Ligand-1 (PSGL-1) and on certain diseased cells, such as B-CLL cells, AML cells, multiple myeloma cells, and B-CLL cells. Two human leukemia models were developed in immunodeficient mice. In the first model, SCID mice were injected with MOLT-4 cells from a human T cell leukemia and later with a **conjugate** between scFv CONY1 and doxorubicin. Tumor growths in the mouse livers weighed significantly less in mice treated with the CONY1-doxorubicin **conjugate** and the percentage of MOLT-4 cells found in bone marrow was low. In the second model, the **conjugate** between scFv CONY1 and doxorubicin significantly reduced the number of tumor cells in bone marrow of SCID/NOD mice that were injected with KG-1 cells from a human AML cell line. The pharmacokinetics of 125I-labeled CONY1 in BALB-C mice were determined

ST human sulfated peptide epitope antibody diagnosis therapy leukemia disease; protein sequence human sulfated epitope antibody

IT B cell (lymphocyte)

(B-CLL cell, antibody binding; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT Glycoproteins

RL: ANT (Analyte); ANST (Analytical study)

(GPIb, GPIba; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT Glycoproteins

RL: ANT (Analyte); ANST (Analytical study)

(PSGL-1 (P-selectin glycoprotein ligand-1); multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT Mus

(T-ALL (MOLT4) and AML-KG1 models; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT Leukemia

(acute myelogenous, cells, antibody binding; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT Platelet (blood)

(adhesion; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT Platelet (blood)

(aggregation; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT Anti-inflammatory agents

Antibacterial agents

Antiviral agents

Cardiovascular agents

Immunomodulators

Thrombolytics

(antibody **conjugates**; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and

- therapeutic uses thereof)
- IT Radionuclides, biological studies
Toxins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibody **conjugates**; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Multiple myeloma
(cells, antibody binding; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Leukemia
(chronic lymphocytic, cells, antibody binding; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(fragments, antigen binding site, Y1-CysKAK; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Glycoproteins
RL: ANT (Analyte); ANST (Analytical study)
(glycocalicins; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Drug delivery systems
(immunoconjugates; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Drug delivery systems
(immunotoxins; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Cell proliferation
(inhibition; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Adhesion, biological
(inhibitor; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Drug delivery systems
(liposomes; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Proteoglycans, analysis
RL: ANT (Analyte); ANST (Analytical study)
(lumicans; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Animal cell
(metastatic, antibody binding; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(multimer antigen binding sites; multimers of peptide epitopes containing

- sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Antitumor agents
 Autoimmune disease
 Cardiovascular system, disease
 Disease models
 Epitopes
 Human
 Inflammation
 Leukemia
 Molecular association
 Protein sequences
 Test kits
 Tumor markers
 cDNA sequences
 (multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Peptides, biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (pentapeptides, **linker**; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Adhesion, biological
 Cell aggregation
 (platelet; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Drug delivery systems
 (polymer-bound; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Artery, disease
 (restenosis; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Antibodies and Immunoglobulins
 RL: ARG (Analytical reagent use); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (single chain, Y1 and Y17; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Functional groups
 (sulfate; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Glycoproteins
 RL: ANT (Analyte); ANST (Analytical study)
 (sulfoglycoproteins; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Interferons
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (α , antibody **conjugates**; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT Fibrinogens
 RL: ANT (Analyte); ANST (Analytical study)

- (γ chain, γ' ; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT 641646-80-2D, **conjugates**
 RL: ARG (Analytical reagent use); PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (amino acid sequence; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT 641646-76-6 641646-78-8 641646-79-9
 RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (amino acid sequence; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT 9004-54-0, Dextran, biological studies 21442-01-3
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drug carrier; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT 212783-31-8 268723-76-8 268723-77-9 442527-61-9
 RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (human sulfated epitope antibody hypervariable region; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT 60-18-4D, L-Tyrosine, sulfated 9001-26-7, Prothrombin 9005-49-6, Heparin, analysis 39346-44-6, Inter- α -trypsin inhibitor 80295-48-3, Complement C4 442528-30-5 442528-31-6 442528-33-8 442528-34-9 442528-35-0 639862-69-4 639862-76-3
 RL: ANT (Analyte); ANST (Analytical study)
 (multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)
- IT 10043-66-0D, Iodine-131, antibody **conjugates**, biological studies 10098-91-6D, Yttrium-90, antibody **conjugates**, biological studies 13968-53-1D, Ruthenium-103, antibody **conjugates**, biological studies 13981-56-1D, Fluorine-18, antibody **conjugates**, biological studies 13982-78-0D, Mercury-203, antibody **conjugates**, biological studies 14041-48-6D, Thulium-165, antibody **conjugates**, biological studies 14119-09-6D, Gallium-67, antibody **conjugates**, biological studies 14158-32-8D, Iodine-126, antibody **conjugates**, biological studies 14331-95-4D, Ruthenium-105, antibody **conjugates**, biological studies 14378-26-8D, Rhenium, isotope of mass 188, antibody **conjugates**, biological studies 14390-71-7D, Tellurium-122, antibody **conjugates**, biological studies 14391-22-1D, Thulium-167, antibody **conjugates**, biological studies 14834-67-4D, Iodine-133, antibody **conjugates**, biological studies 14885-78-0D, Indium-113, antibody **conjugates**, biological studies 14900-13-1D, Thulium-168, antibody **conjugates**, biological studies 14932-42-4D, Xenon-133, antibody **conjugates**, biological studies 14998-63-1D, Rhenium, isotope of mass 186, antibody **conjugates**, biological studies 15715-08-9D, Iodine-123, antibody **conjugates**, biological studies 15750-15-9D, Indium-111, antibody **conjugates**, biological studies 15756-62-4D, Ruthenium-95, antibody **conjugates**, biological studies 15757-14-9D, Gallium-68, antibody **conjugates**, biological studies 15758-35-7D, Ruthenium-97, antibody **conjugates**, biological

studies 15765-39-6D, Bromine-77, antibody **conjugates**,
 biological studies 15776-20-2D, Bismuth-213, antibody **conjugates**
 , biological studies 33455-08-2D, Mercury-207, antibody
conjugates, biological studies 378253-17-9D, Krypton-81m,
 antibody **conjugates**, biological studies 378784-45-3D,
 Technetium-99m, antibody **conjugates**, biological studies
 378784-46-4D, Tellurium-121m, antibody **conjugates**, biological
 studies 378784-50-0D, Tellurium-125m, antibody **conjugates**,
 biological studies

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT 58-85-5D, Biotin, **conjugated** with antigen binding fragments
 9013-20-1D, Streptavidin, **conjugated** with antigen binding
 fragments

RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT 2543-43-3

RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)

(multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT 50-18-0D, Cyclophosphamide, antibody **conjugates** 50-35-1D,
 Thalidomide, antibody **conjugates** 50-78-2D, Aspirin, antibody
conjugates 53-03-2D, Prednisone, antibody
conjugates 53-86-1D, Indomethacin, antibody **conjugates**
 57-22-7D, Vincristine, antibody **conjugates** 127-07-1D,
 Hydroxyurea, antibody **conjugates** 147-94-4D, Cytarabine,
 antibody **conjugates** 305-03-3D, Chlorambucil, antibody
conjugates 9004-61-9D, Hyaluronic acid,
 antibody **conjugates** 9041-08-1D, Dalteparin sodium, antibody
conjugates 11056-06-7D, Bleomycin, antibody **conjugates**
 15307-86-5D, Diclofenac, antibody **conjugates** 15663-27-1D,
 cis-Platinum, antibody **conjugates** 15687-27-1D, Ibuprofen,
 antibody **conjugates** 20830-81-3D, Daunorubicin, antibody
conjugates 21679-14-1D, Fludarabine, antibody **conjugates**
 22204-53-1D, Naproxen, antibody **conjugates** 23214-92-8D,
 Doxorubicin, antibody **conjugates** 25316-40-9D, Adriamycin,
 antibody **conjugates** 30516-87-1D, Zidovudine, antibody
conjugates 33069-62-4D, Taxol, antibody **conjugates**
 38194-50-2D, Sulindac, antibody **conjugates** 51146-56-6D,
 Dexibuprofen, antibody **conjugates** 51803-78-2D, Nimesulide,
 antibody **conjugates** 52549-17-4D, Pranoprofen, antibody
conjugates 58957-92-9D, Idarubicin, antibody **conjugates**
 59277-89-3D, Acyclovir, antibody **conjugates** 73963-72-1D,
 Cilostazol, antibody **conjugates** 74397-12-9D, Limaprost,
 antibody **conjugates** 74711-43-6D, Zaltoprofen, antibody
conjugates 75706-12-6D, Leflunomide, antibody **conjugates**
 80790-68-7D, Morpholinodoxorubicin, antibody **conjugates**
 82410-32-0D, Ganciclovir, antibody **conjugates** 83712-60-1D,
 Defibrotide, antibody **conjugates** 85622-93-1D, Temozolomide,
 antibody **conjugates** 87344-06-7D, antibody **conjugates**
 90101-16-9D, Droxicam, antibody **conjugates** 113440-58-7D,
 Calicheamicin, antibody **conjugates** 162011-90-7D, Rofecoxib,
 antibody **conjugates** 169590-42-5D, Celecoxib, antibody

conjugates 173146-27-5D, Denileukin diftitox, antibody

conjugates 262423-20-1D, Subreum, antibody **conjugates**

425603-01-6D, WinRho SDF, antibody **conjugates** 640734-07-2D,

Clorcromene, antibody **conjugates**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT 641646-77-7 641646-81-3

RL: ARG (Analytical reagent use); PRP (Properties); THU (Therapeutic use);

ANST (Analytical study); BIOL (Biological study); USES (Uses)

(nucleotide sequence; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT	641650-93-3	641650-94-4	641650-95-5	641650-96-6	641650-97-7
	641650-98-8	641650-99-9	641651-00-5	641651-01-6	641651-02-7
	641651-03-8	641651-04-9	641651-05-0	641651-06-1	641651-07-2
	641651-08-3	641651-09-4	641651-10-7	641651-11-8	641651-12-9
	641651-13-0	641651-14-1	641651-15-2	641651-16-3	641651-17-4
	641651-18-5	641651-19-6	641651-20-9	641651-21-0	641651-22-1
	641651-23-2	641651-24-3	641651-25-4	641651-26-5	641651-27-6
	641651-28-7	641651-29-8	641651-30-1	641651-31-2	641651-32-3
	641651-33-4	641651-34-5	641651-35-6	641651-36-7	641651-37-8
	641651-38-9	641651-39-0	641651-40-3	641651-41-4	641651-42-5
	641651-43-6	641651-44-7	641651-45-8	641651-46-9	641651-47-0
	641651-48-1	641651-49-2	641651-50-5	641651-51-6	641651-52-7
	641651-53-8	641651-54-9	641651-55-0	641651-56-1	641651-57-2
	641651-58-3	641651-59-4	641651-60-7	641651-61-8	641651-62-9
	641651-63-0	641651-64-1	641651-65-2	641651-66-3	641651-67-4
	641651-68-5	641651-69-6	641651-70-9	641651-71-0	641651-72-1
	641651-73-2	641653-14-7			

RL: PRP (Properties)

(unclaimed protein sequence; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT	122024-47-9	149298-29-3	245330-86-3	245330-96-5	245331-07-1
	245331-15-1	245331-22-0	245331-32-2	245331-36-6	245331-39-9
	245331-51-5	245331-68-4	245331-74-2	245332-10-9	245333-35-1
	245333-43-1	245333-53-3	245333-62-4	245333-65-7	245333-66-8
	245333-74-8	245333-75-9	245333-76-0	245333-82-8	245333-90-8
	245333-98-6	245334-15-0	245334-24-1	245334-37-6	245334-46-7
	245334-69-4	245334-81-0	245334-95-6	245335-03-9	245335-22-2
	245335-28-8	245335-54-0	245336-31-6	245448-41-3	245448-42-4
	245448-43-5	245448-44-6	245448-45-7	245448-46-8	245448-47-9
	245448-48-0	245448-49-1	245448-50-4	245448-51-5	245448-52-6
	245448-53-7	245448-54-8	245448-55-9	245448-56-0	245448-57-1
	245448-58-2	245448-59-3	245448-60-6	245448-61-7	245448-62-8
	245448-95-7	245448-96-8	245448-97-9	245448-98-0	245448-99-1
	245449-00-7	245449-01-8	245449-02-9	245449-03-0	245449-04-1
	245449-05-2	245449-06-3	245449-07-4	245449-08-5	245449-09-6
	245449-10-9	245449-11-0	245449-12-1	245449-13-2	245449-15-4
	268723-83-7	442527-49-3	442527-50-6	442527-51-7	442527-53-9
	442527-54-0	442527-55-1	442527-56-2	442527-57-3	442527-58-4
	442527-59-5	442527-60-8	442527-62-0	442527-63-1	442527-64-2
	442527-65-3	442527-66-4	442527-67-5	442527-68-6	442527-69-7
	442527-70-0	442527-71-1	442527-72-2	442527-73-3	442527-74-4
	442527-76-6	444882-10-4	641653-15-8	641653-16-9	641653-17-0
	641653-18-1	641653-19-2	641653-20-5	641653-21-6	641653-22-7
	641653-23-8	641653-24-9	641653-25-0	641653-26-1	641653-27-2
	641653-28-3	641653-29-4	641653-30-7	641653-31-8	641653-32-9

641653-33-0 641653-34-1

RL: PRP (Properties)

(unclaimed sequence; multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

IT 53-03-2D, Prednisone, antibody **conjugates**9004-61-9D, **Hyaluronic acid**, antibody **conjugates**


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(multimers of peptide epitopes containing sulfated moieties, antibodies to such epitopes, and diagnostic and therapeutic uses thereof)

RN 53-03-2 HCAPLUS

CN Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9004-61-9 HCAPLUS

CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L46 ANSWER 10 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:951172 HCAPLUS

DN 140:24421

ED Entered STN: 07 Dec 2003

TI Gene expression profiles in response to toxic compounds and their use as kidney toxicity predictive genes

IN Kier, Larry; Nolan, Timothy D.; Sankar, Usha; Derbel, Maher

PA Phase-1 Molecular Toxicology, Inc., USA

SO PCT Int. Appl., 388 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N

CC 4-1 (Toxicology)

Section cross-reference(s): 3

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003100030	A2	20031204	WO 2003-US6196	20030227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-361128P P 20020227

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2003100030 ICM C12N

AB The invention provides kidney toxicity predictive genes which can be used to predict kidney toxicity in response to one or more agents. Multiple sets of kidney toxicity biomarkers are provided which are useful in the kidney toxicity prediction methods. In particular, 376 rat kidney toxicity gene expression markers demonstrate utility in predicting kidney toxicity outcomes. These biomarkers are thoroughly characterized for predictive performance; among the subsets of kidney toxicity genes provided herein are several which demonstrate prediction accuracies in the vicinity of 95%.

ST kidney toxicity gene expression marker prediction

IT Thioredoxins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (1 and 2; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (14-3-3 ζ ; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (25-DX; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Uncoupling protein
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (2; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Connexins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (32; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (ARL184 (ADP-ribosylation factor-like, 184); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (ATF-3 (activating transcription factor 3); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(ATP-stimulated glucocorticoid-receptor translocation promoter; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(Bax; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(Bcl-2; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Apolipoproteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(C-III; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(CCR2; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(CCR5; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(CD44 metastasis suppressor; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(CDK102; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(CDK108; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Chemokine receptors

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(CXCR4; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Cyclins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(D1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(DAD1 (defender against cell death 1); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Calbindins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (D9k; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Selectins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (E-; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Cyclins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (E; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Cyclins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (G; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (GADD153; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (GADD45; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Transport proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (GLUT-1 (glucose transporter 1); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (GRP78 (glucose-regulated protein, 78 kDa); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Ferritins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (H-chain; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (HIF-1 α (hypoxia-inducible factor 1 α); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (HNF-4 (hepatocyte nuclear factor 4); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Glycoproteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (HRG (histidine-rich glycoprotein); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Transcription factors

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (ID1 (inhibitor of differentiation 1); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Transcription factors

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (ID2 (inhibitor of differentiation 2); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (IFRD1 (interferon-regulated developmental regulator 1); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Insulin-like growth factor-binding proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (IGFBP-1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Insulin-like growth factor-binding proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (IGFBP-3; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Protein formation factors

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (IRE-BP (iron-responsive element-binding protein); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (IgE-binding; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (Jagged 1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (L-FABP (liver fatty acid-binding protein); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Ribosomal proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (L13A; gene expression profiles in response to toxic compds. and their

- use as kidney toxicity predictive genes)
- IT Ribosomal proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(L27; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Ribosomal proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(L6; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(LDL; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Rat endogenous retrovirus
(LTR of; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Cytokines
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(MBP (major basic protein), 1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT P-glycoproteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(MDR1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT P-glycoproteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(MDR2; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT P-glycoproteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(MDR3; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Multidrug resistance proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(MRP2; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(Mx1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Cadherins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(N-; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(NGF-inducible anti-proliferative; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

- IT Notch (receptor)
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(Notch1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(OCTN1 (organic cation transporter 1); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(OCTN2 (organic cation transporter 2); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(OCTN3 (organic cation transporter 3); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(PAR-interacting; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(PTEN/MMAC1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(RAD; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(RT1 (rat, 1); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Retinoid X receptors
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(RXR α ; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT DNA microarray technology
DNA microarray technology
Gene expression profiles, animal
(Rat 700 CT chip microarray; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(Ref-1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Ribosomal proteins

- RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(S8; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Ribosomal proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(S9; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(SCP2 (sterol carrier protein 2); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(SGLT1 (sodium-dependent glucose transporter 1); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(SOCS-3 (suppressor of cytokine signaling-3); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Annexins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(V; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(VCAM-1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Anion channel
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(VDAC (voltage-dependent anion channel), VDAC2; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Genetic element
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(VL30 element; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(VMAT (vesicle monoamine transporter); gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(acute-phase, major α 1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (apoptosis-regulating, basic; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Porins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (aquaporin 3; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (c-fos; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (c-jun; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (c-myc; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Calcium-binding proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (calgranulin A; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Calcium-binding proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (calgranulin B; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (calpactin I; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Information systems
 (computerized; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Elongation factors (protein formation)
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (eEF-1 α ; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Initiation factors (protein formation)
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (eIF-4E; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (emerin; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Canis familiaris
 Human

Primates

Rattus

cDNA sequences

(gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Albumins, biological studies
Aromatic hydrocarbon receptors

Calnexin

Calreticulin

Clusterin

Cyclophilins

Decorins

Fibrinogens

Interleukin 10

Interleukin 18

Interleukin 1 β

Macrophage inflammatory protein 1 α

Myelin basic protein

Nerve growth factor receptors

Osteopontin

Proliferating cell nuclear antigen

Thrombin receptors

Thrombomodulin

Transferrins

Urokinase-type plasminogen activator receptors

p53 (protein)

α 1-Acid glycoprotein

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(heme-binding, 23; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Transport proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(hydrogen ion-sodium exchanger; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Dyneins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(light chain 1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(natural killer cell-enhancing factor B; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Toxicity

(nephrotoxicity; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT Proteins

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(nucleic acid-binding, cellular; gene expression profiles in response

- to toxic compds. and their use as kidney toxicity predictive genes)
- IT Transport proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (nucleoside transporter; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Transport proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (organic anion transporter, 3; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Transport proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (organic anion transporter, K1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Transport proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (organic anion transporter, renal; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (p125FAK; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Ras proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (p21c-Ha-ras; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (peroxisomal multifunctional type II; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (peroxisome assembly factor 2; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (phosphatidylethanolamine-binding; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (proteasome activator 28 α ; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (retinol-binding; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use,

- unclassified); BIOL (Biological study); USES (Uses)
 (selenium-containing, P; gene expression profiles in response to toxic
 compds. and their use as kidney toxicity predictive genes)
- IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (senescence marker protein-30; gene expression profiles in response to
 toxic compds. and their use as kidney toxicity predictive genes)
- IT Transport proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (serotonin transporter; gene expression profiles in response to toxic
 compds. and their use as kidney toxicity predictive genes)
- IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (stathmin; gene expression profiles in response to toxic compds. and
 their use as kidney toxicity predictive genes)
- IT Kidney
 (toxicity; gene expression profiles in response to toxic compds. and
 their use as kidney toxicity predictive genes)
- IT Activin receptors
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (type II; gene expression profiles in response to toxic compds. and
 their use as kidney toxicity predictive genes)
- IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (ubiquitin-conjugating; gene expression profiles in response
 to toxic compds. and their use as kidney toxicity predictive genes)
- IT Lipopolysaccharides
 Polyoxyalkylenes, biological studies
 RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,
 unclassified); ANST (Analytical study); BIOL (Biological study)
 (use in design of standard kidney toxicity profile; gene expression
 profiles in response to toxic compds. and their use as kidney toxicity
 predictive genes)
- IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (vacuole membrane protein 1; gene expression profiles in response to
 toxic compds. and their use as kidney toxicity predictive genes)
- IT Proteins
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (zinc finger-containing; gene expression profiles in response to toxic
 compds. and their use as kidney toxicity predictive genes)
- IT Caseins, biological studies
 Tubulins
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (α -; gene expression profiles in response to toxic compds. and
 their use as kidney toxicity predictive genes)
- IT Macrophage inflammatory protein 2
 Peroxisome proliferator-activated receptors
 RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (α ; gene expression profiles in response to toxic compds. and

- their use as kidney toxicity predictive genes)
- IT Microglobulins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(α 1-; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Macroglobulins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(α 2-; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Tubulins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(β -; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Fetuins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(β ; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Integrins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(β 1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Integrins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(β 4; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Actins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(γ -; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT Cholinergic receptors
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ϵ ; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT 9068-26-2, Protein mannosyltransferase
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(1; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT 9029-97-4, 3-Ketoacyl-CoA thiolase
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(2; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT 60267-61-0, Ubiquitin
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(D; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)
- IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(III; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT 9023-09-0, Sulfotransferase
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (K2; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT 9054-89-1, Superoxide dismutase
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (copper-zinc containing; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT 9000-83-3, ATPase
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (ecto-; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT 9000-86-6, Alanine aminotransferase 9001-12-1, Matrix metalloproteinase 1 9001-40-5, Glucose-6-phosphate dehydrogenase 9001-50-7, Glyceraldehyde-3-phosphate dehydrogenase 9001-59-6, Pyruvate kinase 9001-64-3, Malate dehydrogenase 9001-66-5, Monoamine oxidase 9001-83-6, Phosphoglycerate kinase 9004-06-2, Macrophage metalloelastase 9016-12-0, Hypoxanthine-guanine phosphoribosyltransferase 9023-58-9, Argininosuccinate synthetase 9024-60-6, Ornithine decarboxylase 9026-00-0, Cholesterol esterase 9026-23-7, Carbamyl phosphate synthase 9027-34-3, Argininosuccinate lyase 9028-35-7, Hydroxymethylglutaryl-CoA reductase 9028-39-1, 3-Hydroxyisobutyrate dehydrogenase 9028-48-2, NADP isocitrate dehydrogenase 9028-86-8, Aldehyde dehydrogenase 9029-33-8, Adrenodoxin reductase 9030-08-4, UDP-glucuronosyltransferase 9030-42-6 9031-37-2, Ceruloplasmin 9031-61-2, Thymidylate synthase 9031-72-5, Alcohol dehydrogenase 9031-86-1, Aspartoacylase 9033-53-8, Retinol dehydrogenase 9035-58-9, Blood-coagulation factor III 9037-21-2, Tryptophan hydroxylase 9037-53-0, Cholesterol 7 α -hydroxylase 9039-06-9 9044-85-3, 3 β -Hydroxysteroid dehydrogenase 9046-27-9, γ -Glutamyl transpeptidase 9055-67-8, Poly(ADP-ribose) polymerase 9059-22-7, Heme oxygenase 9077-69-4, Inositol polyphosphate multikinase 9079-10-1, N-Hydroxy-2-acetylaminofluorene sulfotransferase 9081-36-1, 25-Hydroxyvitamin D3 1 α -hydroxylase 37228-72-1, Glycine methyltransferase 39391-18-9, Prostaglandin H synthase 56093-23-3, α 1,2-Fucosyltransferase 59088-22-1, 3-Methyladenine DNA glycosylase 60616-82-2, Cathepsin L 61116-22-1, Fatty acyl-coa oxidase 62229-50-9, Epidermal growth factor 67339-09-7, Thiopurine methyltransferase 69403-06-1, Very-long-chain acyl-CoA synthetase 71965-46-3, Cathepsin S 74506-38-0, Medium-chain acyl-CoA dehydrogenase 77106-95-7, Carbonyl reductase 80295-41-6, Complement C3 80497-65-0, Muellerian-inhibiting hormone 81627-83-0, Colony-stimulating factor 1 87397-91-9, Thymosin β 10 91448-99-6, Cystatin c 123644-75-7, Dimethylarginine dimethylaminohydrolase 127464-60-2, Vascular endothelial growth factor 140208-24-8, TIMP-1 141349-86-2, Cyclin-dependent kinase 2 143180-75-0, DNA topoisomerase I 144114-16-9, Focal adhesion kinase 147014-97-9, Cyclin-dependent kinase 4 148348-15-6, Fibroblast growth factor 7 156681-44-6, α -Methylacyl-CoA racemase 165245-96-5, Protein kinase p38mapk 182372-14-1, Caspase 2 184111-06-6, D-Dopachrome tautomerase 189258-14-8, Caspase 7 206138-18-3, Proteinase inhibitor, PSTI-II 329743-16-0, Protein tyrosine phosphatase α 329764-85-4, Cytochrome p 450 1A1 329900-75-6, Cyclooxygenase 2 330207-10-8, Cytochrome P 450 2B1 330596-22-0, Cytochrome p 450 1B1 331462-97-6, Cytochrome P 450 2B2 331823-00-8, Cytochrome P 450 2C11 338969-62-3,

Cytochrome p 450 2A3 440356-80-9, Cytochrome P 450 14DM 455255-58-0,
Cytochrome P 450 2c23

RL: BSU (Biological study, unclassified); BUU (Biological use,
unclassified); BIOL (Biological study); USES (Uses)

(gene expression profiles in response to toxic compds. and their use as
kidney toxicity predictive genes)

IT 134498-15-0 138362-96-6 139821-48-0 139821-65-1, DNA (Rattus
norvegicus α -casein cDNA) 139821-71-9 139821-87-7 139822-39-2
139823-22-6 139823-24-8 139823-59-9 139823-80-6 139824-84-3
139825-73-3, DNA (Rattus norvegicus gene Maobf3) 139837-88-0, DNA
(Rattus norvegicus gene COXII) 139849-13-1 139863-54-0 140044-24-2
140044-41-3 140044-54-8 140044-95-7 140045-26-7 140045-41-6
140045-44-9 140045-74-5 140045-93-8 140046-07-7 140046-14-6
140046-33-9 140046-53-3 140046-68-0 140046-72-6 140047-02-5
140047-20-7 140047-44-5 140047-60-5 140048-01-7 140048-23-3
140048-60-8 140048-66-4 140048-97-1 140065-72-1 140065-90-3
140072-23-7 140072-96-4 140098-21-1 140297-85-4 140297-86-5
140298-16-4 140298-35-7 140298-84-6 140298-97-1 140299-51-0
140302-71-2 140303-13-5 140326-74-5 140326-92-7 140326-94-9
140332-13-4, DNA (Rattus norvegicus β -actin gene) 140334-56-1
140357-69-3 140507-74-0, GenBank M11972 140534-69-6 140536-52-3
140537-48-0 140767-92-6 140770-54-3 140771-04-6 140801-58-7
140816-09-7 140825-52-1 140970-73-6 141003-49-8 141877-88-5
142863-49-8 142863-54-5 143369-37-3 143387-81-9, DNA (rat clone 4B
osteopontin cDNA plus flanks) 143910-48-9 144623-69-8 144623-90-5
145496-01-1 145677-41-4 145971-52-4, DNA (rat argininosuccinate lyase
cDNA plus flanks) 145974-03-4 147037-57-8, DNA (rat clone pRMIS2
muellerian-inhibiting hormone gene plus flanks) 147053-09-6
148167-97-9 148168-17-6 148282-69-3, DNA (Rattus norvegicus gene cdk4)
148282-77-3 148391-72-4 148804-85-7 149480-30-8 149567-00-0
150001-33-5, DNA (rat T-lymphocyte calnexin cDNA) 150278-01-6
150278-04-9 150488-32-7 150886-54-7, DNA (rat NRK-49F cell cyclin G
cDNA plus flanks) 150914-11-7 151319-15-2 151429-46-8 151549-22-3
151577-58-1 151579-60-1 151579-61-2 152281-18-0 152283-44-8
152283-45-9 153663-88-8 153962-38-0 154211-54-8 154298-83-6
154331-92-7 155120-31-3 156255-88-8 156828-65-8 157317-28-7
157934-99-1 160044-91-7 160102-07-8, DNA (Rattus norvegicus gene rad)
160897-42-7 162159-01-5 162455-43-8 163369-53-7 165148-61-8
165221-30-7 165764-61-4 168310-93-8 169076-82-8 169732-79-0
170176-45-1 170334-61-9 170592-32-2 171166-11-3 171796-21-7
172712-78-6 174054-37-6 174448-58-9 175006-50-5 175034-32-9
178296-42-9 178299-05-3 178353-56-5 179492-11-6 179794-70-8
179973-64-9 180173-21-1 180568-28-9 180882-95-5 182739-61-3
185090-50-0 185835-25-0 187859-80-9 194381-51-6 194383-50-1
196024-31-4 197736-87-1 197829-62-2 199432-03-6 200024-91-5
200334-54-9 202112-71-8 202490-99-1 204282-09-7 204418-90-6
204418-91-7 205299-55-4 206913-90-8 206969-37-1 207032-85-7
207772-19-8 207941-92-2 208812-95-7 209827-11-2 209842-67-1
209876-77-7, DNA (Rattus norvegicus caspase-7 cDNA) 210001-46-0
210385-71-0 210450-29-6, DNA (Rattus norvegicus gene mrp3) 210456-72-7
210498-08-1 211062-64-5 211222-98-9 212216-37-0 212664-15-8
212719-89-6 215396-62-6 218350-51-7 222770-32-3 225434-22-0
225543-56-6 225602-44-8 225694-96-2 243111-96-8 243112-03-0
252774-19-9 285544-89-0 299156-44-8 301143-99-7 325611-43-6, DNA
(Rattus norvegicus gene Ipmk) 358274-35-8 382726-30-9 382731-00-2
382732-07-2 382736-82-5 384433-79-8 384493-50-9 384501-39-7
384613-15-4 384725-40-0 384731-87-7 391573-09-4 391814-51-0
392025-09-1 392029-40-2 392193-75-8 398113-42-3 630426-94-7
630426-95-8 630426-96-9 630426-97-0 630426-98-1 630426-99-2

630427-00-8 630427-01-9 630427-02-0 630427-03-1 630427-04-2
 630427-05-3 630427-06-4 630427-07-5 630427-08-6 630427-09-7
 630427-10-0 630427-11-1

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (nucleotide sequence; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT 630427-12-2 630427-13-3 630427-14-4 630427-15-5 630427-16-6
 630427-17-7 630427-18-8 630427-19-9 630427-20-2 630427-21-3
 630427-22-4 630427-23-5 630427-24-6 630427-25-7 630427-26-8
 630427-28-0 630427-29-1 630427-30-4 630427-31-5 630427-32-6
 630427-33-7 630427-34-8 630427-35-9 630427-36-0 630427-37-1
 630427-38-2 630427-39-3 630427-40-6 630427-41-7 630427-42-8
 630427-43-9 630427-44-0 630427-45-1 630427-46-2 630427-47-3
 630427-48-4 630427-49-5 630427-50-8 630427-51-9 630427-52-0
 630427-53-1 630427-54-2 630427-55-3 630427-56-4 630427-57-5
 630427-58-6 630427-59-7 630427-60-0 630427-61-1 630427-62-2
 630427-63-3 630427-64-4 630427-65-5 630427-66-6 630427-67-7
 630427-68-8 630427-69-9 630427-70-2 630427-71-3 630427-72-4
 630427-73-5 630427-74-6 630427-75-7 630427-76-8 630427-77-9
 630427-78-0 630427-79-1 630427-80-4 630427-81-5 630427-82-6
 630427-83-7 630427-84-8 630427-85-9 630427-86-0 630427-87-1
 630427-88-2 630427-89-3 630427-90-6 630427-91-7 630427-92-8
 630427-93-9 630427-94-0 630427-95-1 630427-96-2 630427-97-3
 630427-98-4 630427-99-5 630428-00-1 630428-01-2 630428-02-3
 630428-03-4 630428-04-5 630428-05-6 630428-06-7 630428-07-8
 630428-08-9 630428-09-0 630428-10-3 630428-11-4 630428-12-5
 630428-13-6 630428-14-7 630428-15-8 630428-16-9 630428-17-0
 630428-18-1 630428-19-2 630428-20-5 630428-21-6 630428-22-7
 630428-23-8 630428-24-9 630428-25-0 630428-26-1 630428-27-2
 630428-28-3 630428-29-4 630428-30-7 630428-31-8 630428-32-9
 630428-33-0 630428-34-1 630428-35-2 630428-36-3 630428-37-4
 630428-38-5 630428-39-6 630428-40-9 630428-41-0 630428-42-1
 630428-43-2 630428-44-3 630428-45-4 630428-46-5 630428-47-6
 630428-48-7 630428-49-8 630428-50-1 630428-51-2 630428-52-3
 630428-53-4 630428-54-5 630428-55-6 630428-56-7 630428-57-8
 630428-58-9 630428-59-0 630428-60-3 630428-61-4 630428-62-5
 630428-63-6 630428-64-7 630428-65-8 630428-66-9 630428-67-0
 630428-68-1 630428-69-2 630428-70-5 630428-71-6 630428-72-7
 630428-73-8 630428-74-9 630428-75-0 630428-76-1 630428-77-2
 630428-78-3 630428-79-4 630428-80-7 630428-81-8 630428-82-9
 630428-83-0 630428-84-1 630428-85-2 630428-86-3 630428-87-4
 630428-88-5 630428-89-6 630428-90-9 630428-91-0 630428-92-1
 630428-93-2 631923-13-2 631923-16-5 631923-17-6 631923-18-7
 631923-19-8 631923-20-1 631923-21-2 631923-22-3 631923-23-4
 631923-24-5 631923-25-6 631923-26-7 631923-27-8 631923-28-9
 631923-29-0 631923-30-3 631923-31-4 631923-32-5 631923-33-6
 631923-34-7 631923-35-8 631923-36-9 631923-37-0 631923-38-1
 631923-39-2 631923-40-5 631923-41-6 631923-42-7 631923-43-8
 631923-44-9 631923-45-0 631923-46-1 631923-47-2 631923-48-3
 631923-49-4 631923-50-7 631923-51-8 631923-52-9 631923-53-0
 631923-54-1 631923-55-2 631923-56-3 631923-57-4 631923-58-5
 631923-59-6 631923-60-9 631923-61-0 631923-62-1 631923-63-2
 631923-64-3 631923-65-4 631923-66-5 631923-67-6 631923-68-7
 631923-69-8

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (nucleotide sequence; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT 631923-70-1 631923-71-2 631923-72-3 631923-73-4 631923-74-5
 631923-75-6 631923-76-7 631923-77-8 631923-78-9 631923-79-0
 631923-80-3 631923-81-4 631923-82-5 631923-83-6 631923-84-7
 631923-85-8 631923-86-9 631923-87-0 631923-88-1 631923-89-2
 631923-90-5 631923-91-6 631923-92-7 631923-93-8 631923-94-9
 631923-95-0 631923-96-1 631923-97-2 631923-98-3 631923-99-4
 631924-00-0 631924-01-1 631924-02-2 631924-03-3 631924-04-4
 631924-05-5 631924-06-6 631924-07-7 631924-08-8 631924-09-9
 631924-10-2 631924-11-3 631924-12-4 631924-13-5 631924-14-6
 631924-15-7 631924-16-8 631924-17-9 631924-18-0 631924-19-1
 631924-20-4 631924-21-5 631924-22-6 631924-23-7 631924-24-8
 631924-25-9 631924-26-0 631924-27-1 631924-28-2 631924-29-3
 631924-30-6 631924-31-7 631924-32-8 631924-33-9 631924-34-0
 631924-35-1 631924-36-2 631924-37-3 631924-38-4 631924-39-5
 631924-40-8 631924-41-9 631924-42-0 631924-43-1 631924-44-2
 631924-45-3 631924-46-4 631924-47-5 631924-48-6 631924-49-7
 631924-50-0 631924-51-1 631924-52-2 631924-53-3 631924-54-4
 631924-55-5 631924-56-6 631924-57-7 631924-58-8 631924-59-9
 631924-60-2 631924-61-3 631924-62-4 631924-63-5 631924-64-6
 631924-65-7 631924-66-8 631924-67-9 631924-68-0 631924-69-1
 631924-70-4 631924-71-5 631924-72-6 631924-73-7 631924-74-8
 631924-75-9 631924-76-0 631924-77-1 631924-78-2 631924-79-3
 631924-80-6 631924-81-7 631924-82-8 631924-83-9 631924-84-0
 631924-85-1 631924-86-2 631924-87-3 631924-88-4 631924-89-5
 631924-90-8 631924-91-9

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
 (nucleotide sequence; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT 361540-77-4

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (subunit B; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT 9001-16-5, Cytochrome oxidase

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (subunits II and IV; gene expression profiles in response to toxic compds. and their use as kidney toxicity predictive genes)

IT 50-02-2, Dexamethasone 50-06-6, Phenobarbital, biological studies 50-18-0, Cyclophosphamide 50-28-2, Estradiol, biological studies 50-32-8, Benzo[a]pyrene, biological studies 50-53-3, Chlorpromazine, biological studies 51-21-8, 5-Fluorouracil 53-79-2, Puromycin 54-85-3, Isoniazid 55-98-1, Busulfan 56-23-5, Carbon tetrachloride, biological studies 56-54-2, Quinidine 58-55-9, Theophylline, biological studies 59-05-2, Methotrexate 60-54-8, Tetracycline 62-75-9, Dimethylnitrosamine 66-81-9, Cycloheximide 67-66-3, Chloroform, biological studies 71-43-2, Benzene, biological studies 100-63-0, Phenylhydrazine 103-90-2, Acetaminophen 108-86-1, Bromobenzene, biological studies 127-07-1, Hydroxyurea 154-93-8, Carmustine 446-86-6, Azathioprine 465-65-6, Naloxone 551-06-4, 1-Naphthylisothiocyanate 637-07-0, Clofibrate 1397-89-3, Amphotericin B 1403-66-3, Gentamicin 3521-62-8, Erythromycin estolate 5786-21-0, Clozapine 9004-32-4, Carboxymethyl cellulose sodium salt 10108-64-2, Cadmium chloride 10540-29-1, Tamoxifen 15663-27-1, Cisplatin 18883-66-4, Streptozotocin 22494-42-4, Diflunisal 23214-92-8, Doxorubicin 25322-68-3, Polyethylene glycol 59865-13-3, Cyclosporin A 65277-42-1, Ketoconazole 82410-32-0, Gancyclovir

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,

unclassified); ANST (Analytical study); BIOL (Biological study)
 (use in design of standard kidney toxicity profile; gene expression
 profiles in response to toxic compds. and their use as kidney toxicity
 predictive genes)

IT 60382-71-0, Diacylglycerol kinase

RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (ζ; gene expression profiles in response to toxic compds. and
 their use as kidney toxicity predictive genes)

IT 9034-51-9, Hemoglobin A

RL: BSU (Biological study, unclassified); BUU (Biological use,
 unclassified); BIOL (Biological study); USES (Uses)
 (α1-chain; gene expression profiles in response to toxic compds.
 and their use as kidney toxicity predictive genes)


IT 50-02-2, Dexamethasone

RL: ADV (Adverse effect, including toxicity); ARU (Analytical role,
 unclassified); ANST (Analytical study); BIOL (Biological study)
 (use in design of standard kidney toxicity profile; gene expression
 profiles in response to toxic compds. and their use as kidney toxicity
 predictive genes)

RN 50-02-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
 (11β,16α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 11 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:892567 HCAPLUS

DN 139:386334

ED Entered STN: 14 Nov 2003

TI Production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates

IN Kunz, Arthur; Moran, Justin Keith; Rubino, Joseph Thomas; Jain, Neera;
 Vidunas, Eugene Joseph; Simpson, John McLean; Robbins, Paul David;
 Merchant, Nishith; DiJoseph, John Francis; Ruppen, Mark Edward; Damle,
 Nitin Krishnaji; Popplewell, Andrew George; et al.

PA Wyeth Holdings Corporation, USA

SO PCT Int. Appl., 186 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 15

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003092623	A2	20031113	WO 2003-US13910	20030502
	WO 2003092623	A3	20040318		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,				
	TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-377440P	P	20020502		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003092623	ICM	A61K

AB The present invention relates to methods for. the production of monomeric cytotoxic drug/carrier **conjugates** (the "**conjugates**") with higher drug loading and substantially reduced low **conjugate** fraction (LCF). Cytotoxic drug derivative/antibody **conjugates**, comps. comprising the **conjugates** and uses of the **conjugates** are also described. Particularly, the invention relates to anti-CD22 antibody-monomeric calicheamicin **conjugates**. The invention also relates to the **conjugates** of the invention, to methods of purification of the **conjugates**, to pharmaceutical comps. comprising the **conjugates**, and to uses of the **conjugates**.

ST calicheamicin deriv antibody cytotoxic drug carrier **conjugate**

IT Carbohydrates, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(Aldaric aci; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT CD antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CD33, antibody specific for; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Liquid chromatography
(FPLC, SEC (size exclusion chromatog.); production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Hydrophobic interaction chromatography
(Macro-Prep Me, Macro-Prep t-Bu; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Carbohydrates, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(aldonic acids; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Carbohydrates, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(aldoses; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Carbohydrates, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(amino sugars; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Hormones, animal, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (anti-; production of monomeric calicheamicin derivative cytotoxic
 drug/carrier
conjugates)

IT CD19 (antigen)
 CD20 (antigen)
 CD22 (antigen)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antibody specific for; production of monomeric calicheamicin derivative
 cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
 (carriers; production of monomeric calicheamicin derivative cytotoxic
 drug/carrier **conjugates**)

IT Antibodies and Immunoglobulins
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (**conjugates**, CMC-544 (humanized anti-CD22 antibody (G5/44)
 with calicheamicin); production of monomeric calicheamicin derivative
 cytotoxic
 drug/carrier **conjugates**)

IT Cell proliferation
 (disorder, treatment of; production of monomeric calicheamicin derivative
 cytotoxic drug/carrier **conjugates**)

IT Tubulins
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (dolastatins and auristatins; production of monomeric calicheamicin
 derivative
 cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
 (enteric; production of monomeric calicheamicin derivative cytotoxic
 drug/carrier **conjugates**)

IT Antibodies and Immunoglobulins
 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
 (Analytical study); BIOL (Biological study); USES (Uses)
 (fragments, Fab, F(ab)2; production of monomeric calicheamicin derivative
 cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
 (freeze-dried, of monomeric cytotoxic drug derivative/carrier
conjugate; production of monomeric calicheamicin derivative cytotoxic
 drug/carrier **conjugates**)

IT Antibodies and Immunoglobulins
 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
 (Analytical study); BIOL (Biological study); USES (Uses)
 (fusion products; production of monomeric calicheamicin derivative cytotoxic
 drug/carrier **conjugates**)

IT Glycosides
 RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
 (glucopyranosides, Me α -; production of monomeric calicheamicin
 derivative cytotoxic drug/carrier **conjugates**)

IT Antibodies and Immunoglobulins
 RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological
 study); USES (Uses)
 (heavy chain, variable region; production of monomeric calicheamicin
 derivative
 cytotoxic drug/carrier **conjugates**)

IT Antibodies and Immunoglobulins
 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
 (Analytical study); BIOL (Biological study); USES (Uses)

(humanized; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
(injections, i.p.; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
(injections, i.v.; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
(injections, intraarterial; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
(injections, intramedullar; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
(injections, intrathecal; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
(injections, s.c.; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
(injections, transcutaneous; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
(injections, transdermal; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Monosaccharides
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(ketoses; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Antibodies and Immunoglobulins
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(light chain, variable region; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT B cell (lymphocyte)
(malignancy; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(monoclonal; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Cytotoxic agents
(monomeric; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
(nasal; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Lymphoma
(non-Hodgkin's, treatment of; production of monomeric calicheamicin derivative cytotoxic drug/carrier **conjugates**)

IT Tubulins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (polymerization, inhibitor of; production of monomeric calicheamicin
 derivative
 cytotoxic drug/carrier **conjugates**)

IT Alkylating agents, biological
 Antitumor agents
 Cryoprotectants
 HPLC
 Human
 Linking agents
 Mus
 Protein sequences
 Surfactants
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Alditols
 Lactones
 Polyoxyalkylenes, uses
 Uronic acids
 RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Antibodies and Immunoglobulins
 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
 (Analytical study); BIOL (Biological study); USES (Uses)
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Growth factors, animal
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Antibodies and Immunoglobulins
 RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological
 study); USES (Uses)
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Androgens
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Corticosteroids, biological studies
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Cytokines
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Estrogens
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Interferons

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Interleukin 2
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Interleukins
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Progestogens
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Steroids, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Taxanes
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Tumor necrosis factors
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT Drug delivery systems
(rectal; production of monomeric calicheamicin derivative cytotoxic
drug/carrier **conjugates**)

IT Antibodies and Immunoglobulins
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
(Analytical study); BIOL (Biological study); USES (Uses)
(single chain; production of monomeric calicheamicin derivative cytotoxic
drug/carrier **conjugates**)

IT Drug delivery systems
(sublingual; production of monomeric calicheamicin derivative cytotoxic
drug/carrier **conjugates**)

IT Drug delivery systems
(topical; production of monomeric calicheamicin derivative cytotoxic
drug/carrier **conjugates**)

IT Carcinoma
Leukemia
Neoplasm
Sarcoma
(treatment of; production of monomeric calicheamicin derivative cytotoxic
drug/carrier **conjugates**)

IT Polymerization
(tubulin, inhibitor of; production of monomeric calicheamicin derivative
cytotoxic drug/carrier **conjugates**)

IT Drug delivery systems
(vaginal; production of monomeric calicheamicin derivative cytotoxic

drug/carrier **conjugates**)

IT 207464-48-0, Toyopearl Ether
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(-650M, chromatog. medium; production of monomeric calicheamicin derivative
cytotoxic drug/carrier **conjugates**)

IT 9005-25-8D, Starch, hydroxyethyl derivs.
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(40; production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT 9012-36-6D, Sepharose, derivs.
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(Fast Flow chromatog. medium; production of monomeric calicheamicin
derivative
cytotoxic drug/carrier **conjugates**)

IT 335197-32-5P 369632-97-3P 369632-98-4P 623141-79-7P 623141-80-0P
623141-81-1P 623141-82-2P 623141-83-3P 623141-84-4P 623954-95-0P
623954-96-1P 623954-97-2P 623954-98-3P 623954-99-4P 623955-00-0P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
PRP (Properties); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; production of monomeric calicheamicin derivative
cytotoxic drug/carrier **conjugates**)

IT 124-07-2, Octanoic acid, biological studies 334-48-5, Decanoic acid
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(as additive; production of monomeric calicheamicin derivative cytotoxic
drug/carrier **conjugates**)

IT 65623-82-7, 4-(4-Acetylphenoxy) butanoic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)
(as **linker**; production of monomeric calicheamicin derivative
cytotoxic drug/carrier **conjugates**)

IT 65546-95-4, Sephacryl S-200
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(chromatog.; production of monomeric calicheamicin derivative cytotoxic
drug/carrier **conjugates**)

IT 80449-02-1, Tyrosine kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; production of monomeric calicheamicin derivative cytotoxic
drug/carrier **conjugates**)

IT 50-69-1, Ribose 50-70-4, Sorbitol, uses 50-81-7, Ascorbic acid, uses
50-99-7, Glucose, uses 56-81-5, Glycerol, uses 56-82-6, Glyceraldehyde
57-48-7, Fructose, uses 57-50-1, Sucrose, uses 58-86-6, Xylose, uses
59-05-2, Methotrexate 59-23-4, Galactose, uses 63-42-3, Lactose
65-42-9, Lyxose 69-65-8, Mannitol 69-79-4, Maltose 77-86-1,
Tromethamine 87-79-6, Sorbose 87-89-8, Inositol 89-65-6, Isoascorbic
acid 99-20-7, Trehalose 107-21-1, Ethylene glycol, uses 114-04-5,
Neuraminic acid 115-77-5, Pentaerythritol, uses 147-81-9, Arabinose
526-95-4, Gluconic acid 551-84-8, Xylulose 685-73-4, Galacturonic acid
1398-61-4, Chitin 1758-51-6, Erythrose 2152-76-3, Idose 3416-24-8,
Glucosamine 3458-28-4, Mannose 5556-48-9, Ribulose 5987-68-8,
Altrose 6038-51-3, Allose 6556-12-3, Glucuronic acid 6814-36-4,
Mannuronic acid 7535-00-4, Galactosamine 7647-14-5, Sodium chloride,
uses 9000-07-1, Carrageenan 9000-69-5, Pectins 9004-34-6, Cellulose,
uses 9004-54-0, Dextran 40,, uses **9004-61-9**,
Hyaluronic acid 9005-25-8, Starch, uses 9005-32-7, Alginate
acid 9005-65-6, Polysorbate 80, 9005-79-2, Glycogen, uses 9005-82-7,
Amylose 9007-27-6, Chondroitin 9012-36-6, Agarose 9012-72-0, Glucan
9013-95-0, Levan 9014-63-5, Xylans 9036-88-8, Mannan 9037-22-3,
Amylopectin 9037-55-2, Galactan 9037-90-5, Fructan 9046-38-2,
Galacturonan 9046-40-6, Pectic acid 9057-02-7, Pullulan 9060-75-7,

Arabinan 9072-19-9, Fucoidan 11138-66-2, Xanthan gum 17598-81-1,
 Tagatose 19163-87-2, Gulose 23140-52-5, Psicose 25322-68-3,
 Polyethylene glycol 25322-69-4, Polypropylene glycol 25525-21-7,
 Glucaric acid 29884-64-8, Threose 30077-17-9, Talose 37331-28-5,
 Pustulan 40031-31-0, Erythrulose 53106-52-8, Pentose 60495-58-1,
 Galactocarolose 64612-25-5, Fucan 71927-65-6, Heptose 75634-40-1,
 Dermatan 93780-23-5, Hexose 169799-44-4, Keratin 199297-32-0,
 Pentose

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT 50-18-0, Cyclophosphamide 50-91-9, Floxuridine 51-21-8D,
 5-Fluorouracil, derivs. 51-75-2, Mechlorethamine 52-24-4, Thiotepe
53-03-2, Prednisone 53-79-2, Puromycin 57-22-7, Vincristine
 59-14-3, Broxuridine 69-89-6, Xanthine 70-00-8, Trifluridine
 115-02-6, Azaserine 147-94-4, Cytarabine 320-67-2, Azacitidine
 671-16-9, Procarbazine 865-21-4, Vinblastine 1402-38-6, Actinomycin
 1404-00-8, Mitomycin 1404-15-5, Nogalamycin 2096-42-6, Gougerotin
 2353-33-5, Decitabine 3094-09-5, Doxifluridine 4291-63-8, Cladribine
 4342-03-4, Dacarbazine 4803-27-4, Anthramycin 10540-29-1, Tamoxifen
 11056-06-7, Bleomycin 15663-27-1, Cisplatin 17902-23-7, Tegafur
 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 23214-92-8,
 Doxorubicin 25316-40-9, Adriamycin 31698-14-3, Ancitabine
 33069-62-4D, Taxol, analogs 33419-42-0, Etoposide 35846-53-8D,
 Maytansin, derivs. 41575-94-4, Carboplatin 50935-04-1, Carubicin
 53910-25-1, Pentostatin 54083-22-6, Zorubicin 55726-47-1, Enocitabine
 56124-62-0, Valrubicin 56420-45-2, Epirubicin 57576-44-0, Aclarubicin
 58957-92-9, Idarubicin 60084-10-8, Tiazofurin 62683-29-8,
 Colony-stimulating factor 65271-80-9, Mitoxantrone 71628-96-1,
 Menogaril 83869-56-1, GM-CSF 95058-81-4, Gemcitabine 108212-76-6,
 N-Acetyl- γ -calicheamicin 113440-58-7D, Calicheamicin, derivative
 114797-28-3, Esperamicin 138441-31-3 143011-72-7, G-CSF 154361-50-9,
 Capecitabine 157207-90-4, Hemiasterlin 174722-31-7, Rituximab
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(production of monomeric calicheamicin derivative cytotoxic drug/carrier
conjugates)

IT 623959-72-8 623959-73-9 623959-74-0 623959-75-1 623959-76-2
 623959-77-3 623959-78-4 623959-79-5 623959-80-8 623959-81-9
 623959-82-0 623959-83-1 623959-84-2 623959-85-3 623959-86-4
 623959-87-5 623959-88-6 623959-89-7 623959-90-0 623959-91-1
 623959-92-2 623959-93-3

RL: PRP (Properties)

(unclaimed nucleotide sequence; production of monomeric calicheamicin
 derivative cytotoxic drug/carrier **conjugates**)

IT 623959-65-9 623959-66-0 623959-67-1 623959-68-2 623959-69-3
 623959-70-6 623959-71-7

RL: PRP (Properties)

(unclaimed protein sequence; production of monomeric calicheamicin
 derivative

cytotoxic drug/carrier **conjugates**)

IT 145061-00-3 380648-61-3 623901-97-3 623901-98-4 623901-99-5
 623902-00-1 623902-01-2 623902-02-3 623902-03-4 623902-04-5
 623902-05-6 623960-58-7 623960-59-8 623960-60-1 623960-61-2
 623960-63-4 623960-64-5 623960-65-6 623960-66-7 624752-51-8
 624752-52-9

RL: PRP (Properties)


(unclaimed sequence; production of monomeric calicheamicin derivative
 cytotoxic

drug/carrier **conjugates**)
 IT 9004-61-9, Hyaluronic acid
 RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
 conjugates)
 RN 9004-61-9 HCAPLUS
 CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 53-03-2, Prednisone
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (production of monomeric calicheamicin derivative cytotoxic drug/carrier
 conjugates)
 RN 53-03-2 HCAPLUS
 CN Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- (8CI, 9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



L46 ANSWER 12 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:818517 HCAPLUS
 DN 139:321695
 ED Entered STN: 17 Oct 2003
 TI Genes showing altered patterns of expression in liver necrosis and their
 predictive uses
 IN Kier, Larry; Nolan, Timothy D.; Sankar, Usha; Derbel, Maher
 PA Phase-1 Molecular Toxicology, Inc., USA
 SO PCT Int. Appl., 379 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C12N
 CC 14-14 (Mammalian Pathological Biochemistry)
 Section cross-reference(s): 3, 4
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003085083	A2	20031016	WO 2003-US10141	20030401
	WO 2003085083	A3	20040722		
	WO 2003085083	B1	20040923		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
 UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004076974 A1 20040422 US 2003-404460 20030401
 PRAI US 2002-369287P P 20020401

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2003085083 ICM C12N

AB Genes that show altered levels of expression in the liver during necrosis induced by poisoning are identified for use in predicting liver poisoning by novel substances. The invention provides for a method of predicting the liver toxicity in an individual to an agent. The method comprises obtaining a biol. sample from an individual treated with the agent. The expression of one or more liver toxicity predictive genes in the sample is measured, wherein the genes are selected from a group consisting of partial gene sequences of genes identified as responsive to agents causing liver necrosis. The process generates a test expression profile using data from several points after exposure to the poison. The test expression profile is used with a set of reference expression profiles in a Predictive Model to determine whether the agent will induce liver toxicity in the individual.

ST liver poisoning necrosis gene expression prediction database

IT Presenilins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (1, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (14-3-3, ζ isoform, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Uncoupling protein

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (2, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Progesterone receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (25DX, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Connexins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (32, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Apolipoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (A-II, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Transport proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ADP/ATP carrier, gene for, intoxication regulation of liver expression)

of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ATF-3 (activating transcription factor 3), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Bax, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Apolipoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(C-I, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Apolipoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(C-III, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(C-reactive, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Glycoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(C4bp (complement C4b-binding protein), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Cyclins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(D1, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Cyclins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(D3, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(DBI (diazepam binding inhibitor), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FABP (fatty acid-binding protein), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Cyclins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(G, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Transcription factors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (GADD153, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GADD45, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GRP78 (glucose-regulated protein, 78 kDa), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Ferritins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(H chain, Ferritins, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HREV107, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HRG (histidine-rich glycoprotein), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ID1 (inhibitor of differentiation 1), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IF1 (ATPase F1 inhibitor), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IFRD1 (interferon related developmental regulator 1), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Insulin-like growth factor-binding proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IGFBP-1, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Insulin-like growth factor-binding proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IGFBP-3, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Insulin-like growth factor-binding proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IGFBP-5, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Annexins

- RL: BSU (Biological study, unclassified); BIOL (Biological study)
(II, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Protein formation factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IRE-BP (iron-responsive element-binding protein), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Immunoglobulin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgE type I, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgE-binding, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(I κ B- α (NF- κ B inhibitor α), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Ribosomal proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(L13, L13A, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Ribosomal proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(L6, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MAA (melanoma-associated antigen), ME491, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT P-glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MDR1, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT P-glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MDR2, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Histocompatibility antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MHC (major histocompatibility complex), class I, RT1.A1(f) α -chain, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NF-III (nuclear factor III), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in

liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (NIPK, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PAR-interacting, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (PC3, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-102, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-109, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-117, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-119, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-12, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-123, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-127, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-128, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-131, gene for, intoxication regulation of liver expression of;

genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-137, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-139, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-144, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-145, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-15, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-152, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-154, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-161, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-162, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-164, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-168, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(RCT-175, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-179, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-180, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-181, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-182, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-185, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-189, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-191, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-192, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-200, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-205, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-207, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-209, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-21, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-213, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-214, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-218, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-225, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-227, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-233, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-239, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-241, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-242, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-252, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-256, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-258, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-264, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-270, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-271, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-280, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-288, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-289, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-290, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-291, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-296, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RCT-33, gene for, intoxication regulation of liver expression of;
genes showing altered patterns of expression in liver necrosis and
their predictive uses)

their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-36, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-37, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-38, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-39, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-40, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-48, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-49, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-50, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-52, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-55, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-64, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (RCT-65, gene for, intoxication regulation of liver expression of;

- genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RCT-68, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RCT-72, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RCT-78, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RCT-8, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RCT-83, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RCT-88, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RCT-89, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RCT-92, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (RCT-98, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Ribosomal proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (S17, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Ribosomal proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (S8, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Ribosomal proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (S9, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SCP2 (sterol carrier protein 2), gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TP53, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Annexins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(V, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Anion channel
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VDAC (voltage-dependent anion channel), VDAC2, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Porins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(aquaporin 3, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bile acid-sodium-cotransporter, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Gene, animal
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(c-Ha-ras, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Gene, animal
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(c-jun, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-myc, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cofilin, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Elongation factors (protein formation)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(eEF-1 α , gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and

- their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gap junction-specific, $\beta 1$, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Dynamin 1
Fas antigen
Interleukin 1β
Macrophage inflammatory protein 1α
Proliferating cell nuclear antigen
Stem cell factor
Transthyretin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Liver
(genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Gene expression profiles, animal
(in liver poisoning; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Canis familiaris
Human
Primates
Rattus
(liver toxicol. in; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Lipopolysaccharides
Polyoxyalkylenes, biological studies
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(liver toxicol. of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Necrosis
Poisoning, biological
(liver; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(matrins F, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(matrins G, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Chemokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monocyte chemoattractant protein-1, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Liver, disease
(necrosis; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (nucleoside transporter, nitrobenzylthiosine-sensitive, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nucleosome assembly 1, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Information systems
(of liver gene expression data; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Simulation and Modeling, biological
(of liver intoxication and necrosis; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(organic cation transporter, isoform 3, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(osteoactivin, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p125FAK, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peroxisomal multifunctional enzyme 2, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Toxicology
(prediction of liver intoxication in; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Albumins, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prepro-, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selenium-containing, P, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(senescence marker protein 30, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(stathmin, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Collagens, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (type II, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (ubiquitin-**conjugating**, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (zinc finger-containing, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Macrophage inflammatory protein 2
RL: BSU (Biological study, unclassified); BIOL (Biological study) (α , gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Tubulins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (α -, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Macroglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (α 2-, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Actins
Tubulins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (β -, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (β 1, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT Actins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (γ -, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT 9015-81-0, 17 β -Hydroxysteroid dehydrogenase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (17 β -hydroxysteroid dehydrogenase, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT 9035-81-8, Trypsin inhibitor
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CPI-21, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)
- IT 9001-03-0
RL: BSU (Biological study, unclassified); BIOL (Biological study) (III, gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

- IT 77106-95-7, Carbonyl reductase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (carbonyl reductase, gene for, intoxication regulation of liver
 expression of; genes showing altered patterns of expression in liver
 necrosis and their predictive uses)
- IT 9001-12-1, Matrix metalloproteinase 1 9001-59-6, Pyruvate kinase
 9001-62-1, Lipase 9013-66-5, Glutathione peroxidase 9014-34-0,
 Stearyl-CoA desaturase 9016-12-0, Hypoxanthine-guanine
 phosphoribosyltransferase 9023-58-9, Arginosuccinate synthetase
 9023-93-2, Acetyl-CoA carboxylase 9024-60-6, Ornithine decarboxylase
 9026-00-0, Cholesterol esterase 9026-23-7, Carbamyl phosphate synthetase
 I 9026-51-1, Nucleoside diphosphate kinase 9026-67-9, Choline kinase
 9027-34-3, Argininosuccinate lyase 9027-44-5, HMG CoA synthase
 9028-39-1, 3-Hydroxyisobutyrate dehydrogenase 9028-48-2, NADP-dependent
 isocitrate dehydrogenase 9028-78-8 9028-86-8, Aldehyde dehydrogenase
 9029-78-1, Betaine homocysteine methyltransferase 9031-14-5,
 Lecithin:cholesterol acyltransferase 9031-61-2, Thymidylate synthase
 9032-20-6, NADPH quinone oxidoreductase 9032-25-1, NADH cytochrome b5
 reductase 9033-53-8, Retinol dehydrogenase 9037-21-2, Tryptophan
 hydroxylase 9037-53-0, Cholesterol 7 α -hydroxylase 9044-85-3,
 3 β -Hydroxysteroid dehydrogenase 9045-77-6, Fatty acid synthase
 9054-89-1, Superoxide dismutase 9059-22-7, Heme oxygenase 9068-41-1
 9074-10-6, Biliverdin reductase 9079-10-1, N-Hydroxy-2-
 acetylaminofluorene sulfotransferase 37228-72-1, Glycine
 methyltransferase 37292-81-2, Cytochrome P450 11A1 60616-82-2,
 Cathepsin L 62229-50-9, Epidermal growth factor 67763-96-6,
 Insulin-like growth factor I 71965-46-3, Cathepsin S 78990-62-2,
 Calpain 80449-31-6, Bikunin 82785-45-3, Neuropeptide Y 88160-82-1,
 Thymosin β 10 (human) 88943-21-9, α 1 Inhibitor 3 89964-14-7,
 α -Prothymosin 91448-99-6, Cystatin C 117698-12-1, Paraoxonase
 137632-07-6, ERK 1 kinase 138069-86-0, Ref-1 endonuclease 141436-78-4,
 Protein kinase C 142805-58-1, MAP Kinase kinase 143180-75-0, DNA
 topoisomerase I 144114-16-9, Focal adhesion kinase 147014-97-9, Cyclin
 dependent kinase 4 148710-29-6, Aflatoxin B1 aldehyde reductase
 156681-44-6, α -Methylacyl CoA racemase 182372-15-2, Caspase 6
 191550-14-8, 8-Oxoguanine DNA glycosylase 289898-51-7, JNK1 protein
 kinase 301166-54-1, PTEN phosphatase 329764-85-4, Cytochrome P450 1A1
 330196-93-5, Cytochrome P450 2E1 331462-98-7, Cytochrome P450 3A1
 331823-00-8, Cytochrome P450 2C11 455255-58-0, Cytochrome P450 2C23
 455255-76-2, Cytochrome P450 2D18
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (gene for, intoxication regulation of liver expression of; genes
 showing altered patterns of expression in liver necrosis and their
 predictive uses)
- IT 9001-51-8, Glucokinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (glucokinase, gene for, intoxication regulation of liver expression of;
 genes showing altered patterns of expression in liver necrosis and
 their predictive uses)
- IT 50-02-2, Dexamethasone 50-06-6, Phenobarbital, biological
 studies 50-18-0, Cyclophosphamide 50-28-2, Estradiol, biological
 studies 50-32-8, Benzo[a]pyrene, biological studies 50-53-3,
 Chlorpromazine, biological studies 51-21-8, 5-Fluorouracil 53-79-2,
 Puromycin 54-85-3, Isoniazid 55-98-1, Busulfan 56-23-5, Carbon
 tetrachloride, biological studies 56-54-2, Quinidine 58-55-9,
 Theophylline, biological studies 59-05-2, Methotrexate 60-54-8,
 Tetracycline 62-75-9, Dimethylnitrosamine 64-17-5, Ethanol, biological
 studies 66-81-9, Cycloheximide 67-66-3, Chloroform, biological studies
 71-43-2, Benzene, biological studies 86-84-0, 1-Naphthylisocyanate

100-63-0, Phenylhydrazine 103-90-2, Acetaminophen 108-86-1,
 Bromobenzene, biological studies 127-07-1, Hydroxyurea 154-93-8,
 Carmustine 446-86-6, Azathioprine 465-65-6, Naloxone 637-07-0,
 Clofibrate 1162-65-8, Aflatoxin B1 1397-89-3, Amphotericin B
 1403-66-3, Gentamicin 3521-62-8, Erythromycin estolate 5786-21-0,
 Clozapine 9004-32-4, Carboxymethyl cellulose 10108-64-2, Cadmium
 chloride 10540-29-1, Tamoxifen 15663-27-1, Cisplatin 18883-66-4,
 Streptozotocin 22494-42-4, Diflunisal 23214-92-8, Doxorubicin
 25322-68-3, Polyethylene glycol 59865-13-3, Cyclosporin A 65277-42-1,
 Ketoconazole 82410-32-0, Gancyclovir
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
 unclassified); BIOL (Biological study)

(liver toxicol. of; genes showing altered patterns of expression in
 liver necrosis and their predictive uses)

IT 302355-88-0, RPTP

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (receptor protein tyrosine phosphatase D, gene for, intoxication
 regulation of liver expression of; genes showing altered patterns of
 expression in liver necrosis and their predictive uses)

IT 9000-83-3, ATPase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (sarcoplasmic reticulum, gene for, intoxication regulation of liver
 expression of; genes showing altered patterns of expression in liver
 necrosis and their predictive uses)

IT	613690-29-2	613690-30-5	613690-31-6	613690-32-7	613690-33-8
	613690-34-9	613690-35-0	613690-36-1	613690-37-2	613690-38-3
	613690-39-4	613690-40-7	613690-41-8	613690-42-9	613690-43-0
	613690-44-1	613690-45-2	613690-46-3	613690-47-4	613690-48-5
	613690-49-6	613690-50-9	613690-51-0	613690-52-1	613690-53-2
	613690-54-3	613690-55-4	613690-56-5	613690-57-6	613690-58-7
	613690-59-8	613690-60-1	613690-61-2	613690-62-3	613690-63-4
	613690-64-5	613690-65-6	613690-66-7	613690-67-8	613690-68-9
	613690-69-0	613690-70-3	613690-71-4	613690-72-5	613690-73-6
	613690-74-7	613690-75-8	613690-76-9	613690-77-0	613690-78-1
	613690-79-2	613690-80-5	613690-81-6	613690-82-7	613690-83-8
	613690-84-9	613690-85-0	613690-86-1	613690-87-2	613690-88-3
	613690-89-4	613690-90-7	613690-91-8	613690-92-9	613690-93-0
	613690-94-1	613690-95-2	613690-96-3	613690-97-4	613690-98-5
	613690-99-6	613691-00-2	613691-01-3	613691-02-4	613691-03-5
	613691-04-6	613691-05-7	613691-06-8	613691-07-9	613691-08-0
	613691-09-1	613691-10-4	613691-11-5	613691-12-6	613691-13-7
	613691-14-8	613691-15-9	613691-16-0	613691-17-1	613691-18-2
	613691-19-3	613691-20-6	613691-21-7	613691-22-8	613691-23-9
	613691-24-0	613691-25-1	613691-26-2	613691-27-3	613691-28-4
	613691-29-5	613691-30-8	613691-31-9	613691-32-0	613691-33-1
	613691-34-2	613691-35-3	613691-36-4	613691-37-5	613691-38-6
	613691-39-7	613691-40-0	613691-41-1	613691-42-2	613691-43-3
	613691-44-4	613691-45-5	613691-46-6	613691-47-7	613691-48-8
	613691-49-9	613691-50-2	613691-51-3	613691-52-4	613691-53-5
	613691-54-6	613691-55-7	613691-56-8	613691-57-9	613691-58-0
	613691-59-1	613691-60-4	613691-61-5	613691-62-6	613691-63-7
	613691-64-8	613691-65-9	613691-66-0	613691-67-1	613691-68-2
	613691-69-3	613691-70-6	613691-71-7	613691-72-8	613691-73-9
	613691-74-0	613691-75-1	613691-76-2	613691-77-3	613691-78-4
	613691-79-5	613691-80-8	613691-81-9	613691-82-0	613691-83-1
	613691-84-2	613691-85-3	613691-86-4	613691-87-5	613691-88-6
	613691-89-7	613691-90-0	613691-91-1	613691-92-2	613691-93-3
	613691-94-4	613691-95-5	613691-96-6	613691-97-7	613691-98-8
	613691-99-9	613692-00-5	613692-01-6	613692-02-7	613692-03-8

613692-04-9	613692-05-0	613692-06-1	613692-07-2	613692-08-3
613692-09-4	613692-10-7	613692-11-8	613692-12-9	613692-13-0
613692-14-1	613692-15-2	613692-16-3	613692-17-4	613692-18-5
613692-19-6	613692-20-9	613692-21-0	613692-22-1	613692-23-2
613692-24-3	613692-25-4	613692-26-5	613692-27-6	613692-28-7
613692-29-8	613692-30-1	613692-31-2	613692-32-3	613692-33-4
613692-34-5	613692-35-6	613692-36-7	613692-37-8	613692-38-9
613692-39-0	613692-40-3	613692-41-4	613692-42-5	613692-43-6
613692-44-7	613692-45-8	613692-46-9	613692-47-0	613692-48-1
613692-49-2	613692-50-5	613692-51-6	613692-52-7	613692-53-8
613692-54-9	613692-55-0	613692-56-1	613692-57-2	613692-58-3
613692-59-4	613692-60-7	613692-61-8	613692-62-9	613692-63-0
613692-64-1	613692-65-2	613692-66-3	613692-67-4	613692-68-5

RL: PRP (Properties)

(unclaimed nucleotide sequence; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT	613692-69-6	613692-70-9	613692-71-0	613692-72-1	613692-73-2
	613692-74-3	613692-75-4	613692-76-5	613692-77-6	613692-78-7
	613692-79-8	613692-80-1	613692-81-2	613692-82-3	613692-83-4
	613692-84-5	613692-85-6	613692-86-7	613692-87-8	613692-88-9
	613692-89-0	613692-90-3	613692-91-4	613692-92-5	613692-93-6
	613692-94-7				

RL: PRP (Properties)

(unclaimed nucleotide sequence; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT 9014-08-8, Enolase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(α , gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT 9012-90-2, DNA polymerase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(β , gene for, intoxication regulation of liver expression of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

IT 50-02-2, Dexamethasone


RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)

(liver toxicol. of; genes showing altered patterns of expression in liver necrosis and their predictive uses)

RN 50-02-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L46 ANSWER 13 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:678606 HCAPLUS
 DN 139:197709
 ED Entered STN: 29 Aug 2003
 TI macrolide erythromycin **conjugates** of biologically active
 compounds, methods for their preparation and use, formulation, and
 pharmaceutical applications thereof
 IN Burnet, Michael; Guse, Jan-Hinrich; Gutke, Hans-Jurgen; Beck, Albert;
 Tsotsou, Georgia; Droste-Borel, Irina; Reichert, Jeannette; Luyten,
 Kattie; Busch, Maximilian; Wolff, Michael; Khobzaoui, Moussa; Margutti,
 Simona; Meindl, Thomas; Kim, Gene; Barker, Laurence
 PA Sympore G.m.b.H., Germany
 SO PCT Int. Appl., 183 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 33-7 (Carbohydrates)
 Section cross-reference(s): 1, 15, 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070174	A2	20030828	WO 2003-US4609	20030214
	WO 2003070174	A3	20031113		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2002-357434P	P	20020215		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003070174	ICM	A61K
OS	MARPAT 139:197709	
GI		



- AB Erythromycin macrolide **conjugates** T-(L-C)_m, wherein T is a transportophore, L is a bond or a linker having a mol. weight up to 240 dalton, C is a non-antibiotic therapeutic agent, and m is 1-8, in which the transportophore has an immune selectivity ratio of at least 2, the transportophore is covalently bonded to the non-antibiotic therapeutic agent via the bond or the linker, and the compound has an immune selectivity ratio of at least 2, useful for enhancing efficacy of a therapeutic agent. Thus, macrolide I (R = R1) was prepared in 76% yield via coupling of I (R = H) with diclofenac as antitumor and antibacterial agent and was tested in vitro for its cytotoxicity and immunosuppressive activity using a mouse skin transplant model.
- ST human antiinflammatory vaccine immunosuppression antibacterial antitumor erythromycin prepn cytotoxicity; antiinflammatory vaccine immunosuppression antibacterial antitumor glycoside macrolide prepn erythromycin
- IT Infection
(bacterial; macrolide erythromycin **conjugates** of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)
- IT Anti-inflammatory agents
Antibacterial agents
Antibiotics
Antitumor agents
Cytotoxicity
Human
Inflammation
Neoplasm
Skin
Vaccines
(macrolide erythromycin **conjugates** of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)
- IT Glycosides

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(macrolide erythromycin **conjugates** of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

IT Antibiotics

(macrolide; macrolide erythromycin **conjugates** of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

IT 586410-99-3P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(macrolide erythromycin **conjugates** of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

IT 531-75-9P 96100-89-9P 152235-41-1P 235436-93-8P 276245-85-3P
 501002-55-7P 586410-56-2P 586410-57-3P 586410-58-4P 586410-59-5P
 586410-60-8P 586410-61-9P 586410-62-0P 586410-63-1P 586410-64-2P
 586410-65-3P 586410-66-4P 586410-67-5P 586410-68-6P 586410-69-7P
 586410-70-0P 586410-71-1P 586410-72-2P 586410-73-3P 586410-74-4P
 586410-76-6P 586410-78-8P 586410-80-2P 586410-82-4P 586410-84-6P
 586410-86-8P 586410-87-9P 586410-88-0P 586410-89-1P 586410-90-4P
 586410-92-6P 586410-94-8P 586411-18-9P 586411-20-3P 586411-22-5P
 586411-24-7P 586411-26-9P 586411-28-1P 586411-30-5P 586411-32-7P
 586411-37-2P 586411-39-4P 586411-43-0P 586411-45-2P 586411-47-4P
 586411-49-6P 586411-53-2P 586411-59-8P 586411-65-6P 586411-72-5P
 586411-74-7P 586411-78-1P 586411-80-5P 586411-82-7P
 586411-84-9P 586411-86-1P 586411-88-3P 586411-90-7P
 586411-92-9P 586411-94-1P 586411-98-5P 586412-01-3P 586412-06-8P
 586412-18-2P 586412-26-2P 586412-30-8P 586412-34-2P 586412-38-6P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(macrolide erythromycin **conjugates** of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

IT 586411-06-5P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(macrolide erythromycin **conjugates** of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

IT 516-12-1P 5786-56-1P 117693-41-1P 117693-42-2P 128305-54-4P
 586411-01-0P 586411-03-2P 586411-08-7P 586411-10-1P 586411-12-3P
 586411-14-5P 586411-16-7P 586411-51-0P 586411-56-5P 586411-63-4P
 586411-67-8P 586411-96-3P 586412-03-5P 586412-09-1P 586412-12-6P
 586412-14-8P 586412-16-0P 586412-21-7P 586412-23-9P 586412-28-4P
 586412-43-3P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(macrolide erythromycin **conjugates** of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

IT 586411-76-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(macrolide erythromycin **conjugates** of biol. active compds.
methods for their preparation and use formulation and pharmaceutical
applications thereof)

IT 50-02-2, Dexamethasone 50-24-8, Prednisolone 50-78-2
53-86-1, Indomethacin 56-53-1 61-68-7, Mefenamic acid 76-25-5
, Triamcinolone acetonide 105-36-2, Ethyl bromoacetate 108-30-5,
Succinic anhydride, reactions 109-83-1 110-91-8, Morpholine, reactions
110-94-1, Glutaric acid 305-03-3, Chlorambucil 531-76-0 644-62-2,
Meclofenamic acid 2067-33-6, 5-Bromovaleric acid 2304-94-1
5104-49-4, Flurbiprofen 15307-86-5, Diclofenac 15687-27-1, Ibuprofen
16471-29-7 24280-93-1, Mycophenolic acid 25812-30-0, Gemfibrozil
30516-87-1, AZT 32483-51-5 75330-75-5, Lovastatin 83905-01-5
86386-73-4, Fluconazole 88404-25-5 111321-02-9 152460-10-1
169590-42-5, Celecoxib 192564-13-9, Neotrofin 264621-05-8
501121-34-2 586411-35-0 586411-61-2 586411-69-0 586412-36-4
586412-40-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(macrolide erythromycin **conjugates** of biol. active compds.
methods for their preparation and use formulation and pharmaceutical
applications thereof)

IT 586411-80-5P 586411-84-9P 586411-86-1P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)



(macrolide erythromycin **conjugates** of biol. active compds.
methods for their preparation and use formulation and pharmaceutical
applications thereof)

RN 586411-80-5 HCAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-
 α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-[4-
[[[(11 β ,16 α)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-
1,4-dien-21-yl]oxy]-1,4-dioxobutyl]- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 586411-84-9 HCAPLUS


CN 1-Oxa-6-azacyclopentadecane-13,15-dione, 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-[4-[[[(11 β ,16 α)-9-fluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-3,20-dioxopregna-1,4-dien-21-yl]oxy]-1,4-dioxobutyl]- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12R,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 586411-86-1 HCAPLUS

CN 1-Oxa-6-azacyclopentadecane-13,15-dione, 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-2-O-[4-[[[(11 β)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl]oxy]-1,4-dioxobutyl]-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12R,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






IT 50-02-2, Dexamethasone 50-24-8, Prednisolone
 76-25-5, Triamcinolone acetonide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (macrolide erythromycin **conjugates** of biol. active compds.
 methods for their preparation and use formulation and pharmaceutical
 applications thereof)
 RN 50-02-2 HCAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
 (11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 50-24-8 HCAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11 β)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 76-25-5 HCAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 14 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:678605 HCAPLUS
 DN 139:197708
 ED Entered STN: 29 Aug 2003
 TI macrolide erythromycin **conjugates** of biologically active compounds, methods for their preparation and use, formulation, and pharmaceutical applications thereof
 IN Burnet, Michael; Guse, Jan-Hinrich; Kim, Gene; Beck, Albert; Tsotsou, Georgia; Droste-Borel, Irina; Barker, Laurence; Wolff, Michael; Gutke, Hans-Jurgen
 PA Sympore G.m.b.H., Germany
 SO PCT Int. Appl., 164 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K
 CC 33-7 (Carbohydrates)
 Section cross-reference(s): 1, 15, 63


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070173	A2	20030828	WO 2003-US4596	20030214
	WO 2003070173	A3	20031204		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004005641	A1	20040108	US 2003-367624	20030214
PRAI	US 2002-357589P	P	20020215		

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2003070173 ICM A61K
 OS MARPAT 139:197708
 GI



- AB Erythromycin macrolide **conjugates** T-(L-C)_m, wherein T is a transportophore, L is a bond or a linker having a mol. weight up to 240 **dalton**, C is a non-antibiotic therapeutic agent, and m is 1-8, in which the transportophore has an immune selectivity ratio of at least 2, the transportophore is covalently bonded to the non-antibiotic therapeutic agent via the bond or the linker, and the compound has an immune selectivity ratio of at least 2, useful for enhancing efficacy of a therapeutic agent. Thus, macrolide I (R = R¹) was prepared in 76% yield via coupling of I (R = H) with diclofenac as antitumor and antibacterial agent and was tested in vitro for its cytotoxicity and immunosuppressive activity using a mouse skin transplant model.
- ST human antiinflammatory vaccine immunosuppression antibacterial antitumor erythromycin prepn cytotoxicity; antiinflammatory vaccine immunosuppression antibacterial antitumor glycoside macrolide prepn erythromycin
- IT Infection
 (bacterial; macrolide erythromycin **conjugates** of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)
- IT Anti-inflammatory agents
 Antibacterial agents
 Antibiotics
 Antitumor agents
 Cytotoxicity
 Human
 Inflammation

Neoplasm

Skin

Vaccines

(macrolide erythromycin **conjugates** of biol. active compds.
methods for their preparation and use formulation and pharmaceutical
applications thereof)

IT Glycosides

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)

(macrolide erythromycin **conjugates** of biol. active compds.
methods for their preparation and use formulation and pharmaceutical
applications thereof)

IT Antibiotics

(macrolide erythromycin **conjugates** of biol. active
compds. methods for their preparation and use formulation and pharmaceutical
applications thereof)

IT 586410-99-3P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); RCT
(Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); RACT (Reactant or reagent); USES
(Uses)

(macrolide erythromycin **conjugates** of biol. active compds.
methods for their preparation and use formulation and pharmaceutical
applications thereof)

IT 531-75-9P 96100-89-9P 152235-41-1P 235436-93-8P 276245-85-3P
501002-55-7P 586410-56-2P 586410-57-3P 586410-58-4P 586410-59-5P
586410-60-8P 586410-61-9P 586410-62-0P 586410-63-1P 586410-64-2P
586410-65-3P 586410-66-4P 586410-67-5P 586410-68-6P 586410-69-7P
586410-70-0P 586410-71-1P 586410-72-2P 586410-73-3P 586410-74-4P
586410-76-6P 586410-78-8P 586410-80-2P 586410-82-4P 586410-84-6P
586410-86-8P 586410-87-9P 586410-88-0P 586410-89-1P 586410-90-4P
586410-92-6P 586410-94-8P 586411-18-9P 586411-20-3P 586411-22-5P
586411-24-7P 586411-26-9P 586411-28-1P 586411-30-5P 586411-32-7P
586411-37-2P 586411-39-4P 586411-43-0P 586411-45-2P 586411-47-4P
586411-49-6P 586411-53-2P 586411-59-8P 586411-65-6P 586411-72-5P
586411-74-7P 586411-78-1P **586411-80-5P** 586411-82-7P
586411-84-9P **586411-86-1P** 586411-88-3P 586411-90-7P
586411-92-9P 586411-94-1P 586411-98-5P 586412-01-3P 586412-06-8P
586412-18-2P 586412-26-2P 586412-30-8P 586412-34-2P 586412-38-6P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)

(macrolide erythromycin **conjugates** of biol. active compds.
methods for their preparation and use formulation and pharmaceutical
applications thereof)

IT 586411-06-5P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(macrolide erythromycin **conjugates** of biol. active compds.
methods for their preparation and use formulation and pharmaceutical
applications thereof)

IT 516-12-1P 5786-56-1P 117693-41-1P 117693-42-2P 128305-54-4P
586411-01-0P 586411-03-2P 586411-08-7P 586411-10-1P 586411-12-3P
586411-14-5P 586411-16-7P 586411-51-0P 586411-56-5P 586411-63-4P
586411-67-8P 586411-96-3P 586412-03-5P 586412-09-1P 586412-12-6P
586412-14-8P 586412-16-0P 586412-21-7P 586412-23-9P 586412-28-4P
586412-43-3P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (macrolide erythromycin **conjugates** of biol. active compds.
 methods for their preparation and use formulation and pharmaceutical applications thereof)

IT 586411-76-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (macrolide erythromycin **conjugates** of biol. active compds.
 methods for their preparation and use formulation and pharmaceutical applications thereof)

IT 50-02-2, Dexamethasone 50-24-8, Prednisolone 50-78-2
 53-86-1, Indomethacin 56-53-1 61-68-7, Mefenamic acid 76-25-5
 , Triamcinolone acetonide 105-36-2, Ethyl bromoacetate 108-30-5,
 Succinic anhydride, reactions 109-83-1 110-91-8, Morpholine, reactions
 110-94-1, Glutaric acid 305-03-3, Chlorambucil 531-76-0 644-62-2,
 Meclofenamic acid 2067-33-6, 5-Bromovaleric acid 2304-94-1
 5104-49-4, Flurbiprofen 15307-86-5, Diclofenac 15687-27-1, Ibuprofen
 16471-29-7 24280-93-1, Mycophenolic acid 25812-30-0, Gemfibrozil
 30516-87-1, AZT 32483-51-5 75330-75-5, Lovastatin 83905-01-5
 86386-73-4, Fluconazole 88404-25-5 111321-02-9 152460-10-1
 169590-42-5, Celecoxib 192564-13-9, Neotrofin 264621-05-8
 501121-34-2 586411-35-0 586411-61-2 586411-69-0 586412-36-4
 586412-40-0

RL: RCT (Reactant); RACT (Reactant or reagent)
 (macrolide erythromycin **conjugates** of biol. active compds.
 methods for their preparation and use formulation and pharmaceutical applications thereof)

IT 586411-80-5P 586411-84-9P 586411-86-1P



RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (macrolide erythromycin **conjugates** of biol. active compds.
 methods for their preparation and use formulation and pharmaceutical applications thereof)

RN 586411-80-5 HCAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-[4-[[[(11 β ,16 α)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl]oxy]-1,4-dioxobutyl]- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 586411-84-9 HCAPLUS


CN 1-Oxa-6-azacyclopentadecane-13,15-dione, 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-[4-[[[(11 β ,16 α)-9-fluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-3,20-dioxopregna-1,4-dien-21-yl]oxy]-1,4-dioxobutyl]- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12R,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 586411-86-1 HCAPLUS


CN 1-Oxa-6-azacyclopentadecane-13,15-dione, 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-2-O-[4-[[[(11 β)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl]oxy]-1,4-dioxobutyl]-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12R,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




IT 50-02-2, Dexamethasone 50-24-8, Prednisolone
 76-25-5, Triamcinolone acetonide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (macrolide erythromycin **conjugates** of biol. active compds.
 methods for their preparation and use formulation and pharmaceutical
 applications thereof)
 RN 50-02-2 HCAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
 (11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50-24-8 HCAPLUS
 CN Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11 β)- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 76-25-5 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 15 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:599457 HCAPLUS

DN 140:139633

ED Entered STN: 05 Aug 2003

TI Preparation of enzyme **conjugate** through adipic acid dihydrazide as linker and its use in immunoassays

AU Basu, Anupam; Shrivastav, Tulsidas G.; Kariya, Kiran P.

CS Department of Reproductive Biomedicine, National Institute of Health and Family Welfare, New Delhi, 110067, India

SO Clinical Chemistry (Washington, DC, United States) (2003), 49(8), 1410-1412

CODEN: CLCHAU; ISSN: 0009-9147

PB American Association for Clinical Chemistry

DT Journal

LA English

CC 2-1 (Mammalian Hormones)

Section cross-reference(s): 7

AB The use of adipic acid dihydrazide (ADH) as a linking reagent between glycoenzyme (HRP) and a steroid carboxylic derivative to prepare enzyme **conjugate** for ELISA is described. The **conjugation** of horseradish peroxidase (HRP) to cortisol through ADH as the link was carried out. HRP-ADH was **conjugated** to the carboxylic group of cortisol by the activated ester method for developing competitive direct ELISA. The hydrazide-containing reagents provide a built-in spacer to accommodate greater **steric** accessibility. Results showed that the use of a linking reagent in the enzyme **conjugate** increases the detection limit of the competitive immunoassay. The improvement in the detection limit may be caused by the linker group preventing **steric** hindrance. The lower detection limit of the competitive immunoassay with the use of a HRP-ADH reagent may be treated as an added advantage apart from overcoming the hurdles of direct **conjugation** with HRP. The HRP-ADH reagent may also be used for coupling to nucleic acid for nucleic acid hybridization assays and to proteins for preparing enzyme **conjugates** for immuno-assay and immunochem., and may also be useful for staining glycoproteins and other glycoconjugates on protein blots after periodate oxidation

ST cortisol immunoassay **conjugate** adipic acid dihydrazide


- horseradish peroxidase
- IT Immunoassay
(enzyme-linked immunosorbent assay; preparation of horseradish peroxidase **conjugate** through adipic acid dihydrazide as linker and its use in immunoassays)
- IT 9003-99-ODP, Peroxidase, **conjugate** with cortisol-21-hemisuccinate through adipic acid dihydrazide spacer
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); PNU (Preparation, unclassified); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(horseradish; preparation of horseradish peroxidase **conjugate** through adipic acid dihydrazide as linker and its use in immunoassays)
- IT 9003-99-ODP, Peroxidase, **conjugate** with adipic acid dihydrazide
RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(horseradish; preparation of horseradish peroxidase **conjugate** through adipic acid dihydrazide as linker and its use in immunoassays)
- IT 9003-99-0, Peroxidase
RL: RCT (Reactant); RACT (Reactant or reagent)
(horseradish; preparation of horseradish peroxidase **conjugate** through adipic acid dihydrazide as linker and its use in immunoassays)
- IT 50-23-7, Cortisol
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(preparation of horseradish peroxidase **conjugate** through adipic acid dihydrazide as linker and its use in immunoassays)
- IT 1071-93-8, Adipic acid dihydrazide
RL: NUU (Other use, unclassified); RCT (Reactant); RACT (Reactant or reagent); USES (Uses)
(preparation of horseradish peroxidase **conjugate** through adipic acid dihydrazide as linker and its use in immunoassays)
- IT 2203-97-6, Cortisol-21-hemisuccinate
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of horseradish peroxidase **conjugate** through adipic acid dihydrazide as linker and its use in immunoassays)
- RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) Basu, A; J Immunoassay 2000, V21, P39 HCAPLUS
 - (2) Bayer, E; Methods Enzymol 1990, V184, P174 HCAPLUS
 - (3) Boorsma, D; J Immunol Methods 1979, V30, P245 MEDLINE
 - (4) Dent, A; Bioconjugation: protein coupling techniques for the biomedical sciences 1998, P120
 - (5) Dent, A; Bioconjugation: protein coupling techniques for the biomedical sciences 1998, P121
 - (6) Dent, A; Bioconjugation: protein coupling techniques for the biomedical sciences 1998, P364 HCAPLUS
 - (7) Fleminger, G; Appl Biochem Biotechnol 1990, V23, P123 HCAPLUS
 - (8) Hermanson, G; Bioconjugate techniques 1996, P121
 - (9) Jeanson, A; J Immunol Methods 1988, V111, P261 HCAPLUS
 - (10) Keren, Z; Anal Biochem 1986, V155, P182 HCAPLUS
 - (11) Nakane, P; J Histochem Cytochem 1974, V22, P1084 HCAPLUS
 - (12) Ornstein, L; J Histochem Cytochem 1966, V14, P790
 - (13) O'Shannessy, D; Anal Biochem 1990, V191, P1 HCAPLUS
 - (14) Satoh, A; Anal Biochem 1998, V260, P96 HCAPLUS
 - (15) Schalkwijk, J; J Clin Invest 1985, V76, P198 HCAPLUS
 - (16) Shrivastav, T; Clin Chem 1988, V34, P2205 HCAPLUS
- IT 50-23-7, Cortisol
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)

(preparation of horseradish peroxidase **conjugate** through adipic acid dihydrazide as linker and its use in immunoassays)

RN 50-23-7 HCAPLUS

CN Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 2203-97-6, Cortisol-21-hemisuccinate


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of horseradish peroxidase **conjugate** through adipic acid dihydrazide as linker and its use in immunoassays)

RN 2203-97-6 HCAPLUS

CN Pregn-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, (11 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L46 ANSWER 16 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:518596 HCAPLUS

DN 139:224924

ED Entered STN: 08 Jul 2003

TI GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro

AU Xu, Jian; Lucas, Rudolf; Schuchmann, Marcus; Kuehnle, Simone; Meergans, Thomas; Barreiros, Ana P.; Lohse, Ansgar W.; Otto, Gerd; Wendel, Albrecht

CS Biochemical Pharmacology, University of Konstanz, Mainz, 78457, Germany

SO Journal of Immunology (2003), 171(2), 938-947

CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal
 LA English
 CC 2-10 (Mammalian Hormones)
 Section cross-reference(s): 15

AB Infection remains the major complication of immunosuppressive therapy in organ transplantation. Therefore, reconstitution of the innate immunity against infections, without activation of the adaptive immune responses, to prevent graft rejection is a clin. desirable status in transplant recipients. The authors found that GM-CSF restored TNF mRNA and protein expression without inducing IL-2 production and T cell proliferation in glucocorticoid-immunosuppressed blood from either healthy donors or liver transplant patients. Gene array expts. indicated that GM-CSF selectively restored a variety of dexamethasone-suppressed, LPS-inducible genes relevant for innate immunity. A possible explanation for the lack of GM-CSF to restore T cell proliferation is its enhancement of the release of IL-1 β R antagonist, rather than of IL-1 β itself, since exogenously added IL-1 β induced an IL-2-independent Con A-stimulated proliferation of glucocorticoid-immunosuppressed lymphocytes. Finally, to test the in vivo relevance of the authors' findings, the authors showed that GM-CSF restored the survival of dexamethasone- or cyclosporine A-immunosuppressed mice from an otherwise lethal infection with *Salmonella typhimurium*. In addition to this increased resistance to infection, GM-CSF did not induce graft rejection of a skin allotransplant in cyclosporine A-immunosuppressed mice. The selective restoration potential of GM-CSF suggests its therapeutic use in improving the resistance against infections upon organ transplantation.

ST GMCSF immunity glucocorticoid immunosuppression TNF blood transplant
 IT Chemokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (C-X-C, GCP-2 (granulocyte chemotactic protein 2); GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (C/EBP (CCAAT box/enhancer element-binding protein), subunit B; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)

IT CD antigens
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD27, T-cell activation; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)

IT Cyclins
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (D2; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (ETR101; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)

IT Transcription factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (Egr-1; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)

- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GATA-2; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GATA-3; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Blood
DNA microarray technology
Gene expression profiles, animal
Human
Immunosuppression
Signal transduction, biological
(GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Gene, animal
Glucocorticoids
Lipopolysaccharides
Platelet-activating factor receptors
Proliferating cell nuclear antigen
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Heat-shock proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HSP 70; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Heat-shock proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HSP 90; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ICAM-1 (intercellular adhesion mol. 1), precursor; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Linker for activation of T cells; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NF- κ B (nuclear factor of κ light chain gene enhancer in B-cells), p65- and p100-subunits; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RAP-1 (rhoptry-associated protein 1), RAP-1B; GM-CSF restores innate but

- not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Rho protein (G protein)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RhoA; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SQM1; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Cell proliferation
(T cell; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TFIID (transcription factor IID), 31-kDa subunit; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Cytokine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(WSL protein; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(activated RNA polymerase II transcriptional coactivator p15; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Transplant and Transplantation
(allotransplant, skin; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Skin
(allotransplant; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Tyrosine kinase receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ephrin type-A receptor 4, precursor; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(eukaryotic initiation factor-2-associated, p67, Methionine aminopeptidase 2; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(growth arrest and DNA damage-inducible gene protein; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Immunity

- (innate; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Interleukin 1 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interleukin 1 β ; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Transplant and Transplantation
(liver; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metal-regulatory transcription factor; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Cyclin dependent kinase inhibitors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(p27KIP1; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Interleukin 1 β
Interleukin 6
Interleukin 8
Macrophage inflammatory protein 1 α
Macrophage inflammatory protein 1 β
RANTES (chemokine)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(precursor; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT T cell (lymphocyte)
(proliferation; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Liver
(transplant; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Corticotropin releasing factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type I, precursor; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ubiquitin-**conjugating**, 17-kDa; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(zinc finger-containing, 91; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Interleukin 7 receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α -subunit precursor; GM-CSF restores innate but not adaptive

- immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Macrophage inflammatory protein 2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α ; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Fibronectin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β subunit; CD29 Ag; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β 1; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT 50-02-2, Dexamethasone 59865-13-3, Cyclosporine A 78990-62-2, Calpain 81627-83-0, MCSF 141349-86-2, CDK2 kinase 165245-96-5, p38 Kinase 289899-93-0, c-Jun N-terminal kinase 2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT 83869-56-1, Granulocyte macrophage colony-stimulating factor
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT 142008-29-5, CAMP-dependent protein kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(I, α regulatory subunit; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT 9001-92-7, Protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calcium-dependent; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT 140879-24-9, Proteasome
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(component C2, C3, C5 and C8; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)
- IT 161384-17-4, MMP-14 182762-08-9, Caspase-4
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(precursor; GM-CSF restores innate but not adaptive immune responses in glucocorticoid-immunosuppressed human blood in-vitro in relation to microarray gene expression profile)

RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

- (1) Ashwell, J; Annu Rev Immunol 2000, V18, P309 HCAPLUS
- (2) Azzoni, L; J Immunol 2002, V168, P5764 HCAPLUS
- (3) Baiocchi, R; J Clin Invest 2001, V108, P887 HCAPLUS
- (4) Baldwin, W; Immunity 2001, V14, P369 HCAPLUS
- (5) Bendall, L; Leukemia 1995, V9, P677 MEDLINE
- (6) Benedict, C; Immunity 2001, V15, P617 HCAPLUS
- (7) Bingaman, A; J Immunol 2000, V164, P3065 HCAPLUS

- (8) Black, R; Nature 1997, V385, P729 HCAPLUS
- (9) Boneberg, E; Blood 2000, V95, P270 HCAPLUS
- (10) Briggs, W; Cytokine 1996, V8, P804 HCAPLUS
- (11) Brummer, E; J Leukocyte Biol 2001, V70, P868 HCAPLUS
- (12) Bundschuh, D; J Immunol 1997, V158, P2862 HCAPLUS
- (13) Christopher, K; J Immunol 2002, V169, P522 HCAPLUS
- (14) Clurman, B; Proc Natl Acad Sci USA 1998, V95, P15158 HCAPLUS
- (15) Conti, F; Am J Pathol 2000, V157, P1685 HCAPLUS
- (16) Dobashi, Y; Am J Pathol 1998, V153, P963 HCAPLUS
- (17) Farag, S; Blood 2002, V100, P1935 HCAPLUS
- (18) Ferguson, T; Nat Med 1999, V5, P1231 HCAPLUS
- (19) Fierer, J; J Immunol 2002, V168, P6396 HCAPLUS
- (20) Fishman, J; N Engl J Med 1998, V338, P1741 MEDLINE
- (21) Flohe, S; Shock 1999, V12, P17 MEDLINE
- (22) Flynn, J; Immunity 1995, V2, P561 HCAPLUS
- (23) Freeman, R; Transplantation 1999, V67, P1005
- (24) Guha, M; Cell Signaling 2001, V13, P85 HCAPLUS
- (25) Guillou, P; Transplantation 1982, V33, P414 MEDLINE
- (26) Harrop, J; J Immunol 1998, V161, P1786 HCAPLUS
- (27) Hartung, T; Cytokine 2000, V12, P1570 HCAPLUS
- (28) He, H; Transplantation 2002, V73, P853
- (29) Heinrich, J; J Immunol 2001, V167, P1624 HCAPLUS
- (30) Hennemann, B; Br J Haematol 1998, V102, P1197 HCAPLUS
- (31) Hirata, M; Transplant Int 1998, V11(Suppl 1), P5185
- (32) Jaeger, K; Intensive Care Med 1999, V25, P612 MEDLINE
- (33) Jones, T; Med Oncol 1996, V13, P141 MEDLINE
- (34) Jonsson, J; Liver Transplant 2001, V7, P255 MEDLINE
- (35) Kahan, B; N Engl J Med 1989, V321, P1725 HCAPLUS
- (36) Keane, J; N Engl J Med 2001, V345, P1098 HCAPLUS
- (37) Kim, K; Cancer Lett 2001, V166, P33 HCAPLUS
- (38) Li, Y; Nat Med 1999, V5, P1298 HCAPLUS
- (39) Lucas, R; Blood 1998, V92, P4730 HCAPLUS
- (40) Maier, S; Nat Med 2001, V7, P557 HCAPLUS
- (41) Medzhitov, R; N Engl J Med 2000, V343, P338 HCAPLUS
- (42) Metcalf, D; Blood 1986, V67, P257 HCAPLUS
- (43) Muench, M; Exp Hematol 2000, V28, P961 HCAPLUS
- (44) Navarro, F; Transplantation 2000, V69, P633 MEDLINE
- (45) Oertel, M; Transplantation 2001, V72, P116 MEDLINE
- (46) Patel, R; Clin Microbiol Rev 1997, V10, P86 HCAPLUS
- (47) Plant, J; Infect Immun 1983, V42, P71 HCAPLUS
- (48) Polyak, K; Cell 1994, V78, P59 HCAPLUS
- (49) Randow, F; J Immunol 1997, V158, P2911 HCAPLUS
- (50) Rossini, A; Physiol Rev 1999, V79, P99 HCAPLUS
- (51) Rottenberg, M; J Immunol 1999, V162, P2829 HCAPLUS
- (52) Sahoo, S; Transplantation 2000, V69, P880 HCAPLUS
- (53) Sayegh, M; N Engl J Med 1998, V338, P1813 HCAPLUS
- (54) Schmidt, M; J Immunol 2001, V166, P1344 HCAPLUS
- (55) Shibuya, A; Blood 1991, V78, P3241 MEDLINE
- (56) Smets, L; Adv Exp Med Biol 1999, V457, P607 HCAPLUS
- (57) Souto, J; Am J Pathol 2000, V156, P1811 HCAPLUS
- (58) Sung, R; Mol Ther 2001, V3, P757 HCAPLUS
- (59) Taguchi, K; Blood 1992, V79, P3227 HCAPLUS
- (60) Tiegs, G; J Clin Invest 1994, V93, P2616 HCAPLUS
- (61) Tite, J; J Immunol 1991, V147, P3161 HCAPLUS
- (62) Trindade, E; J Hepatol 1998, V28, P1054 HCAPLUS
- (63) Venema, H; J Med Virol 1994, V42, P188 MEDLINE
- (64) Wells, A; Nat Med 1999, V5, P1303 HCAPLUS
- (65) Williams, M; J Infect Dis 1998, V177, P107 HCAPLUS
- (66) Williams, M; J Infect Dis 1998, V178, P1421 HCAPLUS

IT 50-02-2, Dexamethasone
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GM-CSF restores innate but not adaptive immune responses in
 glucocorticoid-immunosuppressed human blood in-vitro in relation to
 microarray gene expression profile)
 RN 50-02-2 HCAPLUS
 CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
 (11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 17 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:445469 HCAPLUS
 DN 139:302222
 ED Entered STN: 11 Jun 2003
 TI Membrane-initiated steroid signaling (MISS): genomic steroid action starts
 at the plasma membrane
 AU Daufeldt, Sabine; Lanz, Rainer; Allera, Axel
 CS Department of Clinical Biochemistry, University of Bonn, Bonn, 53105,
 Germany
 SO Journal of Steroid Biochemistry and Molecular Biology (2003), 85(1), 9-23
 CODEN: JSBBEZ; ISSN: 0960-0760
 PB : Elsevier Science Ltd.
 DT Journal
 LA English
 CC 2-4 (Mammalian Hormones)
 Section cross-reference(s): 6
 AB Plasma membrane (PM) steroid recognition sites are thought to be
 responsible only for rapid, non-genomic responses without any link to the
 nuclear receptor-mediated genomic effects of steroids. We focused on a PM
 "glucocorticoid-importer" (GC-importer) that imports GC into rat liver
 cells. This site interacts also with particular gestagens (progesterone,
 P; medroxyprogesterone, MP; ethynodiol, Ethy) and estrogens
 (ethinylestradiol, EE2; mestranol), which do not bind to the nuclear GC
 receptor (GR). To elucidate the role of the GC-importer, we transfected a
 rat wild-type hepatocyte (CC-1) and a hepatoma cell line, unable to import
 GC (MH 3924), with a GC+GR-responsive luciferase (luc)-reporter
 gene. Selected steroids were tested for their ability to induce or
 inhibit luc expression. Corticosterone (B) and dexamethasone (Dex), but
 also the GC-antagonists cortexolone (Cortex), P and MP, induced luc. Even
 the PM-impermeable BSA-derivs. of B, Dex and Cortex did so to almost the
 same extent as the free steroids. MH 3924 cells respond stronger than
 CC-1 to luc inducing steroids. Luc expression was inhibited by RU 38 486,
 but also by EE2 and Ethy. The thiol reactive mesylate-derivs. of B, Dex
 and Cortex induced to a considerably lesser extent than the free or

BSA-steroids. The thiol reagent mersalyl blocks cellular entry of GC and inhibits luc induction in CC-1 cells. Incubation with EE2 and B of PM-vesicles, isolated from liver cells, resulted in a decrease of the d. of two 75 and 52 kDa G-proteins reflecting a diminished exchange of GDP by GTP. Conclusion: the PM-residing GC-importer, now renamed "Steroid Hormone Recognition and Effector Complex" (SHREC) is an interdependent part of the complete GC signal propagation in which G-proteins are involved. Free SH-groups of SHREC are a prerequisite for genomic GC activity. Specific interactions between SHREC and GC-agonist/-antagonist trigger steroid-dependent signaling. However, import of the ligand into the cell terminates it. Thus, the PM-related non-genomic steroid responses are clearly linked to the GR-related genomic effects.

- ST steroid signaling genomic nongenomic plasma membrane nucleus SHREC glucocorticoids
- IT Albumins, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (-conjugated glucocorticoids; genomic vs. non-genomic steroid signaling via the SHREC transport protein and possible interaction with the glucocorticoid receptor)
- IT Cell membrane
Signal transduction, biological
(genomic vs. non-genomic steroid signaling via the SHREC transport protein and possible interaction with the glucocorticoid receptor)
- IT Glucocorticoids
Nuclear receptors
Steroids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (genomic vs. non-genomic steroid signaling via the SHREC transport protein and possible interaction with the glucocorticoid receptor)
- IT Liver
(hepatocyte; genomic vs. non-genomic steroid signaling via the SHREC transport protein and possible interaction with the glucocorticoid receptor)
- IT Liver, neoplasm
(hepatoma; genomic vs. non-genomic steroid signaling via the SHREC transport protein and possible interaction with the glucocorticoid receptor)
- IT G proteins (guanine nucleotide-binding proteins)
RL: BSU (Biological study, unclassified); BIOL (Biological study) (of 75 and 52 kDa, involvement in non-genomic steroid signaling; genomic vs. non-genomic steroid signaling via the SHREC transport protein and possible interaction with the glucocorticoid receptor)
- IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (steroid transporter, SHREC (steroid hormone recognition and effector complex); genomic vs. non-genomic steroid signaling via the SHREC transport protein and possible interaction with the glucocorticoid receptor)
- IT 50-02-2, Dexamethasone 50-02-2D, Dexamethasone, BSA- or mersalyl-conjugated 50-22-6, Corticosterone 50-22-6D, Corticosterone, BSA- or mersalyl-conjugated 57-63-6, Ethinylestradiol 57-83-0, Progesterone, biological studies 72-33-3, Mestranol 152-58-9, Cortexolone 152-58-9D, Cortexolone, BSA- or mersalyl-conjugated 492-18-2D, Mersalyl, BSA- or mersalyl-conjugated 520-85-4, Medroxyprogesterone 1231-93-2, Ethynodiol 84371-65-3, RU 38486
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(genomic vs. non-genomic steroid signaling via the SHREC transport protein and possible interaction with the glucocorticoid receptor)

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ali, N; Mol Cell Biochem 1989, V91, P75 HCAPLUS
 - (2) Allera, A; 2. Nebennierenkonferenz, 1991 1993, P1
 - (3) Allera, A; Clin Endocrinol, in press 2003
 - (4) Allera, A; J Steroid Biochem Mol Biol 1992, V42, P737 HCAPLUS
 - (5) Allera, A; J Steroid Biochem Mol Biol 1992, V42, P757 HCAPLUS
 - (6) Allera, A; Proceedings of the 69th Annual Meeting of The Endocrine Society 1987, abstract no 752
 - (7) Borski, R; Trends Endocrinol Metab 2000, V11, P427 HCAPLUS
 - (8) Burger, K; FEBS Lett 1999, V464, P25 HCAPLUS
 - (9) Cadrin, M; J Cell Biochem 1996, V62, P334 HCAPLUS
 - (10) Chambliss, K; Endocrinol Rev 2002, V23, P665 HCAPLUS
 - (11) Daufeldt, S; Inaugural-Dissertation zur Erlangung des Doktorgrades der Math-Naturwissenschaftl, Fakultat der Friedrich-Wilhelms-Universität Bonn 2000
 - (12) Falkenstein, E; Eur J Clin Invest 2000, V30(Suppl 3), P51
 - (13) Filardo, E; J Steroid Biochem Mol Biol 2002, V80, P231 HCAPLUS
 - (14) Grotjan, H; Comput Biol Med 1977, V7, P159 MEDLINE
 - (15) Harrigan, M; Mol Endocrinol 1991, V5, P1331 HCAPLUS
 - (16) Hendry, L; J Steroid Biochem Mol Biol 1995, V55, P173 HCAPLUS
 - (17) Iwasaki, Y; Biochem Biophys Res Commun 1997, V235, P295 HCAPLUS
 - (18) Jasper, J; Am J Physiol 1998, V275, PC634 HCAPLUS
 - (19) Kilic, G; J Biol Chem 2002, V277, P11721 HCAPLUS
 - (20) Knoke, I; Hum Genet 1999, V104, P257 HCAPLUS
 - (21) Kuboshima, S; Adv Perit Dial 2001, V17, P47 MEDLINE
 - (22) Lackner, C; J Steroid Biochem Mol Biol 1998, V64, P69 HCAPLUS
 - (23) Lackner, C; Proceedings of the First International Meeting on Rapid Responses to Steroid Hormones 1998, abstract no 6004
 - (24) Lanz, R; Cell 1999, V97, P17 HCAPLUS
 - (25) Le Mellay, V; J Cell Biol 2000, V79, P173 HCAPLUS
 - (26) Levin, E; Steroids 2002, V67, P471 HCAPLUS
 - (27) Lin, S; Nat Cell Biol 2001, V3, P802 HCAPLUS
 - (28) Lynch, C; FEBS Lett 1986, V200, P333 HCAPLUS
 - (29) Mangelsdorf, D; Cell 1995, V83, P835 HCAPLUS
 - (30) McKenna, N; Endocrinol Rev 1999, V20, P321 HCAPLUS
 - (31) Nishimura, T; Cell Struct Funct 2000, V25, P161 HCAPLUS
 - (32) Orchinik, M; Proc Natl Acad Sci USA 1992, V89, P3830 HCAPLUS
 - (33) Pietras, R; Endocrine 2001, V14, P417 HCAPLUS
 - (34) Razandi, M; Mol Endocrinol 1999, V13, P307 HCAPLUS
 - (35) Russ, M; Eur J Biochem 1994, V219, P325 HCAPLUS
 - (36) Scott, L; Proc Natl Acad Sci USA 2002, V99, P1661 HCAPLUS
 - (37) Simons, S; J Org Chem 1980, V45, P3084 HCAPLUS
 - (38) Simons, S; Proc Natl Acad Sci USA 1981, V78, P3541 HCAPLUS
 - (39) Spindler, K; J Steroid Biochem Mol Biol 1991, V39, P315 HCAPLUS
 - (40) Stevis, P; Endocrinology 1999, V140, P5455 HCAPLUS
 - (41) Sutter-Dub, M; Steroids 2002, V67, P77 HCAPLUS
 - (42) Svoboda, P; Cell Mol Life Sci 2002, V59, P501 HCAPLUS
 - (43) Teruel, M; Science 2002, V295, P1910 HCAPLUS
 - (44) van Iwaarden, P; Biochim Biophys Acta 1992, V1113, P161 HCAPLUS
 - (45) van den Berg, J; J Steroid Biochem Mol Biol 1996, V57, P239 HCAPLUS
 - (46) Verrey, F; Am J Physiol 1999, V277, PF319 HCAPLUS
 - (47) Watson, C; Int Immunopharmacol 2001, V1, P1049 HCAPLUS
 - (48) Watson, C; Proc Soc Exp Biol Med 1999, V220, P9 HCAPLUS
- IT 50-02-2, Dexamethasone 50-02-2D, Dexamethasone, BSA- or mersalyl-conjugated 50-22-6, Corticosterone 50-22-6D, Corticosterone, BSA- or mersalyl-


conjugated

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (genomic vs. non-genomic steroid signaling via the SHREC transport
 protein and possible interaction with the glucocorticoid receptor)

RN 50-02-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
 (11 β ,16 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50-02-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
 (11 β ,16 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50-22-6 HCAPLUS


CN Pregn-4-ene-3,20-dione, 11,21-dihydroxy-, (11 β)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 50-22-6 HCAPLUS
 CN Pregn-4-ene-3,20-dione, 11,21-dihydroxy-, (11β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 18 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:230539 HCAPLUS
 DN 138:379507
 ED Entered STN: 25 Mar 2003
 TI Ubiquitin-proteasome-dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats
 AU Kee, Anthony J.; Combaret, Lydie; Tilignac, Thomas; Souweine, Bertrand; Aurousseau, Eveline; Dalle, Michel; Taillandier, Daniel; Attaix, Didier
 CS Muscle Development Unit, Children's Medical Research Institute, Wentworthville, NSW 2145, Australia
 SO Journal of Physiology (Cambridge, United Kingdom) (2003), 546(3), 765-776
 CODEN: JPHYA7; ISSN: 0022-3751
 PB Cambridge University Press
 DT Journal
 LA English
 CC 2-6 (Mammalian Hormones)
 Section cross-reference(s): 18
 AB The central role of the ubiquitin-proteasome system in the loss of skeletal muscle protein in many wasting conditions has been well established. However, it is unclear what factors are responsible for the suppression of this system during periods of protein gain. Thus, the aim of these studies was to examine the short-term effects of insulin release and nutrients on skeletal muscle protein turnover in young rats starved for 48 h, and then infused i.v. with amino acids (AA), or fed an oral diet. Forty-eight hours of starvation (i.e., prolonged starvation in

young rats) decreased muscle protein synthesis and increased proteasome-dependent proteolysis. Four-hour AA infusion and 4 h of refeeding increased plasma insulin release and AA concns., and stimulated muscle protein synthesis, but had no effect on either total or proteasome-dependent proteolysis, despite decreased plasma corticosterone concns. Both muscle proteasome-dependent proteolysis and the rate of ubiquitination of muscle proteins were not suppressed until 10 h of refeeding. The temporal response of these two measurements correlated with the normalized expression of the 14-kDa E2 (a critical enzyme in substrate ubiquitination in muscle) and the expression of the MSS1 subunit of the 19S regulatory complex of the 26S proteasome. In contrast, the starvation-induced increase in mRNA levels for 20S proteasome subunits was normalized by refeeding within 24 h in muscle, and 6 h in jejunum, resp. In conclusion, unlike protein synthesis, skeletal muscle proteasome-dependent proteolysis is not acutely responsive in vivo to insulin, AA, and/or nutrient intake in refed starved rats. This suggests that distinct and perhaps independent mechanisms are responsible for the nutrient-dependent regulation of protein synthesis and ubiquitin-proteasome-dependent proteolysis following a prolonged period of catabolism. Furthermore, factors other than the expression of ubiquitin-proteasome pathway components appear to be responsible for the suppression of skeletal muscle proteasome-dependent proteolysis by nutrition.

ST insulin ubiquitin proteasome muscle proteolysis nutrition rat
 IT Amino acids, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (branched; ubiquitin-proteasome dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats)
 IT Intestine
 (jejunum; ubiquitin-proteasome dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats)
 IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (skeletal muscle-; ubiquitin-proteasome dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats)
 IT Enzymes, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ubiquitin-**conjugating**; ubiquitin-proteasome dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats)
 IT Nutrition, animal
 Protein degradation
 Starvation, animal
 Translation, genetic
 (ubiquitin-proteasome dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats)
 IT 140879-24-9D, 26S Proteasome, 26S
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MSS1 subunit of 19S regulatory complex of-; ubiquitin-proteasome dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats)
 IT 50-22-6, Corticosterone 56-40-6, Glycine, biological studies
 56-41-7, L-Alanine, biological studies 56-45-1, L-Serine, biological studies 56-85-9, L-Glutamine, biological studies 56-86-0, L-Glutamic acid, biological studies 56-87-1, L-Lysine, biological studies 60-18-4, L-Tyrosine, biological studies 61-90-5, L-Leucine, biological studies 63-68-3, L-Methionine, biological studies 63-91-2, L-Phenylalanine, biological studies 70-26-8, Ornithine 70-47-3, L-Asparagine, biological studies 71-00-1, L-Histidine, biological

studies 72-18-4, L-Valine, biological studies 72-19-5, L-Threonine, biological studies 73-22-3, L-Tryptophan, biological studies 73-32-5, L-Isoleucine, biological studies 74-79-3, L-Arginine, biological studies 107-35-7, Taurine 147-85-3, L-Proline, biological studies 372-75-8, Citrulline 9004-10-8, Insulin, biological studies 140879-24-9D, Proteasome, 20S

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ubiquitin-proteasome dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats)

IT 60267-61-0, Ubiquitin

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ubiquitination; ubiquitin-proteasome dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats)


RE.CNT 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Adegoke, O; J Nutr 1999, V129, P1871 HCAPLUS
- (2) Attaix, D; Adv Mol Cell Biol 1998, V27, P235 HCAPLUS
- (3) Attaix, D; Curr Opin Clin Nutr Metab Care 2001, V4, P45 HCAPLUS
- (4) Bailey, J; J Clin Invest 1996, V97, P1447 HCAPLUS
- (5) Bennet, W; Eur J Clin Invest 1990, V20, P41 HCAPLUS
- (6) Biolo, G; J Clin Invest 1995, V95, P811 HCAPLUS
- (7) Castano, J; Biochemistry 1996, V35, P3782 HCAPLUS
- (8) Chomczynski, P; Anal Biochem 1987, V162, P156 HCAPLUS
- (9) Combaret, L; Am J Kidney Dis 2001, V37(suppl 2), P108S
- (10) Combaret, L; Biochem J 2002, V361, P185 HCAPLUS
- (11) Dardevet, D; Endocrinology 1996, V137, P4087 HCAPLUS
- (12) Fang, C; Clin Sci 1998, V95, P225 HCAPLUS
- (13) Garlick, P; J Nutr 1998, V128, P356S HCAPLUS
- (14) Gelfand, R; J Clin Invest 1987, V80, P1 HCAPLUS
- (15) Goebel, M; Mol Cell Biol 1994, V14, P3022 HCAPLUS
- (16) Gomes, M; Proc Natl Acad Sci U S A 2001, V98, P14440 HCAPLUS
- (17) Huang, J; Proc Natl Acad Sci U S A 1998, V95, P12100 HCAPLUS
- (18) Kohler, A; Mol Cell 2001, V7, P1143 HCAPLUS
- (19) Larbaud, D; Am J Physiol 1996, V271, PE505 HCAPLUS
- (20) Larbaud, D; Clin Sci 2001, V101, P551 HCAPLUS
- (21) Lecker, S; J Clin Invest 1999, V104, P1411 HCAPLUS
- (22) Llovera, M; Int J Mol Med 1988, V2, P69
- (23) Louard, R; J Clin Invest 1992, V90, P2348 HCAPLUS
- (24) Louard, R; J Clin Endocrinol Metab 1994, V79, P278 HCAPLUS
- (25) Lowell, B; Metabolism 1986, V35, P1121 HCAPLUS
- (26) Mansoor, O; Proc Natl Acad Sci USA 1996, V93, P2714 HCAPLUS
- (27) Mason, G; Eur J Biochem 1996, V238, P453 HCAPLUS
- (28) Mason, G; FEBS Lett 1998, V430, P269 HCAPLUS
- (29) Medina, R; Biochem J 1995, V307, P631 HCAPLUS
- (30) Millward, D; Biochem J 1983, V216, P583 HCAPLUS
- (31) Mitch, W; N Engl J Med 1996, V335, P1897 HCAPLUS
- (32) Mortimore, G; Protein Metabolism in Diabetes Mellitus 1992, P125 HCAPLUS
- (33) Navon, A; Mol Cell 2001, V8, P1339 HCAPLUS
- (34) Peters, J; Ubiquitin and the Biology of the Cell 1998
- (35) Pickart, C; Annu Rev Biochem 2001, V70, P503 HCAPLUS
- (36) Pradier, P; Reprod Fertil Dev 1996, V8, P111 HCAPLUS
- (37) Price, S; J Clin Invest 1996, V98, P1703 HCAPLUS
- (38) Rock, K; Cell 1994, V78, P761 HCAPLUS
- (39) Samuels, S; Am J Physiol 1996, V271, PE232 HCAPLUS
- (40) Samuels, S; J Nutr 1995, V125, P520 HCAPLUS
- (41) Shah, O; Am J Physiol Endocrinol Metab 2000, V279, PE715 HCAPLUS
- (42) Sinaud, S; Am J Physiol 1999, V276, PE50 HCAPLUS
- (43) Smith, P; Anal Biochem 1985, V150, P76 HCAPLUS
- (44) Snedecor, G; Statistical Methods, 6th edn 1967

- (45) Sokal, R; Biometry 1969
 (46) Solomon, V; Proc Natl Acad Sci USA 1998, V95, P12602 HCAPLUS
 (47) Stephen, A; J Biol Chem 1996, V271, P15608 HCAPLUS
 (48) Tawa, N; J Clin Invest 1997, V100, P197 HCAPLUS
 (49) Temparis, S; Cancer Res 1994, V54, P5568 HCAPLUS
 (50) Tessari, P; J Clin Invest 1991, V88, P27 HCAPLUS
 (51) Tessari, P; J Clin Invest 1996, V98, P1361 HCAPLUS
 (52) Tiao, G; J Clin Invest 1997, V99, P163 HCAPLUS
 (53) Tischler, M; J Biol Chem 1982, V257, P1613 HCAPLUS
 (54) Voges, D; Annu Rev Biochem 1999, V68, P1015 HCAPLUS
 (55) Voisin, L; J Clin Invest 1996, V97, P1610 HCAPLUS
 (56) Waterlow, J; Nutr Res Rev 1999, V12, P25 HCAPLUS
 (57) Waterlow, J; Protein Turnover in Mammalian Tissues and in the Whole Body 1978
 (58) Watt, P; Am J Physiol 1992, V263, PE453 HCAPLUS
 (59) Williams, A; Surgery 1999, V126, P744 MEDLINE
 (60) Wing, S; Am J Physiol 1993, V264, PE668 HCAPLUS
 (61) Wing, S; Am J Physiol 1994, V267, PE39 HCAPLUS
 (62) Wing, S; Biochem J 1995, V307, P639 HCAPLUS
 (63) Wolfe, R; Curr Opin Clin Nutr Metab Care 2000, V3, P67 HCAPLUS
- IT 50-22-6, Corticosterone
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ubiquitin-proteasome dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats)
 RN 50-22-6 HCAPLUS
 CN Pregn-4-ene-3,20-dione, 11,21-dihydroxy-, (11 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 19 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:154230 HCAPLUS
 DN 138:210277
 ED Entered STN: 28 Feb 2003
 TI Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
 IN Diamond, Scott L.; Gruneich, Jeffrey
 PA The Trustees of the University of Pennsylvania, USA
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K009-22
 ICS A01N037-18; A01N043-04; C12N015-87
 CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 2, 15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003015757	A1	20030227	WO 2002-US26152	20020815
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1424998	A1	20040609	EP 2002-759383	20020815
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
PRAI	US 2001-312729P	P	20010816		
	US 2002-358138P	P	20020220		
	WO 2002-US26152	W	20020815		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2003015757	ICM	A61K009-22
	ICS	A01N037-18; A01N043-04; C12N015-87

AB The invention relates to compns. and methods for a one-step synthetic technique for making cationic steroid or cationic drug mols. for use as delivery vehicles. The invention further relates to methods for using cationic steroid mols. in lipofection or transfection, delivery of drugs, and for treatment of inflammation and other diseases and disorders. The invention also relates to cationic steroid prodrugs and cationic prodrugs and to methods of modifying drugs.

ST DNA lipofection cationic steroid drug delivery

IT Drug delivery systems
(carriers; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)

IT Sialic acids
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(**conjugates**; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)

IT Metabolism, animal
(disorder; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)

IT Drug delivery systems
(injections; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)

IT RNA
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(interfering; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)

IT Transformation, genetic
(lipofection; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)

- IT Drug delivery systems
(nasal; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT Genetic vectors
(nonviral; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT Drug delivery systems
(oral; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT Amines, biological studies
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(polyamines, nonpolymeric; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT Drug delivery systems
(prodrugs, steroid; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT Drug delivery systems
(suppositories; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT Diabetes mellitus
Drug delivery systems
Erythrocyte
Gene therapy
Genetic vectors
Glycocalyx
Human
Infection
Inflammation
Mental disorder
Neoplasm
PCR (polymerase chain reaction)
Plasmid vectors
(synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT Antisense oligonucleotides
Collagens, biological studies
DNA
Estrogens
Fibrins
Glycosaminoglycans, biological studies
Nucleic acids
Oligonucleotides
Peptide nucleic acids
Steroids, biological studies
Tumor necrosis factor receptors
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT Drug delivery systems
(targeted; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT Animal tissue
Organ, animal
(targeting of; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)

- IT Drug delivery systems
(topical; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT Interferons
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(α -2b; synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT 67-68-5, DmsO, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT **50-02-2D, Dexamethasone, conjugates** 56-87-1, Lysine, biological studies 74-79-3D, Arginine, peptides 1115-70-4, Metformin hydrochloride 1182-65-6D, Cholesterol tosylate, **conjugates** 2265-22-7D, **conjugates** 2462-63-7, Dope 6677-96-9D, **conjugates** 9002-98-6D, Polyethylenimine, peptides 9004-10-8, Insulin, biological studies **9004-61-9, Hyaluronic acid** 10540-29-1D, Tamoxifen, **conjugates** 11096-26-7, Erythropoietin 20380-16-9D, **conjugates** 20576-45-8D, Deoxycorticosterone-21 mesylate, **conjugates** 21829-25-4, Nifedipine 25104-18-1, Polylysine 26787-78-0, Amoxicillin 26913-06-4D, Polyethylenimine, peptides 33069-62-4, Paclitaxel **35500-24-4 35500-24-4D, conjugates** 36791-04-5, Ribavirin 38000-06-5, Polylysine 56296-78-7, Fluoxetine hydrochloride 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61177-45-5, Potassium clavulanate 66357-35-5, Ranitidine 68047-06-3D, 4-Hydroxytamoxifen, **conjugates** 73590-58-6, Omeprazole 74381-53-6, Leuprolide acetate 74578-69-1, Ceftriaxone sodium 76095-16-4, Enalapril maleate 76824-35-6, Famotidine 78246-49-8, Paroxetine hydrochloride 79559-97-0, Sertraline hydrochloride 79794-75-5, Loratadine 79902-63-9, Simvastatin **80474-14-2, Fluticasone propionate** 81093-37-0, Pravastatin 81103-11-9, Clarithromycin 81131-70-6, Pravastatin sodium 82427-84-7D, **conjugates** 83905-01-5, Azithromycin 83915-83-7, Lisinopril dihydrate 86386-73-4, Fluconazole 93107-08-5, Ciprofloxacin hydrochloride 94749-08-3, Salmeterol xinafoate 99300-78-4, Venlafaxine hydrochloride 100986-85-4, Levofloxacin 103577-45-3, Lansoprazole 103628-48-4, Sumatriptan succinate 104162-48-3, Dotma 106266-06-2, Risperidone 111470-99-6, Amlodipine besylate 113427-24-0, Epoetin alfa 120202-66-6, Clopidogrel bisulfate 121181-53-1, Filgrastim 124750-99-8, Losartan potassium 129318-43-0, Alendronate sodium 132539-06-1, Olanzapine 134523-03-8, Atorvastatin calcium 137056-72-5, Dc-chol 139639-23-9, Tissue plasminogen activator 144189-73-1, Dotap 153439-40-8, Fexofenadine hydrochloride 162011-90-7, Rofecoxib 168479-03-6, DOSPA 171599-83-0, Sildenafil citrate 679809-58-6, Enoxaparin sodium
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT 71-44-3 6539-14-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
- IT **499984-17-7P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Han; Bioconj Chem 2001, V12, P337 HCAPLUS
- (2) Liotta; US 6153596 2000 HCAPLUS
- (3) Nabel; Proc Nat Acad Sci USA 1993, V90, P11307 HCAPLUS
- (4) Sullivan; US 20010007771 A1 2001


IT 50-02-2D, Dexamethasone, conjugates 2265-22-7D
 , conjugates 6677-96-9D, conjugates
 9004-61-9, Hyaluronic acid 35500-24-4
 35500-24-4D, conjugates 80474-14-2,
 Fluticasone propionate

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)

RN 50-02-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
 (11 β ,16 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 2265-22-7 HCAPLUS


CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-
 [(methylsulfonyl)oxy]-, (11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6677-96-9 HCAPLUS
 CN Pregn-4-ene-3,20-dione, 11,17-dihydroxy-21-[(methylsulfonyl)oxy]-, (11 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 9004-61-9 HCAPLUS
 CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 35500-24-4 HCAPLUS
 CN Pregn-4-ene-3,20-dione, 11-hydroxy-21-[(methylsulfonyl)oxy]-, (11 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 35500-24-4 HCAPLUS
 CN Pregn-4-ene-3,20-dione, 11-hydroxy-21-[(methylsulfonyl)oxy]-, (11 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 80474-14-2 HCAPLUS

CN Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, S-(fluoromethyl) ester, (6 α ,11 β ,16 α ,17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 499984-17-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)

RN 499984-17-7 HCAPLUS

CN Butanimidamide, N-[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]-4-[[[(11 β ,16 α)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl]thio]-, tetrakis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1.

CRN 499984-16-6


CMF C36 H60 F N5 O4 S

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L46 ANSWER 20 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:973325 HCAPLUS
 DN 139:202229
 ED Entered STN: 26 Dec 2002
 TI Synthesis of an enzyme-dependent prodrug and evaluation of its potential
 for colon targeting
 AU Pang, Yi-Nuo; Zhang, Yan; Zhang, Zhi-Rong
 CS West China School of Pharmacy, Sichuan University, Chengdu, 610041, Peop.
 Rep. China
 SO World Journal of Gastroenterology (2002), 8(5), 913-917
 CODEN: WJGAF2; ISSN: 1007-9327
 PB World Journal of Gastroenterology
 DT Journal
 LA English
 CC 63-5 (Pharmaceuticals)
 AB A dexamethasone-succinate-dextran (DSD) **conjugate** was
 synthesized and evaluated its potential for the treatment of inflammatory
 bowel diseases. Dexamethasone was attached to dextran (average mol. weight=70
 400 Dalton) using succinate anhydride in an anhydrous environment
 catalyzed by 4-dimethylaminopyridine and 1, 1'-carbonyldiimidazole. The
 chemical structure of DSD was identified by UV, IR and NMR, and the in vivo

drug release behavior of this prodrug was investigated after oral administration of DSD suspension. The DSD **conjugate** was obtained in two steps and the content of dexamethasone in DSD was 11.28 %. The dextran prodrug was stable in rat stomach and small intestine and negligibly absorbed from these tracts. Four to nine hours after the oral administration, most of the prodrug (>95 %) had moved to the cecum and colon, and was easily hydrolyzed by an endodextranase. Recover of dexamethasone from colon and cecum after administration of DSD **conjugate** was 6-12 folds higher than the recovery after administration of unmodified dexamethasone ($t=2.74$, $P<0.05$). The preferential release of free dexamethasone in cecum and colon over that in the small intestine was statistically significant ($t=2.27$, $P<0.05$). The results of this study indicate that dextran **conjugates** may be useful in selectively delivering glucocorticoids to the colon.

- ST dexamethasone dextran prodrug colon targeting
- IT Intestine
(cecum; synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)
- IT Intestine
(colon; synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)
- IT Hydrolysis
(enzymic; synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)
- IT Drug delivery systems
(prodrugs; synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)
- IT Drug delivery systems
(suspensions; synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)
- IT Anti-inflammatory agents
(synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)
- IT 9025-70-1, Endodextranase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)
- IT 50-02-2, Dexamethasone
RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)
- IT 156228-67-0P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)
- IT 108-30-5, reactions 9004-54-0, Dextran, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)
- IT 3800-86-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)
- RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Adkin, D; Pharm Res 1997, V14, P103 HCAPLUS
- (2) Brondsted, H; J Control Rel 1998, V53, P7 HCAPLUS
- (3) Cavalcanti, O; Drug Dev Ind Pharm 2002, V28, P157 HCAPLUS
- (4) Chavan, M; J Pharm Pharmacol 2001, V53, P895 HCAPLUS
- (5) Cole, E; Int J Pharm 2002, V231, P83 HCAPLUS
- (6) Davaran, S; J Control Release 1999, V58, P279 HCAPLUS
- (7) Fukui, E; Int J Pharm 2000, V204, P7 HCAPLUS
- (8) Fukui, E; J Control Release 2001, V70, P97 HCAPLUS
- (9) Goto, M; J Pharm Pharmacol 2001, V53, P1711 HCAPLUS
- (10) Gupta, V; Int J Pharm 2001, V213, P83 HCAPLUS
- (11) Gupta, V; Int J Pharm 2001, V213, P93 HCAPLUS
- (12) Hebden, J; Pharm Res 1999, V16, P1087 HCAPLUS
- (13) Hu, Z; J Control Rel 1998, V56, P293 HCAPLUS
- (14) Ichinose, K; Anticancer Drugs 2000, V11, P33 HCAPLUS
- (15) Ishibashi, T; I Pharm Sci 1998, V87, P531 HCAPLUS
- (16) Ishibashi, T; J Control Release 1999, V59, P361 HCAPLUS
- (17) Jeong, Y; J Control Rel 2001, V71, P175 HCAPLUS
- (18) Jiang, X; World J Gastroenterol 2002, V8, P158
- (19) Jung, Y; J Pharm Sci 2001, V90, P1767 HCAPLUS
- (20) Kakoulides, E; J Control Rel 1998, V54, P95 HCAPLUS
- (21) Khan, M; J Control Release 1999, V58, P215 MEDLINE
- (22) Kievit, E; Cancer Res 1999, V59, P1417 HCAPLUS
- (23) Krishnaiah, Y; J Control Rel 1998, V55, P245 HCAPLUS
- (24) Krishnaiah, Y; J Control Rel 2001, V77, P87 HCAPLUS
- (25) Lee, J; J pharm Sci 2001, V90, P1787 HCAPLUS
- (26) Leopold, C; Drug Dev Ind Pharm 2000, V26, P1239 HCAPLUS
- (27) Lorenao-Lamosa, M; J Control Rel 1998, V52, P109
- (28) Macleod, G; Int J Pharm 1999, V187, P251 HCAPLUS
- (29) Maris, B; Int J Pharm 2001, V213, P143 HCAPLUS
- (30) Marta, R; J Control Rel 1998, V55, P67
- (31) McLeod, A; J Pharm Sci 1994, V83, P1284 HCAPLUS
- (32) Minami, K; J Pharm Sci 1998, V87, P715 HCAPLUS
- (33) Muraoka, M; J Control Rel 1998, V52, P119 HCAPLUS
- (34) Nykanen, P; Int J Pharm 1999, V184, P251 HCAPLUS
- (35) Nykanen, P; Int J Pharm 2001, V229, P155 HCAPLUS
- (36) Rodriguez, M; J Pharm Pharmacol 2001, V53, P1207 HCAPLUS
- (37) Rudolph, M; Eur J Pharm Biopharm 2001, V51, P183 HCAPLUS
- (38) Sangalli, M; Boll Chim Farm 1999, V138, P68 HCAPLUS
- (39) Sangalli, M; J Control Release 2001, V73, P103 HCAPLUS
- (40) Shibata, N; J Pharm Pharmacol 2001, V53, P441 HCAPLUS
- (41) Sinha, V; Int J Pharm 2001, V224, P19 HCAPLUS
- (42) Sinha, V; Pharm Res 2001, V18, P557 HCAPLUS
- (43) Stubbe, B; J Control Rel 2001, V75, P103 HCAPLUS
- (44) Takaya, T; J Control Release 1998, V50, P111 HCAPLUS
- (45) Takaya, T; J Drug Target 1997, V4, P271 HCAPLUS
- (46) Tozaki, H; J Pharm Pharmacol 1999, V51, P1107 HCAPLUS
- (47) Tozaki, H; J Pharm Pharmacol 1999, V51, P257 HCAPLUS
- (48) Tozaki, H; J Pharm Sci 2001, V90, P89 HCAPLUS
- (49) Villar-Lopez, M; Int J Pharm 1999, V179, P229 HCAPLUS
- (50) Wang, S; J Control Rel 1998, V53, P39 HCAPLUS
- (51) Yang, L; Int J Pharm 2002, V235, P1 HCAPLUS
- (52) Yano, H; J Pharm Sci 2001, V90, P2103 HCAPLUS
- (53) Yano, H; J Pharm Sci 2001, V90, P493 HCAPLUS

IT

50-02-2, Dexamethasone

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); THU
 (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent);
 USES (Uses)


(synthesis of an enzyme-dependent prodrug and evaluation of its

potential for colon targeting)

RN 50-02-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,
(11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 156228-67-0P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)

RN 156228-67-0 HCAPLUS

CN Dextran, (11 β ,16 α)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl butanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 9004-54-0

CMF Unspecified

CCI PMS, MAN


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 3800-86-0

CMF C26 H33 F O8

Absolute stereochemistry.



IT 3800-86-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of an enzyme-dependent prodrug and evaluation of its potential for colon targeting)

RN 3800-86-0 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11 β ,16 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 21 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:964223 HCAPLUS

DN 138:44756

ED Entered STN: 20 Dec 2002

TI **Conjugates** of polysaccharide polymers of natural origin

IN Volpato, Ivo; Bizzini, Bernard Emile; Abreu, Roberto Carlos; Lippmann, Marco

PA Bartholdy-Consultadoria e Servicos Ltd., Port.

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K047-48

CC 63-7 (Pharmaceuticals)

Section cross-reference(s): 1, 17, 40, 62

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100440	A1	20021219	WO 2002-EP6371	20020611
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1399192	A1	20040324	EP 2002-748760	20020611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2004219217 A1 20041104 US 2004-481139 20040614
 PRAI IT 2001-MI1238 A 20010612
 WO 2002-EP6371 W 20020611

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002100440	ICM	A61K047-48
US 2004219217	ECLA	A61K047/48K8

WO 2002100440	ICM	A61K047-48
US 2004219217	ECLA	A61K047/48K8

AB The present invention relates to the use of fibers of polysaccharide polymers of natural origin, preferably of vegetal origin, such as, for instance, cellulose or cotton, or the use of yarns, non-woven fabrics (or felts), or fabrics obtained from those fibers in order to obtain pharmaceutical, cosmetic or hygienic products, or products to be used in the household or in the food industry. In particular, the polysaccharide polymers according to the invention can be used to obtain plasters, gauzes, sanitary cotton wool, vaginal and surgical tampons, bandages, gloves, stockings, masks, curtains, carpets and the like, or to obtain filters or wrappings for food. For example, procaine hydrochloride was directly **conjugated** to cotton fibers through Schiff base; 76.3% procaine was released after 18 h by hydrolysis of the **conjugates**

ST polysaccharide fiber biol active compd **conjugate**

IT Antibodies and Immunoglobulins

RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(IgG, **conjugates** with cotton fibers; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)

IT Cosmetics

(antiaging; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)

IT Fibers

RL: COS (Cosmetic use); FFD (Food or feed use); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cellulosic; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)

IT Wound healing promoters

(cicatrizants; **conjugates** with cotton fibers; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)

IT Food packaging materials

(**conjugates** of polysaccharides with biol. active substances for food industry)

IT Anti-inflammatory agents

Antibacterial agents

Cotton fibers

Fungicides

Medical goods

Nonwoven fabrics

Textiles

Yarns

(**conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)

IT Schiff bases

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(**conjugates** of polysaccharides with biol. active substances)

- for medicinal, cosmetic and hygienic uses)
- IT Disinfectants
Immunostimulants
(**conjugates** with cotton fibers; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT **Corticosteroids**, biological studies
Elastins
Fibrinogens
Glycoproteins
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**conjugates** with cotton fibers; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT Fibronectins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**conjugates** with cotton fibers; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT Acaricides
(cotton fabric-**conjugated**; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT Medical goods
(dressings; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT Food
(filters or wrappings; **conjugates** of polysaccharides with biol. active substances for food industry)
- IT Medical goods
(gauzes; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT Medical goods
(gloves, antiallergic; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT Anesthetics
(local, **conjugates** with cotton fibers; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT Gloves
(medical, antiallergic; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT Synthetic polymeric fibers, biological studies
RL: COS (Cosmetic use); FFD (Food or feed use); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polysaccharides; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT Medical goods
(sanitary napkins; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT Amines, biological studies
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(secondary; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT Medical goods
(tampons; **conjugates** of polysaccharides with biol. active

- substances for medicinal, cosmetic and hygienic uses)
- IT Cosmetics
(wrinkle-preventing; **conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT 98-59-9, Tosyl chloride 111-30-8, Glutaraldehyde 1892-57-5, EDAC 10387-40-3, Potassium thioacetate
RL: RCT (Reactant); RACT (Reactant or reagent)
(**conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT 51-05-8DP, Procaine hydrochloride, **conjugates** with oxidized cotton fibers 52-90-4DP, L-Cysteine, **conjugates** with cotton fibers and biol. active compds. 56-87-1DP, L-Lysine, **conjugates** with cotton fibers and biol. active compds. 120-51-4DP, Benzyl benzoate, azo derivs., **conjugates** with cotton fibers and lysine or polylysine 122-11-2DP, Sulfadimethoxine, **conjugates** with cotton fibers and polylysine 123-08-0DP, 4-Hydroxybenzaldehyde, **conjugates** with derivatized cotton fibers 488-69-7DP, FDP, **conjugates** with cotton fibers and lysine or polylysine 547-32-0DP, Sulfadiazine sodium, **conjugates** with oxidized cotton fibers 1071-93-8DP, Adipic acid dihydrazide, reaction products with Factor VIII, **conjugates** with cotton fibers 1405-87-4DP, Bacitracin, **conjugates** with oxidized cotton fibers and polylysine 1405-97-6DP, Gramicidin, **conjugates** with oxidized cotton fibers and polylysine 9001-12-1DP, Collagenase, **conjugates** with cotton fibers 9001-26-7DP, Prothrombin, **conjugates** with cotton fibers and lysine or polylysine 9001-62-1DP, Lipase, **conjugates** with cotton fibers 9004-61-9DP, Hyaluronic acid, **conjugates** with cotton fibers 9005-49-6DP, Heparin, **conjugates** with cotton fibers 22204-53-1DP, Naproxen, **conjugates** with cotton fibers 25104-18-1DP, Poly(L-lysine), **conjugates** with cotton fibers and biol. active compds. 38000-06-5DP, Poly(L-lysine), **conjugates** with cotton fibers and biol. active compds. 113189-02-9DP, Blood coagulation factor VIII, reaction products with adipic acid dihydrazide, **conjugates** with cotton fibers and cysteine 478256-48-3DP, **conjugates** with cysteine and cotton fibers
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT 52-90-4, L-Cysteine, reactions 56-84-8, L-Aspartic acid, reactions 56-86-0, L-Glutamic acid, reactions 56-87-1, L-Lysine, reactions 302-01-2, Hydrazine, reactions 7783-06-4, Hydrogen sulfide, reactions 29768-80-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(**linker; conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- IT 17333-88-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**linker; conjugates** of polysaccharides with biol. active substances for medicinal, cosmetic and hygienic uses)
- RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) American Cyanamid Co; GB 900803 A 1962 HCAPLUS
 - (2) Cetus Corp; WO 9015628 A 1990 HCAPLUS
 - (3) Ciba Ltd; GB 816750 A 1959 HCAPLUS
 - (4) Edwards, J; BOOK OF ABSTRACTS, 215TH ACS NATIONAL MEETING 1998
 - (5) Kalpaxis, D; INT J BIOCHEM 1985, V17(1), P61 HCAPLUS

- ```

(6) Kuraray Co Ltd; JP 03101618 A 1991 HCAPLUS
(7) M U R S T; WO 9311803 A 1993 HCAPLUS
(8) Roehm Gmbh; DE 4029374 A 1992 HCAPLUS
(9) Scripps Lab Inc; WO 9738312 A 1997 HCAPLUS
(10) Univ Bar Ilan; EP 0611573 A 1994 HCAPLUS
IT 9004-61-9DP, Hyaluronic acid, conjugates with
cotton fibers 478256-48-3DP, conjugates with cysteine
and cotton fibers
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(conjugates of polysaccharides with biol. active substances
for medicinal, cosmetic and hygienic uses)
RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)


```

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 478256-48-3 HCAPLUS

CN Benzoic acid, 4-[[[(11 $\beta$ )-11,17,21-trihydroxy-3,20-dioxopregn-4-en-12-yl]azo]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



```
L46 ANSWER 22 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:932629 HCAPLUS
DN 138:181073
ED Entered STN: 10 Dec 2002
TI Estrogen stimulates arachidonoyl ethanolamide release from human
 endothelial cells and platelet activation
AU Maccarrone, Mauro; Bari, Monica; Battista, Natalia; Finazzi-Agro,
 Alessandro
CS Department of Experimental Medicine and Biochemical Sciences, University
 of Rome Tor Vergata, Rome, I-00133, Italy
SO Blood (2002), 100(12), 4040-4048
 CODEN: BLOOAW; ISSN: 0006-4971
PB American Society of Hematology
DT Journal
LA English
CC 2-4 (Mammalian Hormones)
AB Estrogen replacement therapy has been associated with reduction of
 cardiovascular
 events in postmenopausal women, though the mechanism for this benefit
 remains unclear. At physiol. concns. estrogen activates the anandamide
```

membrane transporter of human endothelial cells and leads to rapid elevation of calcium (apparent within 5 min) and release of nitric oxide (within 15 min). These effects are mediated by estrogen binding to a surface receptor, which shows an apparent dissociation constant ( $K_d$ ) of  $9.4 \pm 1.4$  nM, a maximum binding ( $B_{max}$ ) of  $356 \pm 12$  fmol + mg protein<sup>-1</sup>, and an apparent mol. mass of approx. 60 kDa. The authors also show that estrogen binding to surface receptors leads to stimulation of the anandamide-synthesizing enzyme phospholipase D and to inhibition of the anandamide-hydrolyzing enzyme fatty acid amide hydrolase, the latter effect mediated by 15-lipoxygenase activity. Because the endothelial transporter is shown to move anandamide across the cell membranes bidirectionally, taken together these data suggest that the physiolog. activity of estrogen is to stimulate the release, rather than the uptake, of anandamide from endothelial cells. Moreover, the authors show that anandamide released from estrogen-stimulated endothelial cells, unlike estrogen itself, inhibits the secretion of serotonin from ADP-stimulated platelets. Therefore, it is suggested that the peripheral actions of anandamide could be part of the mol. events responsible for the beneficial effects of estrogen.

- ST estrogen receptor anandamide transporter vascular endothelium platelet activation human; calcium nitric oxide signal transduction estrogen anandamide endocannabinoid
- IT Platelet (blood)  
(activation; estrogen stimulates arachidonoyl ethanolamide release from human endothelial cells and platelet activation)
- IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(arachidonoyl ethanolamide membrane transporter (AMT); estrogen stimulates arachidonoyl ethanolamide release from human endothelial cells and platelet activation)
- IT Cannabinoids  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(endo-; estrogen stimulates arachidonoyl ethanolamide release from human endothelial cells and platelet activation)
- IT Blood vessel  
(endothelium; estrogen stimulates arachidonoyl ethanolamide release from human endothelial cells and platelet activation)
- IT Human  
Signal transduction, biological  
(estrogen stimulates arachidonoyl ethanolamide release from human endothelial cells and platelet activation)
- IT Albumins, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(serum, **conjugate** with  $17\beta$ -estradiol 6-(O-carboxymethyl)oxime; estrogen stimulates arachidonoyl ethanolamide release from human endothelial cells and platelet activation)
- IT Estrogen receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(surface; estrogen stimulates arachidonoyl ethanolamide release from human endothelial cells and platelet activation)
- IT Cannabinoid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(type CB1; estrogen stimulates arachidonoyl ethanolamide release from human endothelial cells and platelet activation)
- IT Vein  
(umbilical, endothelium, human; estrogen stimulates arachidonoyl ethanolamide release from human endothelial cells and platelet activation)
- IT Estrogen receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\beta$ ; estrogen stimulates arachidonoyl ethanolamide release from  
human endothelial cells and platelet activation)

IT 50-23-7, Cortisol 50-28-2, Estradiol, biological studies  
50-67-9, Serotonin, biological studies 57-91-0, 17 $\alpha$ -Estradiol  
58-64-0, 5'-ADP, biological studies 60-92-4, CAMP 7440-70-2, Calcium,  
biological studies 9001-87-0, Phospholipase D 10102-43-9, Nitric  
oxide, biological studies 35048-47-6, 17 $\beta$ -Estradiol  
6-(O-carboxymethyl)oxime 35048-47-6D, 17 $\beta$ -Estradiol  
6-(O-carboxymethyl)oxime, **conjugate** with bovine serum albumin  
82249-77-2, 15-Lipoxygenase 94421-68-8, Anandamide 125978-95-2, Nitric  
oxide synthase 153301-19-0, Fatty acid amide hydrolase

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(estrogen stimulates arachidonoyl ethanolamide release from human  
endothelial cells and platelet activation)

IT 67-42-5, EGTA 145-63-1, Suramin 404-86-4, Capsaicin 1191-85-1, ETYA  
10540-29-1, Tamoxifen 13956-29-1, Cannabidiol 22972-55-0 50903-99-6,  
L-NAME 107761-24-0, ST638 112830-95-2, HU-210 129453-61-8, ICI182780  
138977-28-3, Capsazepine 149301-79-1, Arachidonyl trifluoromethyl ketone  
168273-06-1, SR141716 183718-77-6, AM404 192703-06-3, SR144528

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(estrogen stimulates arachidonoyl ethanolamide release from human  
endothelial cells and platelet activation in relation to modulation by  
various compds.)

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Alberich Jorda, M; Blood 2002, V99, P2786
- (2) Bar, J; Thromb Haemost 2000, V84, P695 HCAPLUS
- (3) Batkai, S; Nat Med 2001, V7, P827 HCAPLUS
- (4) Beltramo, M; Neuroreport 2000, V11, P1231 HCAPLUS
- (5) Berdyshev, E; Chem Phys Lipids 2000, V108, P169 HCAPLUS
- (6) Bisogno, T; J Biol Chem 1997, V272, P3315 HCAPLUS
- (7) Bourgoin, S; J Biol Chem 1992, V267, P11908 HCAPLUS
- (8) Brash, A; J Biol Chem 1999, V274, P23679 HCAPLUS
- (9) Bredt, D; Proc Natl Acad Sci U S A 1990, V87, P682 HCAPLUS
- (10) Camacho, M; J Biol Chem 1995, V270, P17279 HCAPLUS
- (11) Cenci, S; J Clin Invest 2000, V106, P1229 HCAPLUS
- (12) Chen, Z; J Clin Invest 1999, V103, P401 HCAPLUS
- (13) Daniel, J; J Biol Chem 1998, V273, P2024 HCAPLUS
- (14) Di Marzo, V; Biochim Biophys Acta 1998, V1392, P153 HCAPLUS
- (15) Di Marzo, V; Trends Pharmacol Sci 2001, V22, P346 HCAPLUS
- (16) Exton, J; J Biol Chem 1997, V272, P15579 HCAPLUS
- (17) Giuffrida, A; Anal Biochem 2000, V280, P87 HCAPLUS
- (18) Hansen, H; Chem Phys Lipids 2000, V108, P135 HCAPLUS
- (19) Hanus, L; Proc Natl Acad Sci U S A 2001, V98, P3662 HCAPLUS
- (20) Hao, S; Eur J Pharmacol 2000, V392, P147 HCAPLUS
- (21) Hillard, C; Chem Phys Lipids 2000, V108, P123 HCAPLUS
- (22) Jarai, Z; Proc Natl Acad Sci U S A 1999, V96, P14136 HCAPLUS
- (23) Khetawat, G; Blood 2000, V95, P2289 HCAPLUS
- (24) Kunos, G; Chem Phys Lipids 2000, V108, P159 HCAPLUS
- (25) Liu, J; Biochem J 2000, V346, P835 HCAPLUS
- (26) MacDonald, J; Nature 2001, V410, P527
- (27) Maccarrone, M; Anal Biochem 1999, V267, P314 HCAPLUS
- (28) Maccarrone, M; Eur J Biochem 2001, V268, P819 HCAPLUS
- (29) Maccarrone, M; FEBS Lett 1999, V447, P277 HCAPLUS
- (30) Maccarrone, M; J Biol Chem 2000, V275, P13484 HCAPLUS
- (31) Maccarrone, M; J Biol Chem 2000, V275, P31938 HCAPLUS
- (32) Maccarrone, M; J Immunol 2001, V166, P7183 HCAPLUS
- (33) Mendelsohn, M; N Engl J Med 1999, V340, P1801 HCAPLUS

- (34) Moesgaard, B; J Lipid Res 2000, V41, P985 HCAPLUS  
 (35) Najib, A; FEBS Lett 2000, V486, P136 HCAPLUS  
 (36) Nealen, M; Circ Res 2001, V88, P438 HCAPLUS  
 (37) Pertwee, R; Pharmacol Ther 1997, V74, P129 HCAPLUS  
 (38) Piornelli, D; Proc Natl Acad Sci U S A 1999, V96, P5802  
 (39) Razandi, M; Mol Endocrinol 1999, V13, P307 HCAPLUS  
 (40) Rogers, K; Life Sci 2001, V69, P1817 HCAPLUS  
 (41) Sachais, B; Curr Atheroscler Rep 2001, V3, P412 MEDLINE  
 (42) Stefano, G; Blood 2000, V95, P3951 HCAPLUS  
 (43) Stefano, G; Circulation 2000, V101, P1594 HCAPLUS  
 (44) Stefano, G; J Immunol 1999, V163, P3758 HCAPLUS  
 (45) Storey, R; Br J Haematol 2000, V110, P925 HCAPLUS  
 (46) Sun, S; J Neurochem 1999, V73, P334 HCAPLUS  
 (47) Thomas, E; Proc Natl Acad Sci U S A 1997, V94, P14115 HCAPLUS  
 (48) Ueda, N; Chem Phys Lipids 2000, V108, P107 HCAPLUS  
 (49) Ueda, N; J Biol Chem 2001, V276, P35552 HCAPLUS  
 (50) Walker, J; Proc Natl Acad Sci U S A 1999, V96, P12198 HCAPLUS


IT 50-23-7, Cortisol

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (estrogen stimulates arachidonylethanolamide release from human  
 endothelial cells and platelet activation)

RN 50-23-7 HCAPLUS

CN Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11 $\beta$ )- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



L46 ANSWER 23 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2002:928122 HCAPLUS  
 DN 138:12504  
 ED Entered STN: 06 Dec 2002  
 TI Method for assaying biomolecules and other constituents using indicator  
**conjugates** with synthetic nucleounits in lateral flow, liquid, and  
 dry chemistry techniques  
 IN Smith, Jack V.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 46 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM C12Q001-68  
 NCL 435006000  
 CC 9-16 (Biochemical Methods)  
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|



|      |                |    |          |                |          |
|------|----------------|----|----------|----------------|----------|
| PI   | US 2002182600  | A1 | 20021205 | US 2001-829563 | 20010411 |
| PRAI | US 2001-829563 |    | 20010411 |                |          |

## CLASS

|            |       |                                    |
|------------|-------|------------------------------------|
| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|-------|------------------------------------|

|               |     |            |
|---------------|-----|------------|
| US 2002182600 | ICM | C12Q001-68 |
|               | NCL | 435006000  |

AB The present invention is a method for the use of particles made up of nucleotides or fragments of base groups of DNA and RNA mols. herein referred to as synthetic nucleounits which can be used as recognition mols. with specificity and sensitivity significantly greater than that of antibodies which are used in clin. diagnostics, biotechnol., and research. The method for detecting an analyte using nucleounits targeted to the analyte comprises (1) identifying a nucleounit from a mixture of synthetic random sequences of nucleounit libraries, (2) **conjugating** the nucleounit to an indicator for the analyte, and (3) detecting the analyte using the nucleounit-indicator **conjugate** in a buffer. Step 1 is carried out by (a) contacting the analyte with the mixture of synthetic random sequences of nucleounit libraries such that some nucleounits bind the analyte, (b) removing the unbound nucleounits by partitioning, and (c) amplifying the remaining nucleounits by PCR to obtain an enriched solution of nucleounits with high affinity for the analyte. Thus, a method and lateral flow test strip for detection of cytomegalovirus (CMV) presence in a biol. sample such as serum or urine is described. The strip is prepared with three solns., one containing anti-CMV antibodies, one containing

"nucleounit

to CMV antibody **conjugated** to red microparticles" and "red microparticles", and another containing "nucleounit to colored particles". The "nucleounit" may be an oligonucleotide aptamer specific for anti-CMV antibodies.

ST dipstick lateral flow device oligonucleotide aptamer biomol drug detection  
IT Corticosteroids, analysis

RL: ANT (Analyte); ANST (Analytical study)  
(17-hydroxy; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Steroids, analysis

RL: ANT (Analyte); ANST (Analytical study)  
(17-ketogenic; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Proteins

RL: ANT (Analyte); ANST (Analytical study)  
(C-reactive; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Antigens

RL: ANT (Analyte); ANST (Analytical study)  
(EBNA (Epstein-Barr virus-associated nuclear antigen), IgG binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Antigens

RL: ANT (Analyte); ANST (Analytical study)  
(Epstein-Barr early; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Cytomegalovirus

Mycoplasma

Rubella

Toxoplasma

(IgG and IgM binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Helicobacter pylori

Human herpesvirus 1

Human herpesvirus 2

(IgG binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Legionella

(IgG, IgM, and IgA binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Antibodies and Immunoglobulins

RL: ANT (Analyte); ANST (Analytical study)

(IgG, anti-peroxidase; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Antigens

RL: ANT (Analyte); ANST (Analytical study)

(VCA (viral capsid antigen), IgG and IgM binding to Epstein-Barr; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Entamoeba histolytica

(amebiasis; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Proteins

RL: ANT (Analyte); ANST (Analytical study)

(amyloid-associated; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Neutrophil

(antibodies binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Cardiolipins

RL: ANT (Analyte); ANST (Analytical study)

(antibodies binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Antibodies and Immunoglobulins

RL: ANT (Analyte); ANST (Analytical study)

(antinuclear; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Antibodies and Immunoglobulins

RL: ANT (Analyte); ANST (Analytical study)

(autoantibodies, Jo-1; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT Antibodies and Immunoglobulins

RL: ANT (Analyte); ANST (Analytical study)

(autoantibodies, SS-A/Ro; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic

- nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Antibodies and Immunoglobulins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (autoantibodies, SS-B/La; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Antibodies and Immunoglobulins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (autoantibodies, Scl-70; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Antibodies and Immunoglobulins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (autoantibodies, Sm (Smith antigen); method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Antibodies and Immunoglobulins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (autoantibodies, Sm/RNP; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Antigens  
 RL: ANT (Analyte); ANST (Analytical study)  
 (cancer antigen 125; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Hemoglobins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (carboxyhemoglobins; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Latex  
 (colored particles of, **conjugates**; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Metals, biological studies  
 Plastics, biological studies  
 Rubber, biological studies  
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (colored particles of, **conjugates**; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Complement  
 RL: ANT (Analyte); ANST (Analytical study)  
 (components of; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT DNA  
 RL: ANT (Analyte); ANST (Analytical study)  
 (double-stranded, antibodies binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Antigens  
 RL: ANT (Analyte); ANST (Analytical study)  
 (extractable nuclear; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic

- nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Fats and Glyceridic oils, analysis  
 RL: ANT (Analyte); ANST (Analytical study)  
 (fecal; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Proteins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (fetoproteins; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Enzymes, biological studies  
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (galactosaminidase, indicator; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Enzymes, biological studies  
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (glucosaminidase, indicator; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Lipoproteins  
 RL: ANT (Analyte); ANST (Analytical study)  
 (high-d.; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Enzymes, biological studies  
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (hydroxybenzoate hydroxylase, indicator; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Enzymes, biological studies  
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (maltosidase, indicator; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Angiogenesis  
 Blood  
 Blood analysis  
 Human herpesvirus 3  
 Human immunodeficiency virus  
 Leukocyte  
 Urine analysis  
 (method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT Albumins, analysis  
 Alcohols, analysis  
 Antibodies and Immunoglobulins  
 Antibodies and Immunoglobulins  
 Apolipoproteins  
 Bile acids  
 Cannabinoids  
 Carotenes, analysis  
 Catecholamines, analysis

Estrogens  
 Fatty acids, analysis  
 Ferritins  
 Fibrinogens  
 Gastric acid  
 Glycerides, analysis  
 Gonadotropins  
 Haptoglobin  
 Hemoglobins  
 Hemoglobins, methemoglobins  
 Hemopexins  
 Ketone bodies  
 Lecithins  
 Lipoproteins  
 Melanins  
 Mucopolysaccharides, analysis  
 Myelin basic protein  
 Myoglobins  
 Opioids  
 Pentoses  
 Phenols, analysis  
 Phospholipids, analysis  
 Prostaglandins  
 Prostate-specific antigen  
 Rheumatoid factors  
 Thyroglobulin  
 Transcortins  
 Transferrins  
 Transthyretin  
 Vitamins

**$\alpha$  1-Acid glycoprotein**

RL: ANT (Analyte); ANST (Analytical study)  
 (method for assaying biomols. and other constituents using indicator  
**conjugates** with synthetic nucleounits in lateral flow, liquid,  
 and dry chemical techniques)

IT Antibodies and Immunoglobulins

RL: ANT (Analyte); ANST (Analytical study)  
 (microsomal; method for assaying biomols. and other constituents using  
 indicator **conjugates** with synthetic nucleounits in lateral  
 flow, liquid, and dry chemical techniques)

IT Aptamers

(oligonucleotide; method for assaying biomols. and other constituents  
 using indicator **conjugates** with synthetic nucleounits in  
 lateral flow, liquid, and dry chemical techniques)

IT Antibodies and Immunoglobulins

RL: ANT (Analyte); ANST (Analytical study)  
 (thyroid; method for assaying biomols. and other constituents using  
 indicator **conjugates** with synthetic nucleounits in lateral  
 flow, liquid, and dry chemical techniques)

IT Globulins, analysis

RL: ANT (Analyte); ANST (Analytical study)  
 (thyroxine-binding; method for assaying biomols. and other constituents  
 using indicator **conjugates** with synthetic nucleounits in  
 lateral flow, liquid, and dry chemical techniques)

IT Pigments, biological

(urobilinogens; method for assaying biomols. and other constituents  
 using indicator **conjugates** with synthetic nucleounits in  
 lateral flow, liquid, and dry chemical techniques)

IT 128028-50-2, Proteinase-3

- RL: ANT (Analyte); ANST (Analytical study)  
(IgG binding to; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT 50-36-2, Cocaine  
RL: ANT (Analyte); ANST (Analytical study)  
(and metabolites; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT 144-62-7, Ethanedioic acid, analysis  
RL: ANT (Analyte); ANST (Analytical study)  
(buffer/analyte; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT 50-21-5, analysis  
RL: ANT (Analyte); ARU (Analytical role, unclassified); ANST (Analytical study)  
(buffer/analyte; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT 77-86-1, TRIS 77-92-9, Citric acid, analysis 102-71-6, Triethanolamine, analysis 103-47-9, CHES 110-15-6, Succinic acid, analysis 150-25-4, BICINE 463-79-6, Carbonic acid, analysis 497-19-8, Sodium carbonate, analysis 868-14-4, Potassium hydrogen tartrate 877-24-7, Potassium hydrogen phthalate 1132-61-2, MOPS 1135-40-6, CAPS 1303-96-4, Borax 1330-43-4, Sodium tetraborate 4432-31-9, MES 5625-37-6, PIPES 5704-04-1, TRICINE 6976-37-0, BIS-TRIS 7365-44-8, TES 7365-45-9, HEPES 7365-82-4, ACES 7601-89-0, Sodium perchlorate 7601-90-3, Perchloric acid, analysis 7664-38-2, Phosphoric acid, analysis 7664-93-9, Sulfuric acid, analysis 7697-37-2, Nitric acid, analysis 7775-09-9, Sodium chlorate 10043-35-3, Boric acid, analysis 10191-18-1, BES 10196-30-2, 2-Amino-2-ethyl-1-propanol 13530-68-2, Chromic acid 16052-06-5, EPPS 26239-55-4, ADA 29915-38-6, N-Tris[Hydroxymethyl]methyl-3-aminopropanesulfonic acid 64431-96-5, BIS-TRIS PROPANE 68189-43-5, POPSO 68399-77-9, MOPSO 68399-78-0, HEPPSO 68399-79-1, AMPPO 68399-80-4, DIPSO 68399-81-5, TAPSO 73463-39-5, CAPSO 109191-31-3, N-[2-Acetamido]-2-aminoethanesulfonic acid)  
RL: ARU (Analytical role, unclassified); ANST (Analytical study)  
(buffer; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT 9001-60-9, Lactate dehydrogenase 9001-78-9, Alkaline phosphatase 9002-12-4, Uricase  
RL: ANT (Analyte); ANST (Analytical study)  
(indicator/analyte; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)
- IT 53-59-8, NADP 53-84-9, Nicotinamide adenine dinucleotide 69-79-4 83-07-8, 4-Aminoantipyrine 87-66-1, Pyrogallol 91-67-8, N,N-Diethyl-m-toluidine 91-95-2, 3,3'-Diaminobenzidine 108-95-2, Phenol, biological studies 119-90-4 120-83-2, 2,4-Dichlorophenol 121-69-7, Dimethylaniline, biological studies 132-32-1, 3-Amino-9-ethyl carbazole 298-83-9, Nitro Blue Tetrazolium 369-07-3, 2-Nitrophenyl- $\beta$ -D-galactopyranoside 1094-61-7, Nicotinamide mononucleotide 1128-67-2, 3-Methyl-2-benzothiazolinonehydrazone 1851-07-6, Nicotinamide hypoxanthine dinucleotide 2280-44-6, Glucopyranose 2438-80-4 3025-88-5, 2-5, Dimethyl-2,5-dihydroperoxyhexane 3150-24-1 3416-24-8, Glucosamine 5094-33-7,

4-Aminophenyl- $\beta$ -D-galactopyranoside 6160-80-1, 4-Methylumbelliferyl- $\beta$ -D-glucuronide 6556-12-3, Glucuronic acid 6739-64-6, Nicotinamide hypoxanthine dinucleotide phosphate 7240-90-6 7298-93-3,  $\alpha$ -NAD 7535-00-4, Galactosamine 9001-34-7, Galactosidase 9001-37-0, Glucose oxidase 9001-40-5, Glucose-6-phosphate dehydrogenase 9001-45-0, Glucuronidase 9001-46-1, Glutamate dehydrogenase 9001-55-2, Hydroxybutyrate dehydrogenase 9001-64-3, Malate dehydrogenase 9001-65-4, Mannitol dehydrogenase 9001-68-7, NADPH oxidoreductase 9002-17-9, Xanthine oxidase 9003-99-0, Peroxidase 9013-05-2, Phosphatase 9013-79-0, Esterase 9016-17-5, Aryl sulfatase 9016-18-6, Carboxyl esterase 9025-35-8,  $\alpha$ -Galactosidase 9026-00-0, Cholesterol esterase 9028-14-2, Glycerol dehydrogenase 9028-53-9, Glucose dehydrogenase 9028-67-5, Choline oxidase 9028-76-6, Cholesterol oxidase 9028-84-6, Formaldehyde dehydrogenase 9029-44-1, Ascorbate oxidase 9031-11-2,  $\beta$ -Lactosidase 9032-92-2, Glycosidase 9033-06-1, Glucosidase 9035-73-8, Oxidase 9035-82-9, Dehydrogenase 9046-28-0, Glycerophosphate oxidase 9046-59-7, Hydroxylase 9055-15-6, Oxidoreductase 9067-74-7, Arabinosidase 9068-67-1, Sulfatase 9073-63-6, Alcohol oxidase 9075-65-4, Glycerol-3-phosphate dehydrogenase 9082-71-7, Leucine dehydrogenase 10257-31-5, Xylopyranose 26281-43-6 28752-68-3, ABTS 33993-25-8, 2-Naphthyl- $\beta$ -D-galactopyranoside 36473-36-6 36783-03-6, TOPS 37211-66-8, Mannosidase 37329-65-0,  $\beta$ -D-Cellobiosidase 45935-73-7, p-Hydroxybenzene Sulfonate 46032-76-2, Mannopyranose 46489-28-5 50443-29-3 51349-63-4 51652-08-5 54827-17-7, 3,3',5,5'-Tetramethylbenzidine 56846-39-0 56973-46-7 61116-22-1, Acyl-CoA oxidase 72943-20-5 82611-88-9 82692-96-4, ADOS 83777-30-4, DAOS 88795-34-0, ADPS 89299-64-9, Arabinopyranose 90836-13-8, ALOS 91395-87-8 93863-88-8 94129-58-5 96497-76-6 97753-82-7 99304-66-2, DAPS 99304-67-3, MAPS 101764-19-6 102636-89-5, ALPS 110592-38-6 111070-05-4, Fucosidase 112046-91-0 113079-84-8 125858-89-1, Xylosidase 126400-78-0, N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethylaniline 126787-65-3 135622-84-3, Fructose dehydrogenase 138182-21-5 181066-50-2, Bis-MAPS-C 2 207595-15-1 207727-11-5 380637-04-7, MADB 477532-32-4  
 RL: ARG (Analytical reagent use); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(indicator; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT 50-00-0, Formaldehyde, analysis 50-02-2, Dexamethasone 50-06-6, Phenobarbital, analysis 50-22-6, Corticosterone 50-23-7, Cortisol 50-27-1, Estriol 50-28-2, Estradiol, analysis 50-33-9, Phenylbutazone, analysis 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, analysis 50-56-6, Oxytocin, analysis 50-67-9, Serotonin, analysis 50-81-7, Ascorbic acid, analysis 50-99-7, Glucose, analysis 51-06-9, Procainamide 51-35-4, Hydroxyproline 51-48-9, Thyroxine, analysis 52-39-1, Aldosterone 52-90-4, Cysteine, analysis 53-02-1, Tetrahydrocortisol 53-16-7, Estrone, analysis 53-43-0, Dehydroepiandrosterone 54-16-0, 5-Hydroxyindoleacetic acid, analysis 54-36-4, Metyrapone 54-85-3, Isoniazid 55-10-7, Vanillylmandelic acid 56-40-6, Glycine, analysis 56-41-7, Alanine, analysis 56-54-2, Quinidine 56-73-5, Glucose-6-phosphate 56-75-7, Chloramphenicol 56-81-5, Glycerol, analysis 56-85-9, Glutamine, analysis 56-89-3, Cystine, analysis 57-00-1, Creatine 57-12-5, Cyanide, analysis 57-13-6, Urea, analysis 57-27-2, Morphine, analysis 57-41-0, Diphenylhydantoin 57-42-1, Meperidine 57-43-2, Amobarbital 57-48-7, Fructose, analysis 57-50-1, Sucrose, analysis 57-53-4, Meprobamate 57-83-0, Progesterone, analysis 57-88-5, Cholesterol, analysis

58-08-2, Caffeine, analysis 58-22-0, Testosterone 58-25-3, Chlordiazepoxide 58-55-9, Theophylline, analysis 58-86-6, Xylose, analysis 59-05-2, Methotrexate 59-23-4, Galactose, analysis 59-30-3, analysis 59-67-6, Niacin, analysis 60-18-4, Tyrosine, analysis 60-27-5, Creatinine 60-92-4, Cyclic AMP 61-90-5, Leucine, analysis 62-44-2, Phenacetin 63-05-8, Androstenedione 63-42-3, Lactose 63-68-3, Methionine, analysis 63-91-2, Phenylalanine, analysis 64-17-5, Ethanol, analysis 64-77-7, Tolbutamide 64-85-7, 11-Deoxycorticosterone 67-56-1, Methanol, analysis 68-60-0, Tetrahydrodeoxycortisol 68-96-2, 17-Hydroxyprogesterone 69-72-7D, Salicylic acid, derivs. 69-93-2, Uric acid, analysis 70-18-8, Glutathione, analysis 72-18-4, Valine, analysis 72-44-6, Methaqualone 72-69-5, Nortriptyline 73-32-5, Isoleucine, analysis 76-42-6, Oxycodone 76-57-3, Codeine 76-73-3, Secobarbital 76-74-4, Pentobarbital 76-75-5, Thiopental 76-99-3, Methadone 77-10-1, Phencyclidine 77-21-4, Glutethimide 77-41-8, Methsuximide 77-67-8, Ethosuximide 79-14-1, Glycolic acid, analysis 79-83-4, Pantothenic acid 80-92-2 81-25-4, Cholic acid 82-58-6, Lysergic acid 83-44-3, Deoxycholic acid 83-88-5, Riboflavin, analysis 86-34-0, Phensuximide 87-86-5, Pentachlorophenol 97-31-4, Normetanephine 99-66-1, Valproic acid 103-90-2, Acetaminophen 107-21-1, Ethylene glycol, analysis 113-18-8, Ethchlorvynol 123-63-7, Paraldehyde 125-33-7, Primidone 125-64-4, Methypylon 127-17-3, Pyruvic acid, analysis 137-58-6, Lidocaine 143-74-8, Phenolsulfonphthalein 145-13-1, Pregnenolone 152-58-9, 11-Deoxycortisol 298-46-4, Carbamazepine 299-42-3, Ephedrine 300-62-9, Amphetamine 302-04-5, Thiocyanate, analysis 302-17-0, Chloral hydrate 306-08-1, Homovanillic acid 359-83-1, Pentazocine 438-60-8, Protriptyline 439-14-5, Diazepam 451-13-8, Homogentisic acid 466-99-9, Hydromorphone 469-62-5, Propoxyphene 487-90-1, Porphobilinogen 521-18-6, Dihydrotestosterone 525-66-6, Propranolol 537-46-2, Methamphetamine 553-12-8, Protoporphyrin 555-30-6, Methyl dopa 591-81-1,  $\gamma$ -Hydroxybutyric acid 604-75-1, Oxazepam 635-65-4, Bilirubin, analysis 651-48-9, Dehydroepiandrosterone sulfate 846-49-1, Lorazepam 1098-45-9, Pregnanetriol 1319-82-0, Aminocaproic acid 1330-20-7, Xylene, analysis 1393-25-5, Secretin 1403-66-3, Gentamicin 1404-90-6, Vancomycin 1622-61-3, Clonazepam 1668-19-5, Doxepin 3737-09-5, Disopyramide 4205-90-7, Clonidine 4429-04-3, Fructosamine 4685-14-7, Paraquat 4697-36-3, Carbenicillin 5001-33-2, Metanephine 5817-39-0, Reverse triiodothyronine 6027-13-0, Homocysteine 6893-02-3, Triiodothyronine 7439-89-6, Iron, analysis 7439-92-1, Lead, analysis 7439-93-2, Lithium, analysis 7439-95-4, Magnesium, analysis 7439-97-6, Mercury, analysis 7439-98-7, Molybdenum, analysis 7440-02-0, Nickel, analysis 7440-28-0, Thallium, analysis 7440-47-3, Chromium, analysis 7440-57-5, Gold, analysis 7440-66-6, Zinc, analysis 7440-70-2, Calcium, analysis 7782-49-2, Selenium, analysis 7783-06-4, Hydrogen sulfide, analysis 8063-07-8, Kanamycin 9000-86-6, Alanine aminotransferase 9000-92-4, Amylase 9000-94-6, Antithrombin 9001-08-5, Pseudocholinesterase 9001-10-9, Pepsinogen 9001-15-4, Creatine kinase 9001-58-5, Isocitrate dehydrogenase 9001-62-1, Lipase 9001-63-2, Lysozyme 9001-77-8, Acid phosphatase 9001-80-3, Phosphofructokinase 9001-91-6, Plasminogen 9002-60-2, Adrenocorticotrophic hormone, analysis 9002-61-3, Chorionic gonadotropin 9002-64-6, Parathyroid hormone 9002-68-0, Follicle stimulating hormone 9002-71-5, Thyroid stimulating hormone 9002-72-6, Growth hormone 9002-76-0, Gastrin 9004-07-3, Chymotrypsin 9004-10-8, Insulin, analysis 9007-12-9, Calcitonin 9007-92-5, Glucagon, analysis 9014-48-6, Transketolase 9015-94-5, Renin, analysis 9024-52-6, Aldolase 9035-54-5, Placental lactogen 9035-68-1, Proinsulin 9035-81-8, Antitrypsin 11000-17-2, Antidiuretic hormone 11016-39-0,



Properdin 12794-10-4D, Benzodiazepine, derivs. 14797-65-0, Nitrite, analysis 14838-15-4, Phenylpropanolamine 15687-27-1, Ibuprofen 17617-23-1, Flurazepam 20830-75-5, Digoxin 23887-31-2, Clorazepate 24305-27-9, Thyrotropin-releasing hormone 24959-67-9, Bromide, analysis 26316-36-9, Uroporphyrin 27121-71-7, Coproporphyrin 29679-58-1, Fenopufen 32795-44-1, n-Acetylprocainamide 32986-56-4, Tobramycin 37221-79-7, Vasoactive intestinal polypeptide 37517-28-5, Amikacin 39335-01-8, Macroamylase 51481-61-9, Cimetidine 54143-55-4, Flecainide 56391-56-1, Netilmicin 59112-80-0, c-Peptide 59763-91-6, Pancreatic polypeptide 59865-13-3, Cyclosporine 67763-96-6, Somatomedin c 69776-17-6 85876-02-4, Glutamyltransferase 152923-57-4, Lutropin

RL: ANT (Analyte); ANST (Analytical study)

(method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT 7727-37-9, Nitrogen, analysis

RL: ANT (Analyte); ANST (Analytical study)

(protein-associated and nonprotein; method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT 50-02-2, Dexamethasone 50-22-6, Corticosterone

50-23-7, Cortisol


RL: ANT (Analyte); ANST (Analytical study)

(method for assaying biomols. and other constituents using indicator **conjugates** with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

RN 50-02-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11 $\beta$ ,16 $\alpha$ )- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50-22-6 HCAPLUS


CN Pregn-4-ene-3,20-dione, 11,21-dihydroxy-, (11 $\beta$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50-23-7 HCAPLUS  
 CN Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 24 OF 65 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2002:907161 HCAPLUS  
 DN 138:13500  
 ED Entered STN: 29 Nov 2002  
 TI Superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases  
 IN Terman, David S.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 167 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K038-17  
 ICS C12N005-06; C07K014-705  
 NCL 514012000; 435325000; 530350000  
 CC 15-2 (Immunochemistry)  
 Section cross-reference(s): 3, 9, 63

FAN.CNT 1

|      | PATENT NO.      | KIND | DATE     | APPLICATION NO. | DATE     |
|------|-----------------|------|----------|-----------------|----------|
| PI   | US 2002177551   | A1   | 20021128 | US 2001-870759  | 20010530 |
| PRAI | US 2000-208128P | P    | 20000531 |                 |          |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|------------|-------|------------------------------------|
| -----      | ----- | -----                              |

US 2002177551 ICM A61K038-17  
ICS C12N005-06; C07K014-705  
NCL 514012000; 435325000; 530350000

AB The present invention comprises compns. and methods for treating a tumor or neoplastic disease in a host, The methods employ conjugates comprising superantigen polypeptides, nucleic acids with other structures that preferentially bind to tumor cells and are capable of inducing apoptosis. Also provided are superantigen-glycolipid conjugates and vesicles that are loaded onto antigen presenting cells to activate both T cells and NKT cells. Cell-based vaccines comprise tumor cells engineered to express a superantigen along with glycolipids products which, when expressed, render the cells capable of eliciting an effective anti-tumor immune response in a mammal into which these cells are introduced. Included among these compns. are tumor cells, hybrid cells of tumor cells and accessory cells, preferably dendritic cells. Also provided are tumoricidal T cells and NKT cells devoid of inhibitory receptors or inhibitory signaling motifs which are hyperresponsive to the the above compns. and lipid-based tumor associated antigens that can be administered for adoptive immunotherapy of cancer and infectious diseases.

ST superantigen glycolipid conjugate antigen presenting cell cancer infection immunotherapy

IT Animal tissue  
Multiple myeloma  
Prostate gland  
(-specific promoter; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplasm and infection)

IT Albumins, biological studies  
Antibodies and Immunoglobulins  
 $\alpha$ -Fetoproteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(-specific promoter; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplasm and infection)

IT Gene, microbial  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lpxA; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplasm and infection)

IT Gene, microbial  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lpxB; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplasm and infection)

IT Gene, microbial  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lpxC; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplasm and infection)

IT Gene, microbial  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lpxD; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplasm and infection)

IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(55,000-mol.-weight; superantigen-glycolipid conjugates loaded onto

- antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(A; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Apolipoproteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(B; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT CD antigens  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(CD33; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Trypanosoma cruzi  
(Chagas' disease from; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(E1B; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(E6; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(E7; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Apolipoproteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(E; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(GLTP or glycolipid transfer proteins; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Protein motifs  
(ITIM (immunoreceptor tyrosine-based inhibition motif);  
superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Transcription factors  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(I $\kappa$ B- $\alpha$  (NF- $\kappa$ B inhibitor  $\alpha$ );  
superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Receptors

- RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(LOX-1; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Apolipoproteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Lp(a); superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Glycoproteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(MAG (myelin-associated glycoprotein); superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(MHC (major histocompatibility complex), class I; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(MHC (major histocompatibility complex), class II; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Receptors  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(SREC; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(SU (surface); superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Toxins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Shiga-like toxin; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Agglutinins and Lectins  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Siglec 1-7; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Transforming growth factor receptors  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(TGF- $\beta$  receptor, type V; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT T cell (lymphocyte)

- (activation; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(adaptor; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Gene, microbial  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(agr; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Immune tolerance  
(anergy, T cell; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Molecules  
(antitumor; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(apoproteins; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Infection  
(bacterial; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Sialic acids  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(binding lectins; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Gene, animal  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(c-abl; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Gene, animal  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(c-erbB; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Polysaccharides, biological studies  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(capsular; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(carbohydrate-modifying; superantigen-glycolipid conjugates loaded onto

antigen presenting cells for adoptive immunotherapy of neoplasm and infection)

IT Lung, neoplasm  
(carcinoma; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)

IT Sarcoma  
(carcinosarcoma, Walker; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)

IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cell cycle-regulating; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)

IT Erythrocyte  
(cell membrane, sickled; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)

IT Muscle  
(cell; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)

IT Diglycerides  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(digalactosyl, ceramide; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)

IT Hematopoiesis  
(disorders, neoplasm; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)

IT Lymphocyte  
(effector cell; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)

IT Gene, microbial  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(emm-like; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)

IT Toxins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(enterotoxin B; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)

IT Receptors  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(enterotoxin; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)

IT Cell membrane  
(erythrocyte, sickled; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)

IT Toxins

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (erythrocytic; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)

- IT Organelle  
 (exocytotic granule; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Organelle  
 (exosome (exonuclease complex); superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Insulin-like growth factor I receptors  
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (gene; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Lipoproteins  
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (high-d.; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Proteins  
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (immunostimulatory; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Protein motifs  
 (inhibitory signaling; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Receptors  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitory; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Drug delivery systems  
 (injections, i.m.; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Drug delivery systems  
 (injections, i.p.; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Drug delivery systems  
 (injections, i.v.; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Drug delivery systems  
 (injections, intradermal; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Drug delivery systems  
 (injections, s.c.; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)



- IT Drug delivery systems  
(injections; superantigen-glycolipid conjugates loaded onto antigen  
presening cells for adoptive immunotherapy of neoplastic and infectious  
diseases)
- IT Histoplasma capsulatum  
Leishmania donovani  
Neurospora crassa  
Saccharomyces cerevisiae  
(inositolphosphorylceramide extraction; superantigen-glycolipid conjugates  
loaded onto antigen presening cells for adoptive immunotherapy of  
neoplasm and infection)
- IT Lipoproteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(intermediate-d.; superantigen-glycolipid conjugates loaded onto  
antigen presening cells for adoptive immunotherapy of neoplastic and  
infectious diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(lipid-binding; superantigen-glycolipid conjugates loaded onto antigen  
presening cells for adoptive immunotherapy of neoplastic and infectious  
diseases)
- IT Lipopolysaccharides  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(lipoarabinomannans; superantigen-glycolipid conjugates loaded onto  
antigen presening cells for adoptive immunotherapy of neoplastic and  
infectious diseases)
- IT Drug delivery systems  
(liposomes; superantigen-glycolipid conjugates loaded onto antigen  
presening cells for adoptive immunotherapy of neoplastic and infectious  
diseases)
- IT Lipoproteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(low-d., oxidized; superantigen-glycolipid conjugates loaded onto  
antigen presening cells for adoptive immunotherapy of neoplastic and  
infectious diseases)
- IT Lipoproteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(low-d.; superantigen-glycolipid conjugates loaded onto antigen  
presening cells for adoptive immunotherapy of neoplastic and infectious  
diseases)
- IT Leukemia  
(lymphocytic; superantigen-glycolipid conjugates loaded onto antigen  
presening cells for adoptive immunotherapy of neoplastic and infectious  
diseases)
- IT Animal cell  
(mammalian; superantigen-glycolipid conjugates loaded onto antigen  
presening cells for adoptive immunotherapy of neoplastic and infectious  
diseases)
- IT Neoplasm  
(metastasis; superantigen-glycolipid conjugates loaded onto antigen  
presening cells for adoptive immunotherapy of neoplastic and infectious  
diseases)
- IT Blood vessel  
(microvasculature; superantigen-glycolipid conjugates loaded onto

- antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Carbohydrates, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (modifying enzyme; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Signal transduction, biological  
(motif; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Glycolipids  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(myco-; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Lymphocyte  
(natural killer cell; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT T cell (lymphocyte)  
(natural killer; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Gene, animal  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(oncogene; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Sphingolipids  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(phosphosphingolipids; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Sphingosines  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(phytosphingosines; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Mutagenesis  
(point; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prodrug; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplasm and infection)
- IT Drug delivery systems  
(prodrugs; superantigen-glycolipid conjugates loaded onto antigen presenting cells for adoptive immunotherapy of neoplastic and infectious diseases)
- IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prosaposins; superantigen-glycolipid conjugates loaded onto antigen

presening cells for adoptive immunotherapy of neoplastic and infectious diseases)

IT Immunostimulants  
(proteins; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplasm and infection)

IT Glycolipids  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(proteo-; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplastic and infectious diseases)

IT CD1 (antigen)  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(receptor; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplasm and infection)

IT Proteins  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(saposins; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplastic and infectious diseases)

IT Agglutinins and Lectins  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(sialic acid-binding; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplasm and infection)

IT Adhesins  
RL: BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(sialoadhesins; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplastic and infectious diseases)

IT Neoplasm  
(solid; superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplastic and infectious diseases)

IT Sphingomonas paucimobilis  
(superantigen-glycolipid conjugates loaded onto antigen presening cells for adoptive immunotherapy of neoplasm and infection)

IT Adenoviral vectors  
Adoptive immunotherapy  
Alphavirus  
Antigen-presenting cell  
Antitumor agents  
Apoptosis  
Carcinoma  
Dendritic cell  
Epitopes  
Eubacteria  
Eukaryota  
Fibroblast  
Gene therapy  
Human  
Human herpesvirus

Immunological accessory cell  
 Immunosuppressants  
 Infection  
 Influenza virus  
 Invertebrata  
 Leukemia  
 Lymphocyte  
 Lymphoma  
 Macrophage  
 Mammalia  
 Melanoma  
 Molecular cloning  
 Mycobacterium  
 Mycosis  
 Parasite  
 Phage display  
 Prokaryota  
 Protein sequences  
 Sarcoma  
 Staphylococcus  
 Staphylococcus aureus  
 Streptococcus  
 T cell (lymphocyte)  
 Trypanosoma cruzi  
 Yeast

(superantigen-glycolipid conjugates loaded onto antigen presenting cells  
 for adoptive immunotherapy of neoplastic and infectious diseases)

IT Ceramides

Gangliosides

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
 PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological  
 study); PREP (Preparation); USES (Uses)

(superantigen-glycolipid conjugates loaded onto antigen presenting cells  
 for adoptive immunotherapy of neoplastic and infectious diseases)

IT Fatty acids, biological studies

Fusion proteins (chimeric proteins)

Glycolipids

Nucleic acids

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(superantigen-glycolipid conjugates loaded onto antigen presenting cells  
 for adoptive immunotherapy of neoplastic and infectious diseases)

IT Glycosphingolipids

RL: BSU (Biological study, unclassified); PUR (Purification or recovery);  
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(superantigen-glycolipid conjugates loaded onto antigen presenting cells  
 for adoptive immunotherapy of neoplastic and infectious diseases)

IT Oligosaccharides, biological studies

RL: BSU (Biological study, unclassified); PUR (Purification or recovery);  
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(superantigen-glycolipid conjugates loaded onto antigen presenting cells  
 for adoptive immunotherapy of neoplastic and infectious diseases)

IT Polysaccharides, biological studies

RL: BSU (Biological study, unclassified); PUR (Purification or recovery);  
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)